BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014;59:318-27. [PMID: 24115039 DOI: 10.1002/hep.26744] [Cited by in Crossref: 955] [Cited by in F6Publishing: 924] [Article Influence: 119.4] [Reference Citation Analysis]
Number Citing Articles
1 Majerová T, Konvalinka J. Viral proteases as therapeutic targets. Molecular Aspects of Medicine 2022;88:101159. [DOI: 10.1016/j.mam.2022.101159] [Reference Citation Analysis]
2 Ren J, Vaid TM, Lee H, Ojeda I, Johnson ME. Evaluation of interactions between the hepatitis C virus NS3/4A and sulfonamidobenzamide based molecules using molecular docking, molecular dynamics simulations and binding free energy calculations. J Comput Aided Mol Des 2022. [DOI: 10.1007/s10822-022-00490-1] [Reference Citation Analysis]
3 Kayesh MEH, Kohara M, Tsukiyama-kohara K. Epidemiology and Risk Factors for Acute Viral Hepatitis in Bangladesh: An Overview. Microorganisms 2022;10:2266. [DOI: 10.3390/microorganisms10112266] [Reference Citation Analysis]
4 Zitha T, Chen C, Mudawi H, Hussein W, Mukhtar M, Shigidi M, Yousif MEA, Ali MA, Glebe D, Kramvis A. Molecular characterization and genotyping of hepatitis C virus from Sudanese end-stage renal disease patients on haemodialysis. BMC Infect Dis 2022;22:848. [DOI: 10.1186/s12879-022-07833-1] [Reference Citation Analysis]
5 Chen C, Chuang W, Qin A, Zhang W, Zhu L, Zhang G, Chen J, Lo C, Zhou X, Mao X, Shang J, Kuo H, Xie W, Chen C, Lo G, Jun DW, Dang S, Tsai C, Wang T, Lai H, Tseng K, Huang Y, Chen P. A Phase 3 clinical trial validating the potency and safety of an innovative, extra‐long‐acting interferon in chronic hepatitis C. JGH Open 2022;6:782-791. [DOI: 10.1002/jgh3.12825] [Reference Citation Analysis]
6 Qi K, Liu Z, Wang L, Chen Y. Global dynamics of a diffusive SEICR HCV model with nonlinear incidences. Mathematics and Computers in Simulation 2022. [DOI: 10.1016/j.matcom.2022.11.017] [Reference Citation Analysis]
7 Wang H. Hepatitis Viruses and Hepatoma. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm031.pub2] [Reference Citation Analysis]
8 Hsiao P, Hsiao C, Tsai F, Hou Y, Chiu C, Chiang W, Wu K, Li Y, Lin C, Chan J, Chang C, Chu C. From Bench to Bedside: Clinical and Biomedical Investigations on Hepatitis C Virus (HCV) Genotypes and Risk Factors for Albuminuria. Bioengineering 2022;9:509. [DOI: 10.3390/bioengineering9100509] [Reference Citation Analysis]
9 De Francesco MA, Gargiulo F, Zaltron S, Spinetti A, Castelli F, Caruso A. DAA Treatment Failure in a HIV/HBV/HCV Co-Infected Patient Carrying a Chimeric HCV Genotype 4/1b. IJERPH 2022;19:11655. [DOI: 10.3390/ijerph191811655] [Reference Citation Analysis]
10 Okwuraiwe AP, Osuntoki AA, Ebuehi OA, Audu RA. Pattern of HCV Genotypes in HIV/HCV Co-Infected Patients on Antiretroviral Therapy in Nigeria. EJMED 2022;4:30-34. [DOI: 10.24018/ejmed.2022.4.5.1372] [Reference Citation Analysis]
11 Nikolaeva LI, Belyavtsev AN, Shevchenko NG, Stuchinskaya MD, Samokhvalov EI, Dedova AV, Sapronov GV, Shastina NS, Kuprianov VV. The analysis of immunoreactivity of individual B-cell epitopes of hepatitis C virus <i>(Flaviviridae: Hepacivirus: Hepatitis С virus)</i> NS4a antigen. Problems of Virology 2022;67:237-245. [DOI: 10.36233/0507-4088-115] [Reference Citation Analysis]
12 Panigrahi M, Palmer MA, Wilson JA. MicroRNA-122 Regulation of HCV Infections: Insights from Studies of miR-122-Independent Replication. Pathogens 2022;11:1005. [PMID: 36145436 DOI: 10.3390/pathogens11091005] [Reference Citation Analysis]
13 Bartlett SR, Verich A, Carson J, Hosseini‐hooshyar S, Read P, Baker D, Post JJ, Finlayson R, Bloch M, Doyle JS, Shaw D, Hellard M, Martinez M, Marks P, Dore GJ, Matthews GV, Applegate T, Martinello M. Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct‐acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort. Health Science Reports 2022;5. [DOI: 10.1002/hsr2.719] [Reference Citation Analysis]
14 Ren J, Vaid TM, Lee H, Ojeda I, Johnson ME. Evaluation of interactions between the hepatitis C virus NS3/4A and sulfonamidobenzamide based molecules using molecular docking, molecular dynamics simulations and binding free energy calculations.. [DOI: 10.21203/rs.3.rs-1979747/v1] [Reference Citation Analysis]
15 Chen S, Wang H, Dzakah EE, Rashid F, Wang J, Tang S. The Second Human Pegivirus, a Non-Pathogenic RNA Virus with Low Prevalence and Minimal Genetic Diversity. Viruses 2022;14:1844. [DOI: 10.3390/v14091844] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Redwan EM, Aljadawi AA, Uversky VN. Hepatitis C Virus Infection and Intrinsic Disorder in the Signaling Pathways Induced by Toll-Like Receptors. Biology 2022;11:1091. [DOI: 10.3390/biology11071091] [Reference Citation Analysis]
17 Simicic P, Slovic A, Radmanic L, Vince A, Zidovec Lepej S. Molecular Epidemiology and Baseline Resistance of Hepatitis C Virus to Direct Acting Antivirals in Croatia. Pathogens 2022;11:808. [DOI: 10.3390/pathogens11070808] [Reference Citation Analysis]
18 Deng X, Liang Z, Cai W, Li F, Li J, Hu F, Lan Y. Transmission networks of hepatitis C virus among HIV/HCV-coinfected patients in Guangdong, China. Virol J 2022;19:117. [PMID: 35836270 DOI: 10.1186/s12985-022-01849-4] [Reference Citation Analysis]
19 Tariq M, Shoukat AB, Akbar S, Hameed S, Naqvi MZ, Azher A, Saad M, Rizwan M, Nadeem M, Javed A, Ali A, Aziz S. Epidemiology, risk factors, and pathogenesis associated with a superbug: A comprehensive literature review on hepatitis C virus infection. SAGE Open Med 2022;10:20503121221105957. [PMID: 35795865 DOI: 10.1177/20503121221105957] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Breitfeld J, Fischer N, Tsachev I, Marutsov P, Baymakova M, Plhal R, Keuling O, Becher P, Baechlein C. Expanded Diversity and Host Range of Bovine Hepacivirus—Genomic and Serological Evidence in Domestic and Wild Ruminant Species. Viruses 2022;14:1457. [DOI: 10.3390/v14071457] [Reference Citation Analysis]
21 Lopez-Osorio MC, Usme-Ciro JA, Martínez JW, Peláez-Carvajal D, Hernández J, Hoyos S, Restrepo JC, Navas MC. Genetic diversity of hepatitis C virus and resistance associated substitutions to direct-acting antiviral treatment in Colombia. Virus Res 2022;318:198847. [PMID: 35697300 DOI: 10.1016/j.virusres.2022.198847] [Reference Citation Analysis]
22 Liu X, Chen Z, Tang Q, Hu P. Phylogenetic signature and prevalence of natural resistance-associated substitutions for hepatitis C virus genotypes 3a and 3b in southwestern China. J Virus Erad 2022;8:100071. [PMID: 35757658 DOI: 10.1016/j.jve.2022.100071] [Reference Citation Analysis]
23 Stapleton JT. Human Pegivirus Type 1: A Common Human Virus That Is Beneficial in Immune-Mediated Disease? Front Immunol 2022;13:887760. [DOI: 10.3389/fimmu.2022.887760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Huang Y, Qin A, Tsai C, Chen P. Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis. Viruses 2022;14:1128. [DOI: 10.3390/v14061128] [Reference Citation Analysis]
25 Yang J, Liu HX, Su YY, Liang ZS, Rao HY. Distribution and changes in hepatitis C virus genotype in China from 2010 to 2020. World J Clin Cases 2022; 10(14): 4480-4493 [DOI: 10.12998/wjcc.v10.i14.4480] [Reference Citation Analysis]
26 Cherepnin MA, Tsukanov VV, Savchenko AA, Vasyutin AV, Kasparov EV, Tonkikh JL, Borisov AG. Comparison of clinical and laboratory characteristics and frequency of liver fibrosis in patients with chronic viral hepatitis C of the first and third genotypes. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-7-98-103] [Reference Citation Analysis]
27 Kayesh MEH, Kohara M, Tsukiyama-Kohara K. Toll-like Receptor Response to Hepatitis C Virus Infection: A Recent Overview. Int J Mol Sci 2022;23:5475. [PMID: 35628287 DOI: 10.3390/ijms23105475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Pihl AF, Feng S, Offersgaard A, Alzua GP, Augestad EH, Mathiesen CK, Jensen TB, Krarup H, Law M, Prentoe J, Christensen JP, Bukh J, Gottwein JM. Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice. J Hepatol 2022;76:1051-61. [PMID: 34990750 DOI: 10.1016/j.jhep.2021.12.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
29 Li W, Liang J, An J, Liu L, Hou Y, Li L, Zhao W, Cui L, Xue N, Al-dhamin Z, Han T, Nan Y, Zhang L, Granito A. Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-11. [DOI: 10.1155/2022/7395506] [Reference Citation Analysis]
30 Arba M, Wahyudi ST, Zubair MS, Brunt D, Singh M, Wu C. Binding of GS-461203 and Its Halogen Derivatives to HCV Genotype 2a RNA Polymerase Drug Resistance Mutants. Sci Pharm 2022;90:26. [DOI: 10.3390/scipharm90020026] [Reference Citation Analysis]
31 Yi Z, Yuan Z. From Discovery to Cure, A Great Journey of the Hepatitis C Virus Study. Infectious Diseases & Immunity 2022;2:109-112. [DOI: 10.1097/id9.0000000000000050] [Reference Citation Analysis]
32 Sun HY, Cheng CY, Lin CY, Yang CJ, Lee NY, Liou BH, Tang HJ, Liu YM, Lee CY, Chen TC, Huang YC, Lee YT, Tsai MJ, Lu PL, Tsai HC, Wang NC, Hung TC, Cheng SH, Hung CC. Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections. World J Gastroenterol 2022; 28(11): 1172-1183 [DOI: 10.3748/wjg.v28.i11.1172] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Reinecke B, Frericks N, Lauber C, Dinkelborg K, Matthaei A, Vondran FWR, Behrendt P, Haid S, Brown RJP, Pietschmann T. The Human Liver-Expressed Lectin CD302 Restricts Hepatitis C Virus Infection. J Virol 2022;:e0199521. [PMID: 35297672 DOI: 10.1128/jvi.01995-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Quer J, Colomer-castell S, Campos C, Andrés C, Piñana M, Cortese MF, González-sánchez A, Garcia-cehic D, Ibáñez M, Pumarola T, Rodríguez-frías F, Antón A, Tabernero D. Next-Generation Sequencing for Confronting Virus Pandemics. Viruses 2022;14:600. [DOI: 10.3390/v14030600] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
35 Adeboyejo K, Grosche VR, José DP, Ferreira GM, Shimizu JF, King BJ, Tarr AW, Soares MMCN, Ball JK, Mcclure CP, Jardim ACG. Simultaneous determination of HCV genotype and NS5B resistance associated substitutions using dried serum spots from São Paulo state, Brazil. Access Microbiology 2022;4. [DOI: 10.1099/acmi.0.000326] [Reference Citation Analysis]
36 Elsheikh MEA, McClure CP, Tarr AW, Irving WL. Sero-reactivity to three distinct regions within the hepatitis C virus alternative reading frame protein (ARFP/core+1) in patients with chronic HCV genotype-3 infection. J Gen Virol 2022;103. [PMID: 35230930 DOI: 10.1099/jgv.0.001727] [Reference Citation Analysis]
37 O'Toole Á, Pybus OG, Abram ME, Kelly EJ, Rambaut A. Pango lineage designation and assignment using SARS-CoV-2 spike gene nucleotide sequences. BMC Genomics 2022;23:121. [PMID: 35148677 DOI: 10.1186/s12864-022-08358-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
38 Offersgaard A, Duarte Hernandez CR, Finne Pihl A, Prabhakar Venkatesan N, Krarup H, Lin X, Reichl U, Bukh J, Genzel Y, Gottwein JM. High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor. Vaccines 2022;10:249. [DOI: 10.3390/vaccines10020249] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Salas JH, Urbanowicz RA, Guest JD, Frumento N, Figueroa A, Clark KE, Keck Z, Cowton VM, Cole SJ, Patel AH, Fuerst TR, Drummer HE, Major M, Tarr AW, Ball JK, Law M, Pierce BG, Foung SKH, Bailey JR. An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development. Gastroenterology 2022;162:562-74. [PMID: 34655573 DOI: 10.1053/j.gastro.2021.10.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
40 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
41 Chuaypen N, Khlaiphuengsin A, Prasoppokakorn T, Susantitaphong P, Prasithsirikul W, Avihingsanon A, Tangkijvanich P, Praditpornsilpa K. Prevalence and genotype distribution of hepatitis C virus within hemodialysis units in Thailand: role of HCV core antigen in the assessment of viremia. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07074-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Baliashvili D, Averhoff F, Kasradze A, Salyer SJ, Kuchukhidze G, Gamkrelidze A, Imnadze P, Alkhazashvili M, Chanturia G, Chitadze N, Sukhiashvili R, Blanton C, Drobeniuc J, Morgan J, Hagan LM. Risk factors and genotype distribution of hepatitis C virus in Georgia: A nationwide population-based survey. PLoS ONE 2022;17:e0262935. [DOI: 10.1371/journal.pone.0262935] [Reference Citation Analysis]
43 Bankwitz D, Krey T, Pietschmann T. [Development approaches for vaccines against hepatitis C virus infections]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2022. [PMID: 35015104 DOI: 10.1007/s00103-021-03477-9] [Reference Citation Analysis]
44 Kozlowski HN, Sindhwani S, Chan WCW. The Impact of Patient Characteristics on Diagnostic Test Performance. Small Methods 2022;:e2101233. [PMID: 34994108 DOI: 10.1002/smtd.202101233] [Reference Citation Analysis]
45 Mallhi TH, Bokharee N, Khan YH. Togaviridae and Flaviviridae. Encyclopedia of Infection and Immunity 2022. [DOI: 10.1016/b978-0-12-818731-9.00166-x] [Reference Citation Analysis]
46 Moharana M, Pattanayak SK, Khan F. Strategies of detection and challenges for hepatitis C infectious disease. Biosensors for Emerging and Re-Emerging Infectious Diseases 2022. [DOI: 10.1016/b978-0-323-88464-8.00015-4] [Reference Citation Analysis]
47 Kaladhar DS, Srinivasan T. Comparative genomics and molecular epidemiology on hepatitis virus–induced hepatocellular carcinoma. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma 2022. [DOI: 10.1016/b978-0-323-98806-3.00005-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Chen M, Xu Y, Li N, Yin P, Zhou Q, Feng S, Wu T, Wei L, Wang H, Fu Y, Li Y. Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus. Journal of General Virology 2021;102. [DOI: 10.1099/jgv.0.001704] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Popping S, Cento V, Seguin-devaux C, Boucher C, de Salazar A, Heger E, Mor O, Sayan M, Salmon-ceron D, Weis N, Krarup H, de Knegt R, Săndulescu O, Chulanov V, van de Vijver D, García F, Ceccherini-silberstein F. The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures. Viruses 2021;14:16. [DOI: 10.3390/v14010016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Raza MN, Sughra K, Zeeshan N, Anwar MZ, Shahzad MA, Rashid U, Afroz A, Munir H. Recurrence of hepatitis C virus after treatment with pegylated interferon and direct acting antivirals in Punjab Pakistan. Braz J Biol 2021;83:e252610. [PMID: 34909837 DOI: 10.1590/1519-6984.252610] [Reference Citation Analysis]
51 Adeboyejo K, King BJ, Tsoleridis T, Tarr AW, Mclauchlan J, Irving WL, Ball JK, Mcclure CP. Hepatitis C subtyping assay failure in UK patients born in Sub-Saharan Africa: implications for global treatment and elimination.. [DOI: 10.1101/2021.12.14.21267714] [Reference Citation Analysis]
52 Manne V, Ryan J, Wong J, Vengayil G, Basit SA, Gish RG. Hepatitis C Vaccination: Where We Are and Where We Need to Be. Pathogens 2021;10:1619. [PMID: 34959574 DOI: 10.3390/pathogens10121619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Takagi A, Amako Y, Yamane D, Kitab B, Tokunaga Y, El-Gohary A, Kohara M, Tsukiyama-Kohara K. Longer Poly(U) Stretches in the 3'UTR Are Essential for Replication of the Hepatitis C Virus Genotype 4a Clone in in vitro and in vivo. Front Microbiol 2021;12:764816. [PMID: 34899647 DOI: 10.3389/fmicb.2021.764816] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Cabral BCA, Ramos JA, Silveira ALM, Nascimento ÉRDS, Ferreira SB, Coelho HSM, Moura-Neto RS, Villela-Nogueira CA, Hoffmann L, Silva R. Frequency distribution of HCV resistance-associated variants in infected patients treated with direct-acting antivirals. Int J Infect Dis 2021;115:171-7. [PMID: 34902582 DOI: 10.1016/j.ijid.2021.12.320] [Reference Citation Analysis]
55 Fernández Romero JA, Paglini MG, Priano C, Koroch A, Rodríguez Y, Sailer J, Teleshova N. Algal and Cyanobacterial Lectins and Their Antimicrobial Properties. Mar Drugs 2021;19:687. [PMID: 34940686 DOI: 10.3390/md19120687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Witkowska McConnell W, Davis C, Sabir SR, Garrett A, Bradley-Stewart A, Jajesniak P, Reboud J, Xu G, Yang Z, Gunson R, Thomson EC, Cooper JM. Paper microfluidic implementation of loop mediated isothermal amplification for early diagnosis of hepatitis C virus. Nat Commun 2021;12:6994. [PMID: 34848705 DOI: 10.1038/s41467-021-27076-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
57 Eltabbakh M, Abdella HM, Askar S, Abuhashima MA, Shaker MK. Risk stratification of patients with hepatocellular carcinoma undergoing trans arterial chemoembolization using an alpha-fetoprotein model. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00155-y] [Reference Citation Analysis]
58 Ostankova YV, Semenov AV, Zueva EB, Serikova EN, Schemelev AN, Valutite DE, Huinh HK, Egorova SA, Totolian AA. Prevalence of hepatitis B and C viral markers among apparently healthy residents of the Socialist Republic of Vietnam (Southern Vietnam). Russian Journal of Infection and Immunity 2021;11:1131-1140. [DOI: 10.15789/2220-7619-tpo-1793] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Hong CM, Lin YY, Liu CJ, Lai YY, Yeh SH, Yang HC, Kao JH, Hsu SJ, Huang YH, Yang SS, Kuo HT, Cheng PN, Yu ML, Chen PJ. Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan. Viruses 2021;13:2294. [PMID: 34835100 DOI: 10.3390/v13112294] [Reference Citation Analysis]
60 Colon-Moran W, Baer A, Lamture G, Stapleton JT, Fischer JW, Bhattarai N. A short hepatitis C virus NS5A peptide expression by AAV vector modulates human T cell activation and reduces vector immunogenicity. Gene Ther 2021. [PMID: 34759330 DOI: 10.1038/s41434-021-00302-5] [Reference Citation Analysis]
61 Lee H, Jarhad DB, Lee A, Lee C, Jeong LS. 4′‐Selenonucleosides: Regio‐ and Stereoselective Synthesis of Novel Ribavirin and Acadesine Analogs as Anti‐Hepatitis C Virus (HCV) Agents. Asian J of Organic Chemis 2021;10:2993-2999. [DOI: 10.1002/ajoc.202100563] [Reference Citation Analysis]
62 Gargan S, Stevenson NJ. Unravelling the Immunomodulatory Effects of Viral Ion Channels, towards the Treatment of Disease. Viruses 2021;13:2165. [PMID: 34834972 DOI: 10.3390/v13112165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
63 Echeverría N, Comas V, Aldunate F, Perbolianachis P, Moreno P, Cristina J. In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet? . World J Hepatol 2021; 13(10): 1234-1268 [PMID: 34786164 DOI: 10.4254/wjh.v13.i10.1234] [Reference Citation Analysis]
64 Shenge JA, Osiowy C. Rapid Diagnostics for Hepatitis B and C Viruses in Low- and Middle-Income Countries. Front Virol 2021;1:742722. [DOI: 10.3389/fviro.2021.742722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
65 Isakov V, Hedskog C, Wertheim JO, Hostager RE, Parhy B, Schneider AB, Suri V, Mo H, Geivandova N, Morozov V, Bessonova E, Gankina N, Zhdanov K, Abdurakhmanov D, Svarovskaia E. Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia. Int J Infect Dis 2021;113:36-42. [PMID: 34560266 DOI: 10.1016/j.ijid.2021.09.041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
66 Qu LX, Shi Y, Chen KY, Lu YH, Ren H. The distribution of hepatitis C virus infection in Shanghai, China: a time-spatial study. BMC Infect Dis 2021;21:974. [PMID: 34536999 DOI: 10.1186/s12879-021-06577-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
67 Aisyah DN, Story A, Kremyda-vlachou M, Kozlakidis Z, Shalcross L, Hayward A. Assessing hepatitis C virus distribution among vulnerable populations in London using whole genome sequencing: results from the TB-REACH study. Wellcome Open Res 2021;6:229. [DOI: 10.12688/wellcomeopenres.16907.1] [Reference Citation Analysis]
68 Rana R, Dangal R, Singh Y, Gurung RB, Rai B, Sharma AK. Hepatitis C Virus Infection in Pregnancy and Children: Its Implications and Treatment Considerations with Directly Acting Antivirals: A Review. JNMA J Nepal Med Assoc 2021;59:942-53. [PMID: 35199739 DOI: 10.31729/jnma.5501] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Jia Y, Yue W, Gao Q, Tao R, Zhang Y, Fu X, Liu Y, Liu L, Feng Y, Xia X. Characterization of a Novel Hepatitis C Subtype, 6xj, and Its Consequences for Direct-Acting Antiviral Treatment in Yunnan, China. Microbiol Spectr 2021;9:e0029721. [PMID: 34479413 DOI: 10.1128/Spectrum.00297-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Fiorino S, Tateo F, Biase D, Gallo CG, Orlandi PE, Corazza I, Budriesi R, Micucci M, Visani M, Loggi E, Hong W, Pica R, Lari F, Zippi M. SARS-CoV-2: lessons from both the history of medicine and from the biological behavior of other well-known viruses. Future Microbiol 2021;16:1105-33. [PMID: 34468163 DOI: 10.2217/fmb-2021-0064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
71 Liang Y, Hu F, Fan H, Li L, Wan Z, Wang H, Shui J, Zhou Y, Tong Y, Cai W, Tang S. Difference of Intrahost Dynamics of the Second Human Pegivirus and Hepatitis C Virus in HPgV-2/HCV-Coinfected Patients. Front Cell Infect Microbiol 2021;11:728415. [PMID: 34466405 DOI: 10.3389/fcimb.2021.728415] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
72 Gammeltoft KA, Zhou Y, Duarte Hernandez CR, Galli A, Offersgaard A, Costa R, Pham LV, Fahnøe U, Feng S, Scheel TKH, Ramirez S, Bukh J, Gottwein JM. Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro. Antimicrob Agents Chemother 2021;65:e0268020. [PMID: 34097489 DOI: 10.1128/AAC.02680-20] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
73 Hartlage AS, Kapoor A. Hepatitis C Virus Vaccine Research: Time to Put Up or Shut Up. Viruses 2021;13:1596. [PMID: 34452460 DOI: 10.3390/v13081596] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
74 Yang ZK, Pan L, Zhang Y, Luo H, Gao F. Data-driven identification of SARS-CoV-2 subpopulations using PhenoGraph and binary-coded genomic data. Brief Bioinform 2021:bbab307. [PMID: 34382087 DOI: 10.1093/bib/bbab307] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
75 O’toole Á, Pybus OG, Abram ME, Kelly EJ, Rambaut A. Pango lineage designation and assignment using SARS-CoV-2 spike gene nucleotide sequences.. [DOI: 10.1101/2021.08.10.455799] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Nurtjahyani SD, Taufiq Probojati R, Muhammad Ansori AN, Amin M, Handajani R. Haplotype Network Analysis and Phylogenetic Tree Construction of Hepatitis C Virus (HCV) Isolated from Tuban, Indonesia. RJPT 2021. [DOI: 10.52711/0974-360x.2021.00734] [Reference Citation Analysis]
77 Biland B, Haq M, Muhammad S, Subhani M, Gardezi S, Haq N, Tehami N. Frequency Distribution of Hepatitis C Virus Genotypes with Reference to Age and Sex in Various Districts of Khyber Pakhtunkhwa, Pakistan. EMJ Hepatol 2021. [DOI: 10.33590/emjhepatol/20-00268] [Reference Citation Analysis]
78 Shah R, Ahovegbe L, Niebel M, Shepherd J, Thomson EC. Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens. J Hepatol 2021;75:462-73. [PMID: 33974951 DOI: 10.1016/j.jhep.2021.04.045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
79 Jasim SA, Ahmed NS, Mousa AA, Hmed AA, Sofy AR. Phylogenetic tree of NS5A gene of hepatitis C virus from infected Iraqi patients. Materials Today: Proceedings 2021. [DOI: 10.1016/j.matpr.2021.07.409] [Reference Citation Analysis]
80 Morsica G, Vercesi R, Hasson H, Messina E, Uberti-Foppa C, Bagaglio S. Compartmentalization of Resistance-Associated Substitutions in HIV/HCV-Infected Patients: Possible Correlation with Infecting HCV Genotype. Viruses 2021;13:1486. [PMID: 34452351 DOI: 10.3390/v13081486] [Reference Citation Analysis]
81 Kitab B, Kohara M, Tsukiyama-kohara K. Host-Targeting Antivirals for Treatment of Hepatitis C. Advances in Hepatology 2021. [DOI: 10.5772/intechopen.95373] [Reference Citation Analysis]
82 Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638 [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
83 Mohammed AS, Balapure A, Khan AA, Khaja MN, Ganesan R, Dutta JR. Genotyping simplified: rationally designed antisense oligonucleotide-mediated PCR amplification-free colorimetric sensing of viral RNA in HCV genotypes 1 and 3. Analyst 2021;146:4767-74. [PMID: 34231566 DOI: 10.1039/d1an00590a] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
84 Frumento N, Flyak AI, Bailey JR. Mechanisms of HCV resistance to broadly neutralizing antibodies. Curr Opin Virol 2021;50:23-9. [PMID: 34329953 DOI: 10.1016/j.coviro.2021.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Hoa TN, Munshi SU, Ngoc KN, Ngoc CL, Thanh TTT, Akther T, Tabassum S, Parvin N, Baker S, Rahman M. A tightly clustered hepatitis E virus genotype 1a is associated with endemic and outbreak infections in Bangladesh. PLoS One 2021;16:e0255054. [PMID: 34293039 DOI: 10.1371/journal.pone.0255054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
86 Nasimzadeh S, Azaran A, Jalilian S, Makvandi M, Seyedian SS, Keikhaei B, Mehr FJ. Prevalence of occult hepatitis C virus infection in beta-thalassemia major patients in Ahvaz, Iran. Arch Virol 2021;166:2703-10. [PMID: 34275067 DOI: 10.1007/s00705-021-05126-7] [Reference Citation Analysis]
87 Kamel S, Elessawy H, Ashraf O, Elbaz A, Dabbous H, El-sayed M, Ali S, Kamel H. Effectiveness of Direct-Acting Antivirals in Treatment of Elderly Egyptian Chronic Hepatitis C Patients. Gastroenterology Insights 2021;12:336-46. [DOI: 10.3390/gastroent12030031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
88 Martinez MA, Franco S. Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection. Adv Exp Med Biol 2021;1322:139-57. [PMID: 34258740 DOI: 10.1007/978-981-16-0267-2_6] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
89 Ullah N, Kakakhel MA, Bai Y, Xi L, Khan I, Kalra BS, Kumar T, Ahmad H, Shah M, Guanlan L, Zhang C. Prevalence of active HCV infection and genotypic distribution among the general population of district Mardan, Pakistan. Braz J Biol 2021;83:e244977. [PMID: 34287506 DOI: 10.1590/1519-6984.244977] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
90 Phelps CC, Walker CM, Honegger JR. Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial. Viruses 2021;13:1351. [PMID: 34372558 DOI: 10.3390/v13071351] [Reference Citation Analysis]
91 Tung HD, Lee PL, Chen JJ, Kuo HT, Sheu MJ, Cheng CT, Chuang TW, Kao HJ, Wu YH, Pang MG, Lin CH, Hou CY, Tsai HH, Wu LC, Lee C. Hepatitis C Virus Subtypes Novel 6g-Related Subtype and 6w Could Be Indigenous in Southern Taiwan with Characteristic Geographic Distribution. Viruses 2021;13:1316. [PMID: 34372521 DOI: 10.3390/v13071316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Kardani K, Sadat SM, Kardani M, Bolhassani A. The next generation of HCV vaccines: a focus on novel adjuvant development. Expert Rev Vaccines 2021;20:839-55. [PMID: 34114513 DOI: 10.1080/14760584.2021.1941895] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Ahmed M, Mansey AE, Wahsh EA, Gomaa AA, Rabea HM. Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-naïve and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection. Curr Med Sci 2021;41:581-6. [PMID: 34047942 DOI: 10.1007/s11596-021-2363-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Ejeh S, Uzairu A, Shallangwa GA, Abechi SE. In Silico Design, Drug-Likeness and ADMET Properties Estimation of Some Substituted Thienopyrimidines as HCV NS3/4A Protease Inhibitors. Chemistry Africa 2021;4:563-74. [DOI: 10.1007/s42250-021-00250-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Duarte G, Pezzuto P, Barros TD, Mosimann Junior G, Martinez-Espinosa FE. Brazilian Protocol for Sexually Transmitted Infections 2020: viral hepatitis. Rev Soc Bras Med Trop 2021;54:e2020834. [PMID: 34008732 DOI: 10.1590/0037-8682-834-2020] [Reference Citation Analysis]
96 Sarkar K, Chatterjee R, Sinha S, Pramanik N. CLINICAL PROFILE AND THE CIRCULATING GENOTYPES OF HEPATITIS C VIRUS IN A TERTIARY CARE HOSPITAL IN WEST BENGAL. GLOBAL JOURNAL FOR RESEARCH ANALYSIS 2021. [DOI: 10.36106/gjra/6811683] [Reference Citation Analysis]
97 Ullah S, Ali M, Shaheen A, Zia F, Rahman L, Rahman S, Ali H, Din M, Waris A, Shinwari ZK. Sofosbuvir Resistance-associated Substitutions in the Palm Domain of HCV-NS5B RNA Dependent RNA Polymerase; Study of two Sofosbuvir non-responders. Int J Infect Dis 2021:S1201-9712(21)00426-4. [PMID: 34000421 DOI: 10.1016/j.ijid.2021.05.025] [Reference Citation Analysis]
98 Guest JD, Wang R, Elkholy KH, Chagas A, Chao KL, Cleveland TE 4th, Kim YC, Keck ZY, Marin A, Yunus AS, Mariuzza RA, Andrianov AK, Toth EA, Foung SKH, Pierce BG, Fuerst TR. Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer. Proc Natl Acad Sci U S A 2021;118:e2015149118. [PMID: 33431677 DOI: 10.1073/pnas.2015149118] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
99 Chan CP, Uemura H, Kwan TH, Wong NS, Oka S, Chan DPC, Lee SS. Review on the molecular epidemiology of sexually acquired hepatitis C virus infection in the Asia-Pacific region. J Int AIDS Soc 2020;23:e25618. [PMID: 32969173 DOI: 10.1002/jia2.25618] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
100 Shabani M, Sadegh Ehdaei B, Fathi F, Dowran R. A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019. New Microbes New Infect 2021;42:100895. [PMID: 33976895 DOI: 10.1016/j.nmni.2021.100895] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
101 Guest JD, Pierce BG. Structure-Based and Rational Design of a Hepatitis C Virus Vaccine. Viruses 2021;13:837. [PMID: 34063143 DOI: 10.3390/v13050837] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
102 Schlotthauer F, McGregor J, Drummer HE. To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity. Viruses 2021;13:805. [PMID: 33946211 DOI: 10.3390/v13050805] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
103 Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol 2021; 27(16): 1691-1715 [PMID: 33967551 DOI: 10.3748/wjg.v27.i16.1691] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
104 Han D, Wang H, Wujieti B, Zhang B, Cui W, Chen BZ. Insight into the drug resistance mechanisms of GS-9669 caused by mutations of HCV NS5B polymerase via molecular simulation. Comput Struct Biotechnol J 2021;19:2761-74. [PMID: 34093991 DOI: 10.1016/j.csbj.2021.04.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
105 Ahmed HR, Waly NGFM, Abd El-Baky RM, Yahia R, Hetta HF, Elsayed AM, Ibrahem RA. Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C. PLoS One 2021;16:e0249770. [PMID: 33857212 DOI: 10.1371/journal.pone.0249770] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
106 HCVのウイルス学的特徴とHCV genotypeについて:②臨床的意義. Acta hepatologica Japonica 2021;62:197-198. [DOI: 10.2957/kanzo.62.197] [Reference Citation Analysis]
107 Akimov IA, Timofeev DI, Mavzyutov AR, Ivanov MK. Detection of circulating HCV recombinant form RF1_2k/1b in blood serum of patients by real-time RT-PCR. Klin Lab Diagn 2021;66:122-8. [PMID: 33734647 DOI: 10.51620/0869-2084-2021-66-2-122-128] [Reference Citation Analysis]
108 Velázquez-Moctezuma R, Augestad EH, Castelli M, Holmboe Olesen C, Clementi N, Clementi M, Mancini N, Prentoe J. Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies. Vaccines (Basel) 2021;9:291. [PMID: 33804732 DOI: 10.3390/vaccines9030291] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
109 AlMalki WH, Shahid I, Abdalla AN, Johargy AK, Ahmed M, Hassan S. Virological surveillance, molecular phylogeny, and evolutionary dynamics of hepatitis C virus subtypes 1a and 4a isolates in patients from Saudi Arabia. Saudi J Biol Sci 2021;28:1664-77. [PMID: 33732052 DOI: 10.1016/j.sjbs.2020.11.089] [Reference Citation Analysis]
110 Hartlage AS, Dravid P, Walker CM, Kapoor A. Adenovirus-vectored T cell vaccine for hepacivirus shows reduced effectiveness against a CD8 T cell escape variant in rats. PLoS Pathog 2021;17:e1009391. [PMID: 33735321 DOI: 10.1371/journal.ppat.1009391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Duarte G, Pezzuto P, Barros TD, Mosimann Junior G, Martínez-Espinosa FE. [Brazilian Protocol for Sexually Transmitted Infections 2020: viral hepatitis]. Epidemiol Serv Saude 2021;30:e2020834. [PMID: 33729415 DOI: 10.1590/S1679-4974202100016.esp1] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
112 Bulut ME, Topalca US, Murat A, Teke L, Canalp HZ, Ocal M, Bayraktar B. HCV Genotype Distribution of Patients with Chronic Hepatitis C in Istanbul. Sisli Etfal Hastan Tip Bul 2021;55:86-92. [PMID: 33935541 DOI: 10.14744/SEMB.2020.66990] [Reference Citation Analysis]
113 Hussain N, Bungau S, Behl T, Sehgal A, Mahmood M, Manzoor S, Qayyum MA, Khan MI, Moleriu LC, Bilal M. Distribution of hepatitis C virus genotypes in Punjab region, Pakistan, based on a study of 4177 specimens. Infect Genet Evol 2021;91:104811. [PMID: 33741510 DOI: 10.1016/j.meegid.2021.104811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Ward JC, Bowyer S, Chen S, Fernandes Campos GR, Ramirez S, Bukh J, Harris M. Insights into the unique characteristics of hepatitis C virus genotype 3 revealed by development of a robust sub-genomic DBN3a replicon. J Gen Virol 2020;101:1182-90. [PMID: 32897181 DOI: 10.1099/jgv.0.001486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
115 Rajhi M, Haddad-Boubaker S, Chouikha A, Bourquain D, Michel J, Hammami W, Sadraoui A, Touzi H, Ghedira K, Triki H. Identification of two novel hepatitis C virus subtype 2 from Tunisia (2v and 2w). PLoS One 2021;16:e0248249. [PMID: 33705445 DOI: 10.1371/journal.pone.0248249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
116 ElDeeb MK, Ghazal AA, Metwally DE, Elghlied LA. Possible roles of methylenetetrahydrofolate reductase polymorphism and folate status in patients with early hepatitis C virus genotype 4. Arab J Gastroenterol 2021;22:121-6. [PMID: 33664006 DOI: 10.1016/j.ajg.2020.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Law M. Antibody Responses in Hepatitis C Infection. Cold Spring Harb Perspect Med 2021;11:a036962. [PMID: 32341067 DOI: 10.1101/cshperspect.a036962] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
118 Aranday-Cortes E, McClure CP, Davis C, Irving WL, Adeboyejo K, Tong L, da Silva Filipe A, Sreenu V, Agarwal K, Mutimer D, Stone B, Cramp ME, Thomson EC, Ball JK, McLauchlan J. Real-World Outcomes of DAA Treatment and Retreatment in UK-based Patients Infected with HCV Genotypes/Subtypes Endemic in Africa. J Infect Dis 2021:jiab110. [PMID: 33668068 DOI: 10.1093/infdis/jiab110] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
119 Galli A, Ramirez S, Bukh J. Lipid Droplets Accumulation during Hepatitis C Virus Infection in Cell-Culture Varies among Genotype 1-3 Strains and Does Not Correlate with Virus Replication. Viruses 2021;13:389. [PMID: 33671086 DOI: 10.3390/v13030389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Kotova VO, Balakhontseva LA, Bazykina EA, Trotsenko OE, Beldy VN, Kirdyashova SE. Genetic diversity of hepatitis C virus in Nanaian region, Khabarovsk territory. Russian Journal of Infection and Immunity 2021;11:148-156. [DOI: 10.15789/2220-7619-gdo-1265] [Reference Citation Analysis]
121 Roger S, Ducancelle A, Le Guillou-Guillemette H, Gaudy C, Lunel F. HCV virology and diagnosis. Clin Res Hepatol Gastroenterol 2021;45:101626. [PMID: 33636428 DOI: 10.1016/j.clinre.2021.101626] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
122 Ebranati E, Mancon A, Airoldi M, Renica S, Shkjezi R, Dragusha P, Della Ventura C, Ciccaglione AR, Ciccozzi M, Bino S, Tanzi E, Micheli V, Riva E, Galli M, Zehender G. Time and Mode of Epidemic HCV-2 Subtypes Spreading in Europe: Phylodynamics in Italy and Albania. Diagnostics (Basel) 2021;11:327. [PMID: 33671355 DOI: 10.3390/diagnostics11020327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Rahimi P, Sharafi H, Bahramali G, SajadianFard F, Asadi NS, Alavian SM, Iranpur Mobarakeh V, Moravej SZ. Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection. Front Microbiol 2020;11:617375. [PMID: 33584581 DOI: 10.3389/fmicb.2020.617375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
124 Zhang H, Quadeer AA, Mckay MR. Evolutionary modelling of HCV subtypes provides rationale for their different disease outcomes.. [DOI: 10.1101/2021.02.02.429470] [Reference Citation Analysis]
125 Li R, Xie Y, Liu W, Ma Y. Hepatitis C virus genotype and subtype distribution among ethnic minorities in Liaoning Province of China. Medicine (Baltimore) 2021;100:e24137. [PMID: 33466187 DOI: 10.1097/MD.0000000000024137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Ashraf MU, Salman HM, Khalid MF, Khan MHF, Anwar S, Afzal S, Idrees M, Chaudhary SU. CRISPR-Cas13a mediated targeting of hepatitis C virus internal-ribosomal entry site (IRES) as an effective antiviral strategy. Biomed Pharmacother 2021;136:111239. [PMID: 33454599 DOI: 10.1016/j.biopha.2021.111239] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
127 El-Mowafy M, Elgaml A, El-Mesery M, Sultan S, Ahmed TAE, Gomaa AI, Aly M, Mottawea W. Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection. Biology (Basel) 2021;10:55. [PMID: 33451143 DOI: 10.3390/biology10010055] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
128 Cowton VM, Owsianka AM, Fadda V, Ortega-Prieto AM, Cole SJ, Potter JA, Skelton JK, Jeffrey N, Di Lorenzo C, Dorner M, Taylor GL, Patel AH. Development of a structural epitope mimic: an idiotypic approach to HCV vaccine design. NPJ Vaccines 2021;6:7. [PMID: 33420102 DOI: 10.1038/s41541-020-00269-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
129 Isfordink CJ, van de Laar TJW, Rebers SPH, Wessels E, Molenkamp R, Knoester M, Baak BC, van Nieuwkoop C, van Hoek B, Brakenhoff SM, Blokzijl H, Arends JE, van der Valk M, Schinkel J. Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study. Open Forum Infect Dis 2021;8:ofab006. [PMID: 33614815 DOI: 10.1093/ofid/ofab006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
130 Ejeh S, Uzairu A, Shallangwa GA, Abechi SE. Computer-aided identification of a series of novel ligands showing high potency as hepatitis C virus NS3/4A protease inhibitors. Bull Natl Res Cent 2021;45. [DOI: 10.1186/s42269-020-00467-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
131 Papastergiou V, Kranidioti H, Manolakopoulos S. Current Management of HCV Genotype 3 Infection. Hepatitis C: Care and Treatment 2021. [DOI: 10.1007/978-3-030-67762-6_7] [Reference Citation Analysis]
132 Al-busafi SA, Alnaamani K. Hepatitis C-Induced Hepatocellular Carcinoma in the Middle East. Liver Cancer in the Middle East 2021. [DOI: 10.1007/978-3-030-78737-0_17] [Reference Citation Analysis]
133 Bartenschlager R, Tabata K. Hepatitis C Virus (Flaviviridae). Encyclopedia of Virology 2021. [DOI: 10.1016/b978-0-12-814515-9.00032-1] [Reference Citation Analysis]
134 Geretti AM, Atkins M, Nastouli E, Bradshaw D. Laboratory Diagnosis. Hepatitis C: Epidemiology, Prevention and Elimination 2021. [DOI: 10.1007/978-3-030-64649-3_4] [Reference Citation Analysis]
135 Rashed WM. Current HCC Clinical and Research in Egypt. Liver Cancer in the Middle East 2021. [DOI: 10.1007/978-3-030-78737-0_19] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Abdullah, Niaz K, Khan F. Hepatitis C. Influence of Nutrients, Bioactive Compounds, and Plant Extracts in Liver Diseases 2021. [DOI: 10.1016/b978-0-12-816488-4.00014-0] [Reference Citation Analysis]
137 Schmitt A, Sarrazin C. Hepatitis C. Therapie-Handbuch - Gastroenterologie und Hepatologie 2021. [DOI: 10.1016/b978-3-437-23847-5.00046-6] [Reference Citation Analysis]
138 Wiessing L, Giraudon I, Duffell E, Veldhuijzen I, Zimmermann R, Hope V. Epidemiology of Hepatitis C Virus: People Who Inject Drugs and Other Key Populations. Hepatitis C: Epidemiology, Prevention and Elimination 2021. [DOI: 10.1007/978-3-030-64649-3_6] [Reference Citation Analysis]
139 Paraskevis D, Kostaki EG, Kramvis A, Magiorkinis G. Classification, Genetic Diversity and Global Distribution of Hepatitis C Virus (HCV) Genotypes and Subtypes. Hepatitis C: Epidemiology, Prevention and Elimination 2021. [DOI: 10.1007/978-3-030-64649-3_3] [Reference Citation Analysis]
140 Martinez MA, Franco S. Therapy Implications of Hepatitis C Virus Genetic Diversity. Viruses 2020;13:E41. [PMID: 33383891 DOI: 10.3390/v13010041] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
141 Audu RA, Okwuraiwe AP, Ige FA, Adeleye OO, Onyekwere CA, Lesi OA. Hepatitis C viral load and genotypes among Nigerian subjects with chronic infection and implication for patient management: a retrospective review of data. Pan Afr Med J 2020;37:335. [PMID: 33738023 DOI: 10.11604/pamj.2020.37.335.20299] [Reference Citation Analysis]
142 Alshuwaykh O, Kwo PY. Current and future strategies for the treatment of chronic hepatitis C. Clin Mol Hepatol 2021;27:246-56. [PMID: 33317245 DOI: 10.3350/cmh.2020.0230] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
143 Gammeltoft KA, Zhou Y, Galli A, Offersgaard A, Pham LV, Fahnøe U, Feng S, Ramirez S, Bukh J, Gottwein JM. Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro.. [DOI: 10.1101/2020.12.02.408112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
144 Sedeño-Monge V, Laguna-Meraz S, Santos-López G, Panduro A, Sosa-Jurado F, Jose-Abrego A, Meléndez-Mena D, Muñoz-Ramírez MA, Cosme-Chávez M, Roman S. A comprehensive update of the status of hepatitis C virus (HCV) infection in Mexico-A systematic review and meta-analysis (2008-2019). Ann Hepatol 2021;20:100292. [PMID: 33259949 DOI: 10.1016/j.aohep.2020.100292] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
145 Laugel E, Hartard C, Jeulin H, Berger S, Venard V, Bronowicki JP, Schvoerer E. Full-length genome sequencing of RNA viruses-How the approach can enlighten us on hepatitis C and hepatitis E viruses. Rev Med Virol 2021;31:e2197. [PMID: 34260779 DOI: 10.1002/rmv.2197] [Reference Citation Analysis]
146 Mejer N, Fahnøe U, Galli A, Ramirez S, Weiland O, Benfield T, Bukh J. Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity. Antimicrob Agents Chemother 2020;64:e01417-20. [PMID: 32928732 DOI: 10.1128/AAC.01417-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
147 Gewaid H, Aoyagi H, Arita M, Watashi K, Suzuki R, Sakai S, Kumagai K, Yamaji T, Fukasawa M, Kato F, Hishiki T, Mimata A, Sakamaki Y, Ichinose S, Hanada K, Muramatsu M, Wakita T, Aizaki H. Sphingomyelin Is Essential for the Structure and Function of the Double-Membrane Vesicles in Hepatitis C Virus RNA Replication Factories. J Virol. 2020;94. [PMID: 32938759 DOI: 10.1128/jvi.01080-20] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
148 Fernandes Campos GR, Ward J, Chen S, Bittar C, Vilela Rodrigues JP, Martinelli ALC, Souza FF, Pereira LRL, Rahal P, Harris M. A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir. J Gen Virol 2021;102. [PMID: 33141008 DOI: 10.1099/jgv.0.001496] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
149 Valetskyi MI, Petro Mohyla Black Sea National University, 10, 68 Desantnykiv St., Mykolaiv 54003, Ukraine, Zak MU, Chernyshov OV, Sverdlova MV, Potochniak VS. Chronic Viral Hepatitis C: The Evolution of Scientific Views. Ukr ž med bìol sportu 2020;5:9-18. [DOI: 10.26693/jmbs05.05.009] [Reference Citation Analysis]
150 R D.. PREVALENCE OF HEPATITIS C VIRUS GENOTYPES REPORTED FROM A TERTIARY CARE CENTRE OF KERALA. GLOBAL JOURNAL FOR RESEARCH ANALYSIS 2020. [DOI: 10.36106/gjra/2610217] [Reference Citation Analysis]
151 Manso CF, Bibby DF, Lythgow K, Mohamed H, Myers R, Williams D, Piorkowska R, Chan YT, Bowden R, Ansari MA, Ip CLC, Barnes E, Bradshaw D, Mbisa JL. Technical Validation of a Hepatitis C Virus Whole Genome Sequencing Assay for Detection of Genotype and Antiviral Resistance in the Clinical Pathway. Front Microbiol 2020;11:576572. [PMID: 33162957 DOI: 10.3389/fmicb.2020.576572] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
152 Pawlotsky JM. About the absolute need to keep active research on the efficacy of direct-acting antiviral drugs against the hepatitis C virus. J Hepatol 2020;73:752-4. [PMID: 32732060 DOI: 10.1016/j.jhep.2020.06.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
153 Nguyen D, Smith D, Vaughan-Jackson A, Magri A, Barnes E, Simmonds P; STOP-HCV Consortium. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia. J Hepatol 2020;73:794-9. [PMID: 32470499 DOI: 10.1016/j.jhep.2020.05.029] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
154 Ramière C, Charre C, Miailhes P, Bailly F, Radenne S, Uhres AC, Brochier C, Godinot M, Chiarello P, Pradat P, Cotte L; Lyon Acute Hepatitis Study Group. Patterns of Hepatitis C Virus Transmission in Human Immunodeficiency Virus (HIV)-infected and HIV-negative Men Who Have Sex With Men. Clin Infect Dis 2019;69:2127-35. [PMID: 30810158 DOI: 10.1093/cid/ciz160] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 17.5] [Reference Citation Analysis]
155 Ströh LJ, Krey T. HCV Glycoprotein Structure and Implications for B-Cell Vaccine Development. Int J Mol Sci 2020;21:E6781. [PMID: 32947858 DOI: 10.3390/ijms21186781] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
156 Carlson G, Crane TE, Taylor-Piliae RE. Selecting a theoretical framework to explore the social and cognitive uncertainty that hepatitis C treatment represents for people who inject drugs. Appl Nurs Res 2020;56:151339. [PMID: 32907767 DOI: 10.1016/j.apnr.2020.151339] [Reference Citation Analysis]
157 Chiu WN, Hung CH, Lu SN, Chen MY, Tung SY, Wei KL, Lu CK, Chen CH, Hu TH, Hu JH, Chen WM, Chang TS. Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan. J Viral Hepat 2020;27:866-72. [PMID: 32343472 DOI: 10.1111/jvh.13305] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
158 Ikram S, Ahmad J, Rehman IU, Durdagi S. Potent novel inhibitors against hepatitis C virus NS3 (HCV NS3 GT-3a) protease domain. J Mol Graph Model 2020;101:107727. [PMID: 33027738 DOI: 10.1016/j.jmgm.2020.107727] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Tong Y, Li Q, Li R, Xu Y, Pan Y, Niu J, Zhong J. A Novel Approach To Display Structural Proteins of Hepatitis C Virus Quasispecies in Patients Reveals a Key Role of E2 HVR1 in Viral Evolution. J Virol 2020;94:e00622-20. [PMID: 32554700 DOI: 10.1128/JVI.00622-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
160 Qin YJ, Sha RC, Feng YC, Huang YC. Comparison of double antigen sandwich and indirect enzyme-linked immunosorbent assay for the diagnosis of hepatitis C virus antibodies. J Clin Lab Anal 2020;34:e23481. [PMID: 33245583 DOI: 10.1002/jcla.23481] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
161 Rodrigues de Melo T, César da Silva Sá G, Vilar Cordeiro L, Thiago Ramalho de Figueiredo P, Benvindo Ferreira S, Pereira de Sousa A. PERFIL EPIDEMIOLÓGICO DA HEPATITE C NO BRASIL NO PERÍODO 2013 - 2018. RIS 2020;7:1358-1370. [DOI: 10.35621/23587490.v7.n1.p1358-1370] [Reference Citation Analysis]
162 Castro GLC, Amoras EDGS, Araújo MSM, Conde SRSDS, Vallinoto ACR. Hepatitis C virus genotypes and associated risk factors in the state of Pará, Northern Brazil. Braz J Infect Dis 2020;24:304-9. [PMID: 32735876 DOI: 10.1016/j.bjid.2020.06.010] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
163 Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, du Plessis L, Pybus OG. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol 2020;5:1403-7. [PMID: 32669681 DOI: 10.1038/s41564-020-0770-5] [Cited by in Crossref: 1564] [Cited by in F6Publishing: 1648] [Article Influence: 782.0] [Reference Citation Analysis]
164 Sepulveda-Crespo D, Resino S, Martinez I. Hepatitis C virus vaccine design: focus on the humoral immune response. J Biomed Sci 2020;27:78. [PMID: 32631318 DOI: 10.1186/s12929-020-00669-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
165 García Deltoro M, Ricart Olmos C. Hepatitis C virus infection and new treatment strategies. Enferm Infecc Microbiol Clin (Engl Ed) 2019;37 Suppl 1:15-9. [PMID: 31138418 DOI: 10.1016/S0213-005X(19)30177-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
166 Elia G, Caringella F, Lanave G, Martella V, Losurdo M, Tittarelli M, Colitti B, Decaro N, Buonavoglia C. Genetic heterogeneity of bovine hepacivirus in Italy. Transbound Emerg Dis 2020;67:2731-40. [PMID: 32426936 DOI: 10.1111/tbed.13628] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
167 Sepulveda-Crespo D, Resino S, Martinez I. Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants. Vaccines (Basel) 2020;8:E313. [PMID: 32560440 DOI: 10.3390/vaccines8020313] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
168 Czarnota A, Offersgaard A, Pihl AF, Prentoe J, Bukh J, Gottwein JM, Bieńkowska-Szewczyk K, Grzyb K. Specific Antibodies Induced by Immunization with Hepatitis B Virus-Like Particles Carrying Hepatitis C Virus Envelope Glycoprotein 2 Epitopes Show Differential Neutralization Efficiency. Vaccines (Basel) 2020;8:E294. [PMID: 32532076 DOI: 10.3390/vaccines8020294] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
169 Donnison T, von Delft A, Brown A, Swadling L, Hutchings C, Hanke T, Chinnakannan S, Barnes E. Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes. Vaccine 2020;38:5036-48. [PMID: 32532545 DOI: 10.1016/j.vaccine.2020.05.042] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
170 Douglas MW, Tay ES, Eden JS, George J. Hepatitis C Virus Genotype 8 Infection-Successful Treatment With Sofosbuvir/Velpatasvir. J Infect Dis 2019;220:720-2. [PMID: 30958539 DOI: 10.1093/infdis/jiz155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
171 Kandangwa M, Liu Q. HCV-2a NS5A downregulates viral translation predominantly through domain I. Biochem Biophys Res Commun 2020;529:77-84. [PMID: 32560823 DOI: 10.1016/j.bbrc.2020.05.177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
172 Warkad SD, Nimse SB, Song KS, Kim T. Development of a Method for Screening and Genotyping of HCV 1a, 1b, 2, 3, 4, and 6 Genotypes. ACS Omega 2020;5:10794-9. [PMID: 32455199 DOI: 10.1021/acsomega.0c00386] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
173 Babin Y. Recan: Python tool for analysis of recombination events in viral genomes. JOSS 2020;5:2014. [DOI: 10.21105/joss.02014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
174 Dutta S, Biswas A, Choudhury P, Bakshi S, Chowdhury P, Bhattacharyya M, Chakraborty S, Dutta S, Sadhukhan PC. Study of Hepatitis C Virus infection among multi-transfused patients with inherited β-globin synthesis gene defect, in the eastern region of India.. [DOI: 10.1101/2020.05.06.20092049] [Reference Citation Analysis]
175 Wasitthankasem R, Pimsingh N, Treesun K, Posuwan N, Vichaiwattana P, Auphimai C, Thongpan I, Tongsima S, Vongpunsawad S, Poovorawan Y. Prevalence of Hepatitis C Virus in an Endemic Area of Thailand: Burden Assessment toward HCV Elimination. Am J Trop Med Hyg 2020;103:175-82. [PMID: 32394881 DOI: 10.4269/ajtmh.19-0817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
176 Rodgers MA, Gomathi S, Vallari A, Saravanan S, Lucas GM, Mehta S, Solomon SS, Cloherty GA. Diverse HCV Strains And HIV URFS Identified Amongst People Who Inject Drugs In India. Sci Rep 2020;10:7214. [PMID: 32350342 DOI: 10.1038/s41598-020-64309-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
177 Nikonova AA, Isakov IY, Zverev VV. Immune response to respiratory syncytial virus infection (<i>Orthopneumovirus</i>). Russian Journal of Infection and Immunity 2020;11:223-236. [DOI: 10.15789/2220-7619-irt-1300] [Reference Citation Analysis]
178 Ranjbar Kermani F, Amini Kafi-Abad S, Mousavi Hossein K, Maghsudlu M, Sharifi Z, Mansournia MA. Association of HCV genotype with viral load among Iranian blood donors: a penalized logistic regression. Med J Islam Repub Iran 2019;33:149. [PMID: 32280655 DOI: 10.34171/mjiri.33.149] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
179 Mumtaz S, Ahmed J, Gul A, Tariq SA, Siraj S, Sarwar T. Genetic Diversity of Hepatitis C Virus Genotype 3a Based on Complete Core Protein in Peshawar, Pakistan. Jundishapur J Microbiol 2020;13. [DOI: 10.5812/jjm.98942] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
180 Kazmierski WM, Baskaran S, Walker JT, Miriyala N, Meesala R, Beesu M, Adjabeng G, Grimes RM, Hamatake R, Leivers MR, Crosby R, Xia B, Remlinger K. GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage. J Med Chem 2020;63:4155-70. [PMID: 32202782 DOI: 10.1021/acs.jmedchem.9b02176] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
181 Massoud O. Hepatitis C: looking into the future. Expert Rev Gastroenterol Hepatol 2020;14:367-74. [PMID: 32216467 DOI: 10.1080/17474124.2020.1746641] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
182 Ferenci P. Impact and management of patients with multiple hepatitis C virus genotypes. Clinical Dilemmas in Viral Liver Disease 2020. [DOI: 10.1002/9781119533481.ch12] [Reference Citation Analysis]
183 Qin Z, Yan A. QSAR studies on hepatitis C virus NS5A protein tetracyclic inhibitors in wild type and mutants by CoMFA and CoMSIA. SAR QSAR Environ Res 2020;31:281-311. [PMID: 32208783 DOI: 10.1080/1062936X.2020.1740889] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
184 Donnison T, Chinnakannan S, Cicconi P, Barnes E. Hepatitis C vaccines: how close are we to the promised land? In: Foster GR, Reddy KR, editors. Clinical Dilemmas in Viral Liver Disease. Wiley; 2020. pp. 208-15. [DOI: 10.1002/9781119533481.ch36] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
185 Bhatia M, Gupta E. Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection-A brief review of literature. J Family Med Prim Care 2020;9:531-8. [PMID: 32318377 DOI: 10.4103/jfmpc.jfmpc_943_19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
186 Romero-López C, Berzal-Herranz A. The Role of the RNA-RNA Interactome in the Hepatitis C Virus Life Cycle. Int J Mol Sci 2020;21:E1479. [PMID: 32098260 DOI: 10.3390/ijms21041479] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
187 Timm J, Kosovrasti K, Henes M, Leidner F, Hou S, Ali A, Kurt Yilmaz N, Schiffer CA. Molecular and Structural Mechanism of Pan-Genotypic HCV NS3/4A Protease Inhibition by Glecaprevir. ACS Chem Biol 2020;15:342-52. [PMID: 31868341 DOI: 10.1021/acschembio.9b00675] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
188 Elkhoudary MM, Selim BM, Abdelsalam RA, Hadad GM, El-gindy A. Development and validation of a simple HPTLC method for the determination of new hepatitis C subtype 4 antiviral agents in their tablet dosage form. JPC-J Planar Chromat 2020;33:71-7. [DOI: 10.1007/s00764-019-00006-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
189 Duncan JD, Urbanowicz RA, Tarr AW, Ball JK. Hepatitis C Virus Vaccine: Challenges and Prospects. Vaccines (Basel) 2020;8:E90. [PMID: 32079254 DOI: 10.3390/vaccines8010090] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 17.0] [Reference Citation Analysis]
190 Seeger C, Mason WS, Lai MM. Molecular Biology of Hepatitis Viruses. The Liver 2020. [DOI: 10.1002/9781119436812.ch62] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
191 Goya S, Galiano M, Nauwelaers I, Trento A, Openshaw PJ, Mistchenko AS, Zambon M, Viegas M. Toward unified molecular surveillance of RSV: A proposal for genotype definition. Influenza Other Respir Viruses 2020;14:274-85. [PMID: 32022426 DOI: 10.1111/irv.12715] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
192 Cox AL. Challenges and Promise of a Hepatitis C Virus Vaccine. Cold Spring Harb Perspect Med 2020;10:a036947. [PMID: 31548228 DOI: 10.1101/cshperspect.a036947] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
193 Han AX, Parker E, Scholer F, Maurer-Stroh S, Russell CA. Phylogenetic Clustering by Linear Integer Programming (PhyCLIP). Mol Biol Evol 2019;36:1580-95. [PMID: 30854550 DOI: 10.1093/molbev/msz053] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 17.0] [Reference Citation Analysis]
194 Singh D, Soni S, Khan S, Sarangi AN, Yennamalli RM, Aggarwal R, Veerapu NS. Genome-Wide Mutagenesis of Hepatitis C Virus Reveals Ability of Genome To Overcome Detrimental Mutations. J Virol 2020;94:e01327-19. [PMID: 31723027 DOI: 10.1128/JVI.01327-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
195 Jung N, Mayet W, Mertens P, Meyer (federführend) J, Müller O, Pfeifer M, Schellinger P, Weiss N, Wendtner C. ERKRANKUNGEN DER VERDAUUNGSORGANE. Rationelle Diagnostik und Therapie in der Inneren Medizin 2020. [DOI: 10.1016/b978-3-437-06282-7.50008-5] [Reference Citation Analysis]
196 Kanto T, Yoshio S. Hepatitis C. Liver Immunology 2020. [DOI: 10.1007/978-3-030-51709-0_17] [Reference Citation Analysis]
197 Adinolfi LE, Mangoni ED, Marrone A, Zampino R, Rinaldi L. Viral Hepatitis C. Liver Diseases 2020. [DOI: 10.1007/978-3-030-24432-3_17] [Reference Citation Analysis]
198 Freissmuth M. Antivirale Pharmaka. Pharmakologie und Toxikologie 2020. [DOI: 10.1007/978-3-662-58304-3_58] [Reference Citation Analysis]
199 da Justa Pires Neto R, Hyppolito EB, Bezerra da Silva Junior G. Viral Hepatitis and Kidney Disease. Tropical Nephrology 2020. [DOI: 10.1007/978-3-030-44500-3_15] [Reference Citation Analysis]
200 Domingo E. Long-term virus evolution in nature. Virus as Populations 2020. [DOI: 10.1016/b978-0-12-816331-3.00007-6] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
201 Rossotti R, Puoti M. Sexually Transmitted Hepatitis. Sexually Transmitted Infections 2020. [DOI: 10.1007/978-3-030-02200-6_13] [Reference Citation Analysis]
202 Öz S, Köroğlu M, Özbek A, Demiray T, Karabay O, Trak G, Altindiş M. Sakarya İlinde Hepatit C Virüs Genotip Dağılımı; Üç Yıllık Retrospektif Çalışma. Online Türk Sağlık Bilimleri Dergisi 2019. [DOI: 10.26453/otjhs.480164] [Reference Citation Analysis]
203 Sallam M, Batarseh R, Natsheh A, Abbadi J, Al-Fraihat E, Yaseen A, Kaddomi D, Khamees N, Mahafzah A, Şahin GÖ. An update on hepatitis C virus genotype distribution in Jordan: a 12-year retrospective study from a tertiary care teaching hospital in Amman. BMC Infect Dis 2019;20:3. [PMID: 31892307 DOI: 10.1186/s12879-019-4735-3] [Reference Citation Analysis]
204 Lee KC, Cheng YT, Lin CY, Kuo CJ, Chien RN, Yeh CT, Chang ML. Impact of mixed cryoglobulinemia on patients with spontaneous hepatitis C virus clearance: A 13-year prospective cohort study. Eur J Clin Invest 2020;50:e13189. [PMID: 31782138 DOI: 10.1111/eci.13189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
205 Rabaan AA, Al-Ahmed SH, Bazzi AM, Alfouzan WA, Alsuliman SA, Aldrazi FA, Haque S. Overview of hepatitis C infection, molecular biology, and new treatment. J Infect Public Health 2020;13:773-83. [PMID: 31870632 DOI: 10.1016/j.jiph.2019.11.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
206 Del-Rios NHA, de Araujo LA, Martins RMB, Guimarães RA, de Matos MAD, Caetano KAA, Pinheiro RS, da Silva França DD, da Silva LN, Teles SA, Dos Santos Carneiro MA. Molecular and epidemiological aspects of hepatitis C virus infection among crack cocaine users. J Med Virol 2020;92:1239-45. [PMID: 31746475 DOI: 10.1002/jmv.25632] [Reference Citation Analysis]
207 Childs K, Davis C, Cannon M, Montague S, Filipe A, Tong L, Simmonds P, Smith D, Thomson EC, Dusheiko G, Agarwal K. Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C. J Hepatol 2019;71:1099-105. [PMID: 31400349 DOI: 10.1016/j.jhep.2019.07.025] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 13.0] [Reference Citation Analysis]
208 Pawlotsky JM. DAA failures in African patients with "unusual" HCV subtypes: Hey! Didn't you know there was another world? J Hepatol 2019;71:1070-2. [PMID: 31648816 DOI: 10.1016/j.jhep.2019.09.021] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
209 Lanini S, Ustianowski A, Pisapia R, Zumla A, Ippolito G. Viral Hepatitis. Infectious Disease Clinics of North America 2019;33:1045-62. [DOI: 10.1016/j.idc.2019.08.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 15.0] [Reference Citation Analysis]
210 Wassenaar TM, Jun SR, Robeson M, Ussery DW. Comparative genomics of hepatitis A virus, hepatitis C virus, and hepatitis E virus provides insights into the evolutionary history of Hepatovirus species. Microbiologyopen 2020;9:e973. [PMID: 31742930 DOI: 10.1002/mbo3.973] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
211 Due OT, Chaikledkaew U, Genuino AJM, Sobhonslidsuk A, Thakkinstian A. Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6. Biomed Res Int 2019;2019:2301291. [PMID: 31815126 DOI: 10.1155/2019/2301291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
212 Spitz N, Barros JJ, do Ó KM, Brandão-Mello CE, Araujo NM. The First Complete Genome Sequences of Hepatitis C Virus Subtype 2b from Latin America: Molecular Characterization and Phylogeographic Analysis. Viruses 2019;11:E1000. [PMID: 31683566 DOI: 10.3390/v11111000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
213 Johnson J, Freedman H, Logan M, Wong JAJ, Hockman D, Chen C, He J, Beard MR, Eyre NS, Baumert TF, Tyrrell DL, Law JLM, Houghton M. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1. J Virol 2019;93:e00810-19. [PMID: 31462563 DOI: 10.1128/JVI.00810-19] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
214 Serdari D, Kostaki EG, Paraskevis D, Stamatakis A, Kapli P. Automated, phylogeny-based genotype delimitation of the Hepatitis Viruses HBV and HCV. PeerJ 2019;7:e7754. [PMID: 31667012 DOI: 10.7717/peerj.7754] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
215 Andrade E, Rocha D, Fontana-Maurell M, Costa E, Ribeiro M, Godoy DT, Ferreira AGP, Tanuri A, Brindeiro R, Alvarez P. Resistance mutations of NS3 and NS5b in treatment-naïve patients infected with hepatitis C virus in Santa Catarina and Rio Grande do Sul states, Brazil. Genet Mol Biol 2020;43:e20180237. [PMID: 31644681 DOI: 10.1590/1678-4685-GMB-2018-0237] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
216 Nazario de Moraes L, Tommasini Grotto RM, Targino Valente G, de Carvalho Sampaio H, Magro AJ, Fogaça L, Wolf IR, Perahia D, Faria Silva G, Plana Simões R. A novel molecular mechanism to explain mutations of the HCV protease associated with resistance against covalently bound inhibitors. Virus Res 2019;274:197778. [PMID: 31618615 DOI: 10.1016/j.virusres.2019.197778] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
217 Hostager R, Ragonnet-Cronin M, Murrell B, Hedskog C, Osinusi A, Susser S, Sarrazin C, Svarovskaia E, Wertheim JO. Hepatitis C virus genotype 1 and 2 recombinant genomes and the phylogeographic history of the 2k/1b lineage. Virus Evol 2019;5:vez041. [PMID: 31616569 DOI: 10.1093/ve/vez041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
218 Fu X, Mao L, Wan Z, Xu R, Ma Y, Shen L, Jin X, Zhang C. High proportion of coxsackievirus B3 genotype A in hand, foot and mouth disease in Zhenjiang, China, 2011–2016. International Journal of Infectious Diseases 2019;87:1-7. [DOI: 10.1016/j.ijid.2019.07.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
219 Khan MA, Khan SA, Hamayun M, Ali M, Idrees M. Sequence variability of HCV 3a isolates based on core gene in patients from Lahore, Pakistan. Future Virology 2019;14:641-53. [DOI: 10.2217/fvl-2019-0086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
220 Filskov J, Andersen P, Agger EM, Bukh J. HCV p7 as a novel vaccine-target inducing multifunctional CD4+ and CD8+ T-cells targeting liver cells expressing the viral antigen. Sci Rep 2019;9:14085. [PMID: 31575882 DOI: 10.1038/s41598-019-50365-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
221 Arca-Lafuente S, Martínez-Román P, Mate-Cano I, Madrid R, Briz V. Nanotechnology: A reality for diagnosis of HCV infectious disease. J Infect 2020;80:8-15. [PMID: 31580870 DOI: 10.1016/j.jinf.2019.09.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
222 Parr JB, Lodge EK, Holzmayer V, Pepin J, Frost EH, Fried MW, McGivern DR, Lemon SM, Keeler C, Emch M, Mwandagalirwa K, Tshefu A, Fwamba F, Muwonga J, Meshnick SR, Cloherty G. An Efficient, Large-Scale Survey of Hepatitis C Viremia in the Democratic Republic of the Congo Using Dried Blood Spots. Clin Infect Dis 2018;66:254-60. [PMID: 29048459 DOI: 10.1093/cid/cix771] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
223 Wu R, Geng D, Chi X, Wang X, Gao X, Xu H, Shi Y, Guan Y, Wang Y, Jin J, Ding Y, Niu J. Computational analysis of naturally occurring resistance-associated substitutions in genes NS3, NS5A, and NS5B among 86 subtypes of hepatitis C virus worldwide. Infect Drug Resist. 2019;12:2987-3015. [PMID: 31571951 DOI: 10.2147/idr.s218584] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
224 Asante-Appiah E, Ingravallo P, McMonagle P, Bystol K, Xia E, Curry S, Qiu P, Black S, Chase R, Liu R, Lahser F. Interplay of Amino Acid Residues at Positions 28 and 31 in NS5A Defines Resistance Pathways in HCV GT2. Antimicrob Agents Chemother 2019:AAC. [PMID: 31527040 DOI: 10.1128/AAC.01269-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
225 Uribe-Noguez LA, Mata-Marín JA, Ocaña-Mondragón A, Pompa-Mera EN, Ribas-Aparicio RM, Arroyo-Anduiza CI, Gomez-Torres ME, Chaparro-Sánchez A, Gaytán-Martínez J, Mauss S. Comparison of direct sequencing of the NS5B region with the Versant HCV genotype 2.0 assay for genotyping of viral isolates in Mexico. J Infect Chemother 2020;26:205-10. [PMID: 31537472 DOI: 10.1016/j.jiac.2019.08.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
226 Lu G, Ou J, Zhao J, Li S. Presence of a Novel Subtype of Bovine Hepacivirus in China and Expanded Classification of Bovine Hepacivirus Strains Worldwide into 7 Subtypes. Viruses 2019;11:E843. [PMID: 31514278 DOI: 10.3390/v11090843] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
227 Janiak M, Perlejewski K, Grabarczyk P, Kubicka-Russel D, Zagordi O, Berak H, Osuch S, Pawełczyk A, Bukowska-Ośko I, Płoski R, Laskus T, Caraballo Cortés K. Hepatitis C virus (HCV) genotype 1b displays higher genetic variability of hypervariable region 1 (HVR1) than genotype 3. Sci Rep 2019;9:12846. [PMID: 31492939 DOI: 10.1038/s41598-019-49258-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
228 Chaturvedi N, Svarovskaia ES, Mo H, Osinusi AO, Brainard DM, Subramanian GM, McHutchison JG, Zeuzem S, Fellay J. Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes. Elife 2019;8:e42542. [PMID: 31478832 DOI: 10.7554/eLife.42542] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
229 Ul Abideen Z, Siddique S, Nasrullah I, Khan JS, Rehman S, Tong Y, Qamar R, Butt AM. A 2-year retrospective study of viral and host-associated risk factors in Pakistani hepatocellular carcinoma patients. Eur J Gastroenterol Hepatol 2019;31:1103-9. [PMID: 30829691 DOI: 10.1097/MEG.0000000000001384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
230 Charlton MR, Gane EJ, Shukla A, Dashtseren B, Duger D, Muljono DH, Payawal DA, Jargalsaikhan G, Purnomo HD, Cua IH, Hasan I, Sollano J Jr, Win KM, Lesmana LA, Salih M, Thi Thu Thuy P, Shankar R, Saraswat VA. International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation. Transplantation 2019;103:733-46. [PMID: 30335692 DOI: 10.1097/TP.0000000000002453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
231 Pérez AB, Chueca N, Macías J, Pineda JA, Salmerón J, Rivero-Juárez A, Hidalgo-Tenorio C, Espinosa MD, Téllez F, Von-Wichmann MÁ, Omar M, Santos J, Hernández-Quero J, Antón JJ, Collado A, Lozano AB, García-Deltoro M, Casado M, Pascasio JM, Selfa A, Rosales JM, De la Iglesia A, Arenas JI, García-Bujalance S, Ríos MJ, Bernal E, Martínez O, García-Herola A, Vélez M, Rincón P, García F. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort. PLoS One 2019;14:e0221231. [PMID: 31469856 DOI: 10.1371/journal.pone.0221231] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
232 Goletti S, Zuyten S, Goeminne L, Verhofstede C, Rodriguez-Villalobos H, Bodeus M, Stärkel P, Horsmans Y, Kabamba-Mukadi B. Comparison of Sanger sequencing for hepatitis C virus genotyping with a commercial line probe assay in a tertiary hospital. BMC Infect Dis 2019;19:738. [PMID: 31438880 DOI: 10.1186/s12879-019-4386-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
233 Simicic P, Grgic I, Santak M, Vince A, Lepej SZ. Frequency of baseline NS5A resistance-associated substitutions in patients infected with genotype 1 of hepatitis C virus in Croatia. Microb Pathog 2019;136:103694. [PMID: 31446041 DOI: 10.1016/j.micpath.2019.103694] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
234 Ren J, Ojeda I, Patel M, Johnson ME, Lee H. Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease. Bioorg Med Chem Lett 2019;29:2349-53. [PMID: 31201062 DOI: 10.1016/j.bmcl.2019.06.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
235 Chen JJ, Tung HD, Lee PL, Kuo HT, Sheu MJ, Cheng CT, Chuang TW, Kao HJ, Lu NM, Wu LC, Lee C. High prevalence of genotype 6 hepatitis C virus infection in Southern Taiwan using Abbott genotype assays. J Formos Med Assoc 2020;119:413-9. [PMID: 31420113 DOI: 10.1016/j.jfma.2019.07.021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
236 Tagnouokam-Ngoupo PA, Ngoufack MN, Kenmoe S, Lissock SF, Amougou-Atsama M, Banai R, Ngono L, Njouom R. Hepatitis C virus genotyping based on Core and NS5B regions in Cameroonian patients. Virol J 2019;16:101. [PMID: 31399103 DOI: 10.1186/s12985-019-1214-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
237 Brady Z, Stoykova Z. Hepatitis C virus genotype analysis in patients with chronic hepatitis in North Eastern Bulgaria. J Drug Assess. 2019;8:146-149. [PMID: 31552145 DOI: 10.1080/21556660.2019.1654484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
238 Han B, Martin R, Xu S, Parvangada A, Svarovskaia ES, Mo H, Dvory-Sobol H. Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-naïve subjects. Antiviral Res 2019;170:104574. [PMID: 31394118 DOI: 10.1016/j.antiviral.2019.104574] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
239 Peres-da-Silva A, Antunes D, Quintanilha Torres AL, Caffarena ER, Lampe E. Effects of the Q80K Polymorphism on the Physicochemical Properties of Hepatitis C Virus Subtype 1a NS3 Protease. Viruses 2019;11:E691. [PMID: 31366046 DOI: 10.3390/v11080691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
240 Cotter TG, Jensen DM. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther 2019;13:2565-77. [PMID: 31534310 DOI: 10.2147/DDDT.S172512] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
241 Childs-Kean LM, Brumwell NA, Lodl EF. Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C. Infect Drug Resist 2019;12:2259-68. [PMID: 31413603 DOI: 10.2147/IDR.S171338] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
242 Cuypers L, Thijssen M, Shakibzadeh A, Sabahi F, Ravanshad M, Pourkarim MR. Next-generation sequencing for the clinical management of hepatitis C virus infections: does one test fits all purposes? Crit Rev Clin Lab Sci 2019;56:420-34. [PMID: 31317801 DOI: 10.1080/10408363.2019.1637394] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
243 Paraskevis D, Stylianou DC, Hezka J, Stern Z, Oikonomopoulou M, Mamais I, Kostrikis LG; Cyprus PWID Network. HCV Phylogeography of the General Population and High-Risk Groups in Cyprus Identifies the Island as a Global Sink for and Source of Infection. Sci Rep 2019;9:10077. [PMID: 31296903 DOI: 10.1038/s41598-019-46552-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
244 Park S, Jackman JA, Cho N. Comparing the Membrane-Interaction Profiles of Two Antiviral Peptides: Insights into Structure–Function Relationship. Langmuir 2019;35:9934-43. [DOI: 10.1021/acs.langmuir.9b01052] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
245 Timm J, Kosovrasti K, Henes M, Leidner F, Hou S, Ali A, Kurt-yilmaz N, Schiffer CA. Molecular and structural mechanism of pan-genotypic HCV NS3/4A protease inhibition by glecaprevir.. [DOI: 10.1101/692392] [Reference Citation Analysis]
246 Bellocchi MC, Aragri M, Carioti L, Fabeni L, Pipitone RM, Brancaccio G, Sorbo MC, Barbaliscia S, Di Maio VC, Bronte F, Grimaudo S, Mazzucco W, Frigeri F, Cantone M, Pinto A, Perno CF, Craxì A, Gaeta GB, Di Marco V, Ceccherini-Silberstein F. NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients. Cells 2019;8:E666. [PMID: 31269695 DOI: 10.3390/cells8070666] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
247 Khedhiri M, Ghedira K, Chouikha A, Touzi H, Sadraoui A, Hammemi W, Triki H. Tracing the epidemic history of hepatitis C virus genotype 1b in Tunisia and in the world, using a Bayesian coalescent approach. Infect Genet Evol 2019;75:103944. [PMID: 31260787 DOI: 10.1016/j.meegid.2019.103944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
248 Fernández-Caso B, Fernández-Caballero JÁ, Chueca N, Rojo E, de Salazar A, García Buey L, Cardeñoso L, García F. Infection with multiple hepatitis C virus genotypes detected using commercial tests should be confirmed using next generation sequencing. Sci Rep 2019;9:9264. [PMID: 31239457 DOI: 10.1038/s41598-019-42605-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
249 Peiffer KH, Kuhnhenn L, Stelzl E, Dietz J, Susser S, Tal AO, Finkelmeier F, Zuckerman E, Cornberg M, Barak M, Piazzolla V, Mangia A, Zeuzem S, Kessler HH, Vermehren J, Sarrazin C. Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras. J Clin Microbiol 2019;57:e00060-19. [PMID: 31043467 DOI: 10.1128/JCM.00060-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
250 Lioznov DA, Dunaeva NV, Chung NH, Gorchakova OV, Antonova TV. Chronic hepatitis C: modern condition of the problem. Nefrologiâ (St -Peterbg ) 2019;23:36-46. [DOI: 10.24884/1561-6274-2019-23-4-36-46] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
251 Darweesh SK, Elsaeed K, Omar H, El Raziky M, Elakel W, Elserafy M, Ismail SA, Gomaa AA, Mehrez M, El Kassas M, Abdullah M, Shaker MK, Esmat G, El Shazly Y, Doss W, Waked I. High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study. Expert Rev Gastroenterol Hepatol 2019;13:907-14. [PMID: 31173527 DOI: 10.1080/17474124.2019.1629287] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
252 Cheng YT, Cheng JS, Lin CH, Chen TH, Lee KC, Chang ML. Rheumatoid factor and immunoglobulin M mark hepatitis C-associated mixed cryoglobulinaemia: an 8-year prospective study. Clin Microbiol Infect. 2020;26:366-372. [PMID: 31229596 DOI: 10.1016/j.cmi.2019.06.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
253 Urbanowicz RA, Ball JK, Tarr AW. Cloning and Analysis of Authentic Patient-Derived HCV E1/E2 Glycoproteins. Methods Mol Biol 2019;1911:275-94. [PMID: 30593633 DOI: 10.1007/978-1-4939-8976-8_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
254 Li H, Zahid MN, Wang S, Shaw GM. Molecular Identification of Transmitted/Founder Hepatitis C Viruses and Their Progeny by Single Genome Sequencing. Methods Mol Biol 2019;1911:139-55. [PMID: 30593623 DOI: 10.1007/978-1-4939-8976-8_9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
255 Yong KSM, Her Z, Chen Q. Humanized Mouse Models for the Study of Hepatitis C and Host Interactions. Cells 2019;8:E604. [PMID: 31213010 DOI: 10.3390/cells8060604] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
256 Nii-Trebi NI, Brown CA, Osei YD, Ampofo WK, Nyarko AK. Core encoding sequences of Hepatitis C virus in Ghanaian blood donors are predominantly mosaics of different genotype 2 strains and cannot distinguish subtypes. BMC Infect Dis 2019;19:533. [PMID: 31208352 DOI: 10.1186/s12879-019-4155-4] [Reference Citation Analysis]
257 Nguyen T, Delaugerre C, Valantin MA, Amiel C, Netzer E, L'Yavanc T, Ohayon M, Israel G, Valin N, Day N, Kreplak G, Pialoux G, Calvez V, Molina JM, Marcelin AG, Todesco E. Uncommon Detection of Mixed HCV Genotype Infections in Recently Infected Men Who Have Sex with Men. Int J Antimicrob Agents 2019;54:513-7. [PMID: 31195120 DOI: 10.1016/j.ijantimicag.2019.06.001] [Reference Citation Analysis]
258 Bettaieb J, Chouikha A, Khedhiri M, Kharroubi G, Badreddine M, Bel Hadj Hmida N, Gharbi A, Hammemi W, Sadraoui A, Ben Yahia A, Meddeb Z, Ben Salah A, Triki H. Hepatitis C virus epidemiology in Central-West Tunisia: a population-based cross-sectional study. Arch Virol 2019;164:2243-53. [PMID: 31179516 DOI: 10.1007/s00705-019-04308-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
259 Oestringer BP, Bolivar JH, Claridge JK, Almanea L, Chipot C, Dehez F, Holzmann N, Schnell JR, Zitzmann N. Hepatitis C virus sequence divergence preserves p7 viroporin structural and dynamic features. Sci Rep 2019;9:8383. [PMID: 31182749 DOI: 10.1038/s41598-019-44413-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
260 Han Q, Fan X, Wang X, Wang Y, Deng H, Zhang X, Zhang K, Li N, Liu Z. High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting. Virol J 2019;16:74. [PMID: 31159813 DOI: 10.1186/s12985-019-1184-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
261 Banda DH, Perin PM, Brown RJP, Todt D, Solodenko W, Hoffmeyer P, Kumar Sahu K, Houghton M, Meuleman P, Müller R, Kirschning A, Pietschmann T. A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors. J Hepatol 2019;70:1082-92. [PMID: 30769006 DOI: 10.1016/j.jhep.2019.01.033] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
262 von Massow G, Garcia-Cehic D, Gregori J, Rodriguez-Frias F, Macià MD, Escarda A, Esteban JI, Quer J. Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype. Infect Drug Resist 2019;12:947-55. [PMID: 31118701 DOI: 10.2147/IDR.S195441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
263 Campione E, Dattola A, Di Prete M, Di Paolo D, Ferlosio A, Orlandi A, Bianchi L. Sofosbuvir induced leucocytoclasic vasculitis: a case report. BMC Dermatol 2019;19:6. [PMID: 31096980 DOI: 10.1186/s12895-019-0086-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
264 Lu G, Ou J, Sun Y, Wu L, Xu H, Zhang G, Li S. Natural recombination of equine hepacivirus subtype 1 within the NS5A and NS5B genes. Virology 2019;533:93-8. [PMID: 31136896 DOI: 10.1016/j.virol.2019.05.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
265 Chen M, Ma Y, Chen H, Dai J, Luo H, Jia M, Song Z. Complete genome sequencing and evolutionary analysis of HCV subtype 6xg from IDUs in Yunnan, China. PLoS One 2019;14:e0217010. [PMID: 31095618 DOI: 10.1371/journal.pone.0217010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
266 Nouhin J, Iwamoto M, Prak S, Dousset JP, Phon K, Heng S, Kerleguer A, Le Paih M, Dussart P, Maman D, Rouet F. Molecular epidemiology of hepatitis C virus in Cambodia during 2016-2017. Sci Rep 2019;9:7314. [PMID: 31086236 DOI: 10.1038/s41598-019-43785-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
267 Teimoori A, Ebrahimi S, Keshtkar N, Khaghani S, Salmanzadeh S, Ghafari S. Prevalence and genetic diversity of HCV among HIV-1 infected individuals living in Ahvaz, Iran. BMC Infect Dis 2019;19:389. [PMID: 31068133 DOI: 10.1186/s12879-019-4052-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
268 Wang M, Liao Q, Xu R, Song D, Huang J, You Q, Shan Z, Huang K, Rong X, Fu Y. Hepatitis C virus 3b strains in injection drug users in Guangdong Province, China, may have originated in Yunnan Province. Arch Virol 2019;164:1761-70. [DOI: 10.1007/s00705-019-04260-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
269 Sharafi H, Ghalamkari S, Hassanshahi A, Alavian SM. Pooled Prevalence of NS5A Resistance-Associated Substitutions in Chronic HCV Genotype 3 Infection: A Study Based on Deposited Sequences in GenBank. Microb Drug Resist 2019;25:1072-9. [PMID: 31021305 DOI: 10.1089/mdr.2018.0358] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
270 Ye M, Chen X, Wang Y, Duo L, Zhang C, Zheng YT. Identification of a New HCV Subtype 6xg Among Injection Drug Users in Kachin, Myanmar. Front Microbiol 2019;10:814. [PMID: 31057519 DOI: 10.3389/fmicb.2019.00814] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
271 Te H, Doucette K. Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant 2019;33. [DOI: 10.1111/ctr.13514] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
272 Lapa D, Garbuglia AR, Capobianchi MR, Del Porto P. Hepatitis C Virus Genetic Variability, Human Immune Response, and Genome Polymorphisms: Which Is the Interplay? Cells 2019;8:E305. [PMID: 30987134 DOI: 10.3390/cells8040305] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
273 Singer JB, Thomson EC, Hughes J, Aranday-Cortes E, McLauchlan J, da Silva Filipe A, Tong L, Manso CF, Gifford RJ, Robertson DL, Barnes E, Ansari MA, Mbisa JL, Bibby DF, Bradshaw D, Smith D. Interpreting Viral Deep Sequencing Data with GLUE. Viruses 2019;11:E323. [PMID: 30987147 DOI: 10.3390/v11040323] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
274 Wahid B, Naeem N, Altaf S, Ilyas N. Increasing Prevalence of Untypable and Mixed Genotypes of Hepatitis C Virus in Pakistan: Latest Trends in 2018. Viral Immunol 2019;32:192-4. [PMID: 30939104 DOI: 10.1089/vim.2018.0152] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
275 Navarro-de la Cruz D, Pérez-castro S, Trigo-daporta M, Aguilera-guirao A. Prevalence and distribution of hepatitis C virus genotypes in Galicia during the period 2000–2015. Enfermedades infecciosas y microbiologia clinica (English ed ) 2019;37:256-259. [DOI: 10.1016/j.eimce.2018.03.017] [Reference Citation Analysis]
276 Chub EV, Sivolobova GF, Netesov SV, Kochneva GV. Recombinant Variants of Hepatitis C Virus in Siberia. Mol Genet Microbiol Virol 2019;34:97-109. [DOI: 10.3103/s0891416819020034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
277 Weber J, Sahoo MK, Taylor N, Shi RZ, Pinsky BA. Evaluation of the Aptima HCV Quant Dx Assay Using Serum and Dried Blood Spots. J Clin Microbiol 2019;57:e00030-19. [PMID: 30760534 DOI: 10.1128/JCM.00030-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
278 Rivett L, Alexander G. Is the conquest of Hepatitis C imminent? Expert Rev Mol Med 2019;21:e3. [PMID: 30909984 DOI: 10.1017/erm.2019.3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
279 Venkatesan A, Prabhu Dass J F. Review on chemogenomic approaches towards hepatitis C viral targets. J Cell Biochem 2019;120:12167-81. [PMID: 30887580 DOI: 10.1002/jcb.28581] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
280 Costa VD, Delvaux N, Brandão-Mello CE, Nunes EP, de Sousa PSF, de Souza Rodrigues LLLX, Lampe E, do Amaral Mello FC. Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1. Clin Res Hepatol Gastroenterol 2019;43:700-6. [PMID: 30880098 DOI: 10.1016/j.clinre.2019.02.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
281 Coppola N, Alessio L, Onorato L, Sagnelli C, Macera M, Sagnelli E, Pisaturo M. Epidemiology and management of hepatitis C virus infections in immigrant populations. Infect Dis Poverty 2019;8:17. [PMID: 30871599 DOI: 10.1186/s40249-019-0528-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
282 Le Ngoc C, Tran Thi Thanh T, Tran Thi Lan P, Nguyen Mai T, Nguyen Hoa T, Nghiem My N, Le Van T, Le Manh H, Le Thanh P, Nguyen Van Vinh C, Thwaites G, Cooke G, Heilek GM, Shikuma C, Le T, Baker S, Rahman M; VIZIONS consortium. Differential prevalence and geographic distribution of hepatitis C virus genotypes in acute and chronic hepatitis C patients in Vietnam. PLoS One 2019;14:e0212734. [PMID: 30865664 DOI: 10.1371/journal.pone.0212734] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
283 Kao JH, Lin CY, Chuang WL, Cheng YY, Hu JY, Liang WK, Friebe P, Palmer S, Huang CS. Clinical evaluation of IntelliPlexTM HCV genotyping kit for hepatitis C virus genotyping. Diagn Microbiol Infect Dis 2019;94:344-8. [PMID: 30975461 DOI: 10.1016/j.diagmicrobio.2019.02.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
284 Petruzziello A, Loquercio G, Sabatino R, Balaban DV, Ullah Khan N, Piccirillo M, Rodrigo L, di Capua L, Guzzo A, Labonia F, Botti G. Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review. J Clin Lab Anal 2019;33:e22876. [PMID: 30843304 DOI: 10.1002/jcla.22876] [Reference Citation Analysis]
285 Petruzziello A, Loquercio G, Sabatino R, Balaban DV, Ullah Khan N, Piccirillo M, Rodrigo L, di Capua L, Guzzo A, Labonia F, Botti G. Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review. J Clin Lab Anal. 2019;33:e22876. [PMID: 30843304 DOI: 10.1002/jcla.22876] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
286 Ganova-Raeva L, Dimitrova Z, Alexiev I, Punkova L, Sue A, Xia GL, Gancheva A, Dimitrova R, Kostadinova A, Golkocheva-Markova E, Khudyakov Y. HCV transmission in high-risk communities in Bulgaria. PLoS One 2019;14:e0212350. [PMID: 30835739 DOI: 10.1371/journal.pone.0212350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
287 Wang B, Krüger L, Machnowska P, Eshetu A, Gunsenheimer-Bartmeyer B, Bremer V, Hauser A, Bannert N, Bock CT. Characterization of a hepatitis C virus genotype 1 divergent isolate from an HIV-1 coinfected individual in Germany assigned to a new subtype 1o. Virol J 2019;16:28. [PMID: 30832687 DOI: 10.1186/s12985-019-1135-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
288 Mettikanont P, Bunchorntavakul C, Reddy KR. Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection. Aliment Pharmacol Ther 2019;49:492-505. [PMID: 30687952 DOI: 10.1111/apt.15100] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
289 Bamford CG, Mclauchlan J. Comparative host genomics: how has human evolution affected our immune defence against hepatitis C virus? Future Virology 2019;14:125-128. [DOI: 10.2217/fvl-2019-0017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
290 Irshad M, Gupta P, Irshad K. Immunopathogenesis of Liver Injury During Hepatitis C Virus Infection. Viral Immunol 2019;32:112-20. [PMID: 30817236 DOI: 10.1089/vim.2018.0124] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
291 Cannon MD, Agarwal K, Dusheiko G. Hepatitis C: Treatment. Evidence-based Gastroenterology and Hepatology 4e 2019. [DOI: 10.1002/9781119211419.ch31] [Reference Citation Analysis]
292 Yabaji PM, Shankarkumar A, Shukla A, Bhatia S. Hepatitis C virus infection in a tertiary care hospital in Mumbai, India: Identification of a mixed and novel genotype. Indian J Med Microbiol 2018;36:352-6. [PMID: 30429386 DOI: 10.4103/ijmm.IJMM_18_221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
293 Selek MB, Baylan O, Karagöz E, Özyurt M. Changes in hepatitis C virus genotype distribution in chronic hepatitis C infection patients. Indian J Med Microbiol 2018;36:416-21. [PMID: 30429397 DOI: 10.4103/ijmm.IJMM_18_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
294 Hedskog C, Parhy B, Chang S, Zeuzem S, Moreno C, Shafran SD, Borgia SM, Asselah T, Alric L, Abergel A, Chen JJ, Collier J, Kapoor D, Hyland RH, Simmonds P, Mo H, Svarovskaia ES. Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV Classification. Open Forum Infect Dis 2019;6:ofz076. [PMID: 30949527 DOI: 10.1093/ofid/ofz076] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 15.7] [Reference Citation Analysis]
295 Petruzziello A, Sabatino R, Loquercio G, Guzzo A, Di Capua L, Labonia F, Cozzolino A, Azzaro R, Botti G. Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy. PLoS One 2019;14:e0212033. [PMID: 30785909 DOI: 10.1371/journal.pone.0212033] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
296 Bagaglio S, Messina E, Hasson H, Galli A, Uberti-Foppa C, Morsica G. Geographic Distribution of HCV-GT3 Subtypes and Naturally Occurring Resistance Associated Substitutions. Viruses 2019;11:E148. [PMID: 30754682 DOI: 10.3390/v11020148] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
297 Todesco E, Day N, Amiel C, Elaerts S, Schneider V, Roudière L, Hué S, Liotier JY, Bottero J, L'Yavanc T, Ohayon M, Gosset D, Thibault V, Surgers L, Chas J, Akhavan S, Velter A, Katlama C, Kreplak G, Marcelin AG, Valantin MA. High clustering of acute HCV infections and high rate of associated STIs among Parisian HIV-positive male patients. Int J Antimicrob Agents 2019;53:678-81. [PMID: 30742957 DOI: 10.1016/j.ijantimicag.2019.02.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
298 Velázquez-Moctezuma R, Galli A, Law M, Bukh J, Prentoe J. Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms. J Virol 2019;93:e01909-18. [PMID: 30487284 DOI: 10.1128/JVI.01909-18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
299 Walker A, Ennker KS, Kaiser R, Lübke N, Timm J. A pan-genotypic Hepatitis C Virus NS5A amplification method for reliable genotyping and resistance testing. J Clin Virol 2019;113:8-13. [PMID: 30771598 DOI: 10.1016/j.jcv.2019.01.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
300 Pietschmann T, Brown RJP. Hepatitis C Virus. Trends Microbiol. 2019;27:379-380. [PMID: 30709707 DOI: 10.1016/j.tim.2019.01.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
301 Marascio N, Quirino A, Barreca GS, Galati L, Costa C, Pisani V, Mazzitelli M, Matera G, Liberto MC, Focà A, Torti C. Discussion on critical points for a tailored therapy to cure hepatitis C virus infection. Clin Mol Hepatol 2019;25:30-6. [PMID: 30669818 DOI: 10.3350/cmh.2018.0061] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
302 Olmstead AD, Montoya V, Chui CK, Dong W, Joy JB, Tai V, Poon AFY, Nguyen T, Brumme CJ, Martinello M, Matthews GV, Richard Harrigan P, Dore GJ, Applegate TL, Grebely J, Howe AYM. A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections. Infect Genet Evol 2019;69:76-84. [PMID: 30654177 DOI: 10.1016/j.meegid.2019.01.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
303 Mahmoudvand S, Shokri S, Taherkhani R, Farshadpour F. Hepatitis C virus core protein modulates several signaling pathways involved in hepatocellular carcinoma. World J Gastroenterol 2019; 25(1): 42-58 [PMID: 30643357 DOI: 10.3748/wjg.v25.i1.42] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 37] [Article Influence: 11.7] [Reference Citation Analysis]
304 McNaughton AL, D'Arienzo V, Ansari MA, Lumley SF, Littlejohn M, Revill P, McKeating JA, Matthews PC. Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood. Gastroenterology 2019;156:384-99. [PMID: 30268787 DOI: 10.1053/j.gastro.2018.07.058] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 25.0] [Reference Citation Analysis]
305 Bailey JR, Barnes E, Cox AL. Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. Gastroenterology 2019;156:418-30. [PMID: 30268785 DOI: 10.1053/j.gastro.2018.08.060] [Cited by in Crossref: 116] [Cited by in F6Publishing: 117] [Article Influence: 38.7] [Reference Citation Analysis]
306 Chub EV, Sivolobova GF, Netesov SV, Kochneva GV. Recombinant variants of HCV in Siberia, Russia. Mol genet mikrobiol virusol 2019;37:64. [DOI: 10.17116/molgen20193702164] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
307 Goel A, Ahmed A, Waked I. Clinical Epidemiology of Hepatitis C Virus. Clinical Epidemiology of Chronic Liver Diseases 2019. [DOI: 10.1007/978-3-319-94355-8_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
308 Cottone C, Bhamidimarri KR. Evaluating CKD/ESRD patient with hepatitis C infection: How to interpret diagnostic testing and assess liver injury. Semin Dial 2019;32:119-26. [PMID: 30599462 DOI: 10.1111/sdi.12760] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
309 Soi V, Daifi C, Yee J, Adams E. Pathophysiology and Treatment of Hepatitis B and C Infections in Patients With End-Stage Renal Disease. Adv Chronic Kidney Dis 2019;26:41-50. [PMID: 30876616 DOI: 10.1053/j.ackd.2018.10.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
310 Zheng Y, Shimamoto S, Maruno T, Kobayashi Y, Matsuura Y, Kawahara K, Yoshida T, Ohkubo T. N-terminal HCV core protein fragment decreases 20S proteasome activity in the presence of PA28γ. Biochem Biophys Res Commun 2019;509:590-5. [PMID: 30602418 DOI: 10.1016/j.bbrc.2018.12.167] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
311 Rance E, Tanner JE, Alfieri C. Genomic-Scale Interaction Involving Complementary Sequences in the Hepatitis C Virus 5'UTR Domain IIa and the RNA-Dependent RNA Polymerase Coding Region Promotes Efficient Virus Replication. Viruses 2018;11:E17. [PMID: 30597844 DOI: 10.3390/v11010017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
312 Husic-Selimovic A, Sofic A, Jahic E, Prohic D, Merhemic Z. Impact of Different Sources of Infection on Therapy Response in Chronic Hepatitis C. Med Arch 2018;72:182-6. [PMID: 30061763 DOI: 10.5455/medarh.2018.72.182-186] [Reference Citation Analysis]
313 Ezeilo MC, Engwa GA, Iroha RI, Odimegwu DN. High Anti-HCV Seroprevalence and Low Performance of ICT Strip in Diagnosing Hepatitis C Virus Infection in Children in Enugu Metropolis. TOVJ 2018;12:149-56. [DOI: 10.2174/1874357901812010149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
314 Singer JB, Thomson EC, McLauchlan J, Hughes J, Gifford RJ. GLUE: a flexible software system for virus sequence data. BMC Bioinformatics 2018;19:532. [PMID: 30563445 DOI: 10.1186/s12859-018-2459-9] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 15.0] [Reference Citation Analysis]
315 Sharma G, Raheja H, Das S. Hepatitis C virus: Enslavement of host factors. IUBMB Life 2018;70:41-9. [PMID: 29281185 DOI: 10.1002/iub.1702] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
316 Muljono DH. Effective drugs on the road to HCV elimination and a therapeutic gap to close. Lancet Gastroenterol Hepatol 2019;4:86-8. [PMID: 30555049 DOI: 10.1016/S2468-1253(18)30417-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
317 Jafri SM, Gordon SC. Epidemiology of Hepatitis C. Clin Liver Dis (Hoboken) 2018;12:140-2. [PMID: 30988931 DOI: 10.1002/cld.783] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
318 Spearman CW, Sonderup MW. Direct-acting antiviral therapy in sub-Saharan Africa. Lancet Gastroenterol Hepatol 2019;4:85-6. [PMID: 30552057 DOI: 10.1016/S2468-1253(18)30413-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
319 Kumar A, Rajput MK, Paliwal D, Yadav A, Chhabra R, Singh S. Genotyping & diagnostic methods for hepatitis C virus: A need of low-resource countries. Indian J Med Res 2018;147:445-55. [PMID: 30082568 DOI: 10.4103/ijmr.IJMR_1850_16] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
320 Bouacida L, Suin V, Hutse V, Boudewijns M, Cartuyvels R, Debaisieux L, De Laere E, Hallin M, Hougardy N, Lagrou K, Oris E, Padalko E, Reynders M, Roussel G, Senterre JM, Stalpaert M, Ursi D, Vael C, Vaira D, Van Acker J, Verstrepen W, Van Gucht S, Kabamba B, Quoilin S, Muyldermans G. Distribution of HCV genotypes in Belgium from 2008 to 2015. PLoS One 2018;13:e0207584. [PMID: 30517127 DOI: 10.1371/journal.pone.0207584] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
321 Chen M, Zheng F, Yuan G, Duan X, Rong L, Liu J, Feng S, Wang Z, Wang M, Feng Y, Zhou Q, Li J, Deng K, Li C, Xia J, Rao G, Zhou Y, Fu Y, Li YP. Development of an Infectious Cell Culture System for Hepatitis C Virus Genotype 6a Clinical Isolate Using a Novel Strategy and Its Sensitivity to Direct-Acting Antivirals. Front Microbiol 2018;9:2950. [PMID: 30564209 DOI: 10.3389/fmicb.2018.02950] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
322 Kalafateli M, Buzzetti E, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Pharmacological interventions for acute hepatitis C infection. Cochrane Database Syst Rev 2018;12:CD011644. [PMID: 30521693 DOI: 10.1002/14651858.CD011644.pub3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
323 Ashraf MU, Iman K, Khalid MF, Salman HM, Shafi T, Rafi M, Javaid N, Hussain R, Ahmad F, Shahzad-Ul-Hussan S, Mirza S, Shafiq M, Afzal S, Hamera S, Anwar S, Qazi R, Idrees M, Qureshi SA, Chaudhary SU. Evolution of efficacious pangenotypic hepatitis C virus therapies. Med Res Rev 2019;39:1091-136. [PMID: 30506705 DOI: 10.1002/med.21554] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
324 Chaturvedi N, Svarovskaia ES, Mo H, Osinusi AO, Brainard DM, Subramanian GM, Mchutchison JG, Zeuzem S, Fellay J. Pervasive Adaptation of Hepatitis C Virus to Interferon Lambda Polymorphism Across Multiple Genotypes.. [DOI: 10.1101/484071] [Reference Citation Analysis]
325 Assih M, Ouattara AK, Diarra B, Yonli AT, Compaore TR, Obiri-Yeboah D, Djigma FW, Karou S, Simpore J. Genetic diversity of hepatitis viruses in West-African countries from 1996 to 2018. World J Hepatol 2018; 10(11): 807-821 [PMID: 30533182 DOI: 10.4254/wjh.v10.i11.807] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
326 Underwood AP, Walker MR, Brasher NA, Eltahla AA, Maher L, Luciani F, Lloyd AR, Bull RA. Understanding the Determinants of BnAb Induction in Acute HCV Infection. Viruses 2018;10:E659. [PMID: 30469363 DOI: 10.3390/v10110659] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
327 San SN, Matsumoto J, Saito Y, Koike M, Sakaue H, Kato Y, Fujiyoshi M, Ariyoshi N, Yamada H. Minor contribution of CYP3A5 to the metabolism of hepatitis C protease inhibitor paritaprevir in vitro. Xenobiotica 2019;49:935-44. [PMID: 30227770 DOI: 10.1080/00498254.2018.1524947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
328 Iwona BO, Karol P, Kamila CC, Pollak A, Hanna B, Agnieszka P, Andrzej H, Kosińska J, Płoski R, Tomasz L, Marek R. Next-generation sequencing analysis of new genotypes appearing during antiviral treatment of chronic hepatitis C reveals that these are selected from pre-existing minor strains. J Gen Virol 2018;99:1633-42. [PMID: 30394872 DOI: 10.1099/jgv.0.001160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
329 Caporossi A, Kulkarni O, Blum M, Leroy V, Morand P, Larrat S, François O. Using high-throughput sequencing for investigating intra-host hepatitis C evolution over long retrospective periods. Infect Genet Evol 2019;67:136-44. [PMID: 30395998 DOI: 10.1016/j.meegid.2018.11.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
330 Lu J, Zhang L, Xu X, Chen Y, Zhou Y, Zhang Z, Fu G, Chen G. Hepatitis C virus genotype diversity and distribution among methadone maintenance treatment patients in Jiangsu, China. Drug Alcohol Depend 2019;194:101-6. [PMID: 30419403 DOI: 10.1016/j.drugalcdep.2018.09.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
331 Asselah T, Lee SS, Yao BB, Nguyen T, Wong F, Mahomed A, Lim SG, Abergel A, Sasadeusz J, Gane E, Zadeikis N, Schnell G, Zhang Z, Porcalla A, Mensa FJ, Nguyen K. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. Lancet Gastroenterol Hepatol. 2019;4:45-51. [PMID: 30393106 DOI: 10.1016/s2468-1253(18)30341-8] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 10.5] [Reference Citation Analysis]
332 Minosse C, Selleri M, Giombini E, Bartolini B, Capobianchi MR, Cerilli S, Loiacono L, Taibi C, D'Offizi G, McPhee F, Garbuglia A. Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents. Infect Drug Resist 2018;11:2117-27. [PMID: 30464554 DOI: 10.2147/IDR.S179158] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
333 Yang R, Wei L. Profile of the VERSANT HCV genotype 2.0 assay. Expert Rev Mol Diagn 2018;18:995-1004. [PMID: 30372355 DOI: 10.1080/14737159.2018.1541740] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
334 Marohnic CC, Birkenmeyer LG, Bogdan MF, Frias EC, Otis KS, Palafox MAP, McSherry TD, Gregory SD, Zhao C, Gutierrez RA, Prostko JC, Muerhoff AS. Engineering of the hepatitis C virus helicase for enhanced seroreactivity. J Virol Methods 2019;264:11-7. [PMID: 30381240 DOI: 10.1016/j.jviromet.2018.10.019] [Reference Citation Analysis]
335 Vermehren J, Park JS, Jacobson IM, Zeuzem S. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol 2018;69:1178-87. [PMID: 30006068 DOI: 10.1016/j.jhep.2018.07.002] [Cited by in Crossref: 74] [Cited by in F6Publishing: 78] [Article Influence: 18.5] [Reference Citation Analysis]
336 Babady E. Molecular Monitoring of Viral Infections. Advances in Molecular Pathology 2018;1:65-80. [DOI: 10.1016/j.yamp.2018.06.006] [Reference Citation Analysis]
337 Youngberg S, Brandt E, Barve A, Machineni S, Jones CT, Dabovic K, Jones CL, Colvin RA. A first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending oral dose study to assess the safety, tolerability, and pharmacokinetics of BZF961 with and without ritonavir in healthy adult volunteers. J Drug Assess 2018;7:66-74. [PMID: 30370176 DOI: 10.1080/21556660.2018.1535438] [Reference Citation Analysis]
338 Dinu S, Țârdei G, Ceaușu E, Florescu SA, Micu L, Ecobici AM, Mihăilă M, Oprișan G. Detection of anti-protease inhibitors resistance mutations in HCV strains infecting treatment-naïve chronic patients from Romania. Revista Romana de Medicina de Laborator 2018;26:443-9. [DOI: 10.2478/rrlm-2018-0029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
339 Tavares RCF, de Castro Amaral Feldner AC, Pinho JRR, de Mello Malta F, Carvalho-Filho RJ, Santana RAF, de Castro VFD, Dastoli GTF, Lima JC, Ferraz MLCG. Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus. Infect Drug Resist 2018;11:1993-2000. [PMID: 30464541 DOI: 10.2147/IDR.S169512] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
340 Schlottau K, Fereidouni S, Beer M, Hoffmann B. Molecular identification and characterization of nonprimate hepaciviruses in equines. Arch Virol 2019;164:391-400. [PMID: 30361815 DOI: 10.1007/s00705-018-4077-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
341 Han AX, Parker E, Scholer F, Maurer-stroh S, Russell CA. Phylogenetic Clustering by Linear Integer Programming (PhyCLIP).. [DOI: 10.1101/446716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
342 Du G, Li X, Musa TH, Ji Y, Wu B, He Y, Ni Q, Su L, Li W, Ge Y. The nationwide distribution and trends of hepatitis C virus genotypes in mainland China. J Med Virol 2019;91:401-10. [PMID: 30192393 DOI: 10.1002/jmv.25311] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
343 Omran D, Alboraie M, Zayed RA, Wifi MN, Naguib M, Eltabbakh M, Abdellah M, Sherief AF, Maklad S, Eldemellawy HH, Saad OK, Khamiss DM, El Kassas M. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol 2018; 24(38): 4330-4340 [PMID: 30344418 DOI: 10.3748/wjg.v24.i38.4330] [Cited by in CrossRef: 83] [Cited by in F6Publishing: 79] [Article Influence: 20.8] [Reference Citation Analysis]
344 Warkad SD, Nimse SB, Song KS, Kim T. HCV Detection, Discrimination, and Genotyping Technologies. Sensors (Basel) 2018;18:E3423. [PMID: 30322029 DOI: 10.3390/s18103423] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
345 Perales C. Quasispecies dynamics and clinical significance of hepatitis C virus (HCV) antiviral resistance. Int J Antimicrob Agents 2020;56:105562. [PMID: 30315919 DOI: 10.1016/j.ijantimicag.2018.10.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
346 Lohmann V. Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development. Med Microbiol Immunol 2019;208:3-24. [PMID: 30298360 DOI: 10.1007/s00430-018-0566-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
347 Schnell G, Krishnan P, Tripathi R, Beyer J, Reisch T, Irvin M, Dekhtyar T, Lu L, Ng TI, Xie W, Pilot-Matias T, Collins C. Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir. PLoS One 2018;13:e0205186. [PMID: 30286205 DOI: 10.1371/journal.pone.0205186] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
348 Wei L, Omata M, Lim Y, Xie Q, Hou JL, Jia J, Hedskog C, Martin R, Doehle B, Yang J, De-oertel S, Massetto B, Kersey K, Brainard DM, Svarovskaia E, Mo H, Han K, Mizokami M, Duan Z. HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China. Antiviral Research 2018;158:178-84. [DOI: 10.1016/j.antiviral.2018.08.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
349 Deming P. Hepatitis C virus infection. J Am Coll Clin Pharm 2018;1:46-49. [DOI: 10.1002/jac5.1034] [Reference Citation Analysis]
350 Hong CM, Liu CH, Su TH, Yang HC, Chen PJ, Chen YW, Kao JH, Liu CJ. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data. J Microbiol Immunol Infect 2020;53:569-77. [PMID: 30316726 DOI: 10.1016/j.jmii.2018.09.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
351 Krishnan P, Pilot-Matias T, Schnell G, Tripathi R, Ng TI, Reisch T, Beyer J, Dekhtyar T, Irvin M, Xie W, Larsen L, Mensa FJ, Collins C. Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials. Antimicrob Agents Chemother 2018;62:e01249-18. [PMID: 30061289 DOI: 10.1128/AAC.01249-18] [Cited by in Crossref: 48] [Cited by in F6Publishing: 58] [Article Influence: 12.0] [Reference Citation Analysis]
352 Kahyesh-Esfandiary R, Sadigh ZA, Esghaei M, Bastani MN, Donyavi T, Najafi A, Fakhim A, Bokharaei-Salim F. Detection of HCV genome in peripheral blood mononuclear cells of Iranian seropositive and HCV RNA negative in plasma of patients with beta-thalassemia major: Occult HCV infection. J Med Virol. 2019;91:107-114. [PMID: 30091793 DOI: 10.1002/jmv.25279] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
353 Andrade E, Rocha D, Fontana-Maurell M, Costa E, Ribeiro M, de Godoy DT, Ferreira AGP, Tanuri A, Alvarez P, Brindeiro R. One-step real-time PCR assay for detection and quantification of RNA HCV to monitor patients under treatment in Brazil. Braz J Infect Dis 2018;22:418-23. [PMID: 30243981 DOI: 10.1016/j.bjid.2018.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
354 Knight LL, Wagner K, Leyva Y, Bruce VR, White KAM, Talamantes YS, Price B, Page K, Carvour ML. Talking About Hepatitis C: FAQs From Young Adults Who Inject Drugs. Health Promot Pract 2018;19:815-22. [PMID: 30227752 DOI: 10.1177/1524839918799455] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
355 Nguyen T, Akhavan S, Caby F, Bonyhay L, Larrouy L, Gervais A, Lebray P, Poynard T, Calmus Y, Simon A, Valantin MA, Calvez V, Marcelin AG, Todesco E. Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing. Int J Antimicrob Agents 2019;53:80-3. [PMID: 30236959 DOI: 10.1016/j.ijantimicag.2018.09.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
356 Yeşilbağ K, Baechlein C, Kadiroğlu B, Baldan Toker E, Alpay G, Becher P. Presence of bovine hepacivirus in Turkish cattle. Vet Microbiol 2018;225:1-5. [PMID: 30322519 DOI: 10.1016/j.vetmic.2018.09.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
357 Soria ME, Gregori J, Chen Q, García-Cehic D, Llorens M, de Ávila AI, Beach NM, Domingo E, Rodríguez-Frías F, Buti M, Esteban R, Esteban JI, Quer J, Perales C. Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus. BMC Infect Dis 2018;18:446. [PMID: 30176817 DOI: 10.1186/s12879-018-3356-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
358 Javed F, Manzoor S. HCV non-structural NS4A protein of genotype 3a induces mitochondria mediated death by activating Bax and the caspase cascade. Microb Pathog 2018;124:346-55. [PMID: 30179714 DOI: 10.1016/j.micpath.2018.08.065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
359 Ng TI, Pilot-Matias T, Tripathi R, Schnell G, Krishnan P, Reisch T, Beyer J, Dekhtyar T, Irvin M, Lu L, Asatryan A, Campbell A, Yao B, Lovell S, Mensa F, Lawitz EJ, Kort J, Collins C. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection. Viruses 2018;10:E462. [PMID: 30154359 DOI: 10.3390/v10090462] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
360 Matthew AN, Leidner F, Newton A, Petropoulos CJ, Huang W, Ali A, KurtYilmaz N, Schiffer CA. Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease. Structure 2018;26:1360-1372.e5. [PMID: 30146168 DOI: 10.1016/j.str.2018.07.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
361 Palladino C, Ezeonwumelu IJ, Marcelino R, Briz V, Moranguinho I, Serejo F, Velosa JF, Marinho RT, Borrego P, Taveira N. Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. Sci Rep. 2018;8:12266. [PMID: 30116054 DOI: 10.1038/s41598-018-30528-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
362 Sedeno-Monge V, Vallejo-Ruiz V, Sosa-Jurado F, Santos-Lopez G. Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma. J Biosci 2017;42:509-21. [PMID: 29358564 DOI: 10.1007/s12038-017-9695-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
363 Sagnelli E, Starace M, Minichini C, Pisaturo M, Macera M, Sagnelli C, Coppola N. Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure. Infection 2018;46:761-83. [DOI: 10.1007/s15010-018-1188-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
364 Niebel M, Singer JB, Nickbakhsh S, Gifford RJ, Thomson EC. Hepatitis C and the absence of genomic data in low-income countries: a barrier on the road to elimination? Lancet Gastroenterol Hepatol 2017;2:700-1. [PMID: 28895545 DOI: 10.1016/S2468-1253(17)30257-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
365 Zhou S, Williford SE, McGivern DR, Burch CL, Hu F, Benzine T, Ingravallo P, Asante-Appiah E, Howe AYM, Swanstrom R, Lemon SM. Evolutionary pathways to NS5A inhibitor resistance in genotype 1 hepatitis C virus. Antiviral Res 2018;158:45-51. [PMID: 30081054 DOI: 10.1016/j.antiviral.2018.07.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
366 Kinchen VJ, Bailey JR. Defining Breadth of Hepatitis C Virus Neutralization. Front Immunol 2018;9:1703. [PMID: 30116237 DOI: 10.3389/fimmu.2018.01703] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
367 Lanini S, Pisapia R, Capobianchi MR, Ippolito G. Global epidemiology of viral hepatitis and national needs for complete control. Expert Rev Anti Infect Ther 2018;16:625-39. [PMID: 30067107 DOI: 10.1080/14787210.2018.1505503] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
368 Iveren WN. Genotypic variation, demographic characteristics and risk factors of hepatitis C virus in Scotland. J Public Health Epidemiol 2018;10:241-250. [DOI: 10.5897/jphe2018.1031] [Reference Citation Analysis]
369 Ramirez S, Bukh J. Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies. Antiviral Res 2018;158:264-87. [PMID: 30059723 DOI: 10.1016/j.antiviral.2018.07.014] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
370 Humes D, Ramirez S, Jensen TB, Li YP, Gottwein JM, Bukh J. Recombinant hepatitis C virus genotype 5a infectious cell culture systems expressing minimal JFH1 NS5B sequences permit polymerase inhibitor studies. Virology 2018;522:177-92. [PMID: 30032031 DOI: 10.1016/j.virol.2018.05.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
371 Dikopoulos N, Backhus J, Dollinger M. [The news in hepatitis C therapy]. MMW Fortschr Med 2017;159:43-52. [PMID: 29086258 DOI: 10.1007/s15006-017-9595-4] [Reference Citation Analysis]
372 Warkad SD, Nimse SB, Song KS, Chantratita W, Pongthanapisith V, Nawale LU, Kim T. Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples. Virol J 2018;15:107. [PMID: 29996859 DOI: 10.1186/s12985-018-1017-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
373 Knops E, Sierra S, Kalaghatgi P, Heger E, Kaiser R, Kalinina OV. Epistatic Interactions in NS5A of Hepatitis C Virus Suggest Drug Resistance Mechanisms. Genes (Basel) 2018;9:E343. [PMID: 29986475 DOI: 10.3390/genes9070343] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
374 Schlottau K, Wernike K, Forth L, Holsteg M, Höper D, Beer M, Hoffmann B. Presence of two different bovine hepacivirus clusters in Germany. Transbound Emerg Dis 2018;65:1705-11. [PMID: 29971937 DOI: 10.1111/tbed.12930] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
375 Borgia SM, Hedskog C, Parhy B, Hyland RH, Stamm LM, Brainard DM, Subramanian MG, Mchutchison JG, Mo H, Svarovskaia E, Shafran SD. Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. The Journal of Infectious Diseases 2018;218:1722-9. [DOI: 10.1093/infdis/jiy401] [Cited by in Crossref: 143] [Cited by in F6Publishing: 147] [Article Influence: 35.8] [Reference Citation Analysis]
376 Shoukry NH. Hepatitis C Vaccines, Antibodies, and T Cells. Front Immunol 2018;9:1480. [PMID: 30002657 DOI: 10.3389/fimmu.2018.01480] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 12.3] [Reference Citation Analysis]
377 Cowton VM, Singer JB, Gifford RJ, Patel AH. Predicting the Effectiveness of Hepatitis C Virus Neutralizing Antibodies by Bioinformatic Analysis of Conserved Epitope Residues Using Public Sequence Data. Front Immunol 2018;9:1470. [PMID: 30013555 DOI: 10.3389/fimmu.2018.01470] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
378 Navarro-de la Cruz D, Pérez-Castro S, Trigo-Daporta M, Aguilera-Guirao A. Prevalence and distribution of hepatitis C virus genotypes in Galicia during the period 2000-2015. Enferm Infecc Microbiol Clin (Engl Ed) 2019;37:256-9. [PMID: 29759421 DOI: 10.1016/j.eimc.2018.03.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
379 Shahid I, Ibrahim MM, Nawaz MU, Imam MT, Almalki WH. Resistance-Associated Substitutions/Variants Correlate to Therapeutic Outcomes of Novel Direct-Acting Antivirals in Different HCV Genotype Treated Individuals. Genotyping 2018. [DOI: 10.5772/intechopen.76395] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
380 D'Angelo P, Jaspe RC, Loureiro CL, Gutiérrez C, Sulbarán MZ, Sulbarán Y, Toro F, Pujol FH. Performance of molecular methods for identification of unusual subtypes of hepatitis C virus genotype 2. Biomedica 2018;38:282-8. [PMID: 30184351 DOI: 10.7705/biomedica.v38i0.3864] [Reference Citation Analysis]
381 Shahnazarian V, Ramai D, Reddy M, Mohanty S. Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges. Ann Gastroenterol 2018;31:541-51. [PMID: 30174390 DOI: 10.20524/aog.2018.0281] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
382 Huang K, Chen J, Xu R, Jiang X, Ma X, Jia M, Wang M, Huang J, Liao Q, Shan Z, Dailey C, Song X, Lu L, Li C, Rong X, Zhang M, Fu Y. Molecular evolution of hepatitis C virus in China: A nationwide study. Virology 2018;516:210-8. [PMID: 29407379 DOI: 10.1016/j.virol.2018.01.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
383 Ružić M, Pellicano R, Fabri M, Luzza F, Boccuto L, Brkić S, Abenavoli L. Hepatitis C virus-induced hepatocellular carcinoma: a narrative review. Panminerva Med 2018;60:185-91. [PMID: 29856183 DOI: 10.23736/S0031-0808.18.03472-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
384 Oberoi RK, Zhao W, Sidhu DS, Viani RM, Trinh R, Liu W. A Phase 1 Study to Evaluate the Effect of Crushing, Cutting Into Half, or Grinding of Glecaprevir/Pibrentasvir Tablets on Exposures in Healthy Subjects. Journal of Pharmaceutical Sciences 2018;107:1724-30. [DOI: 10.1016/j.xphs.2018.02.015] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
385 Pedersen MS, Fahnøe U, Hansen TA, Pedersen AG, Jenssen H, Bukh J, Schønning K. A near full-length open reading frame next generation sequencing assay for genotyping and identification of resistance-associated variants in hepatitis C virus. J Clin Virol 2018;105:49-56. [PMID: 29886373 DOI: 10.1016/j.jcv.2018.05.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
386 Jamil Z, Waheed Y, Malik M, Durrani AA. Effect of Sofosbuvir plus Ribavirin therapy on hepatitis C patients in Pakistan: a retrospective study. PeerJ 2018;6:e4853. [PMID: 29844992 DOI: 10.7717/peerj.4853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
387 Guest JD, Pierce BG. Computational Modeling of Hepatitis C Virus Envelope Glycoprotein Structure and Recognition. Front Immunol 2018;9:1117. [PMID: 29892287 DOI: 10.3389/fimmu.2018.01117] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
388 Culasso ACA, Monzani MC, Baré P, Campos RH. Evolutionary dynamics of Hepatitis C virus in a chronic HIV co-infected patient and its correlation with the immune status. Infect Genet Evol 2018;63:30-8. [PMID: 29733983 DOI: 10.1016/j.meegid.2018.05.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
389 Hezode C, Reau N, Svarovskaia ES, Doehle BP, Shanmugam R, Dvory-Sobol H, Hedskog C, McNally J, Osinusi A, Brainard DM, Miller MD, Mo H, Roberts SK, O'Leary JG, Shafran SD, Zeuzem S. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J Hepatol 2018;68:895-903. [PMID: 29221887 DOI: 10.1016/j.jhep.2017.11.032] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 17.8] [Reference Citation Analysis]
390 Forni D, Cagliani R, Pontremoli C, Pozzoli U, Vertemara J, De Gioia L, Clerici M, Sironi M. Evolutionary Analysis Provides Insight Into the Origin and Adaptation of HCV. Front Microbiol 2018;9:854. [PMID: 29765366 DOI: 10.3389/fmicb.2018.00854] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
391 Al-Kubaisy W, Daud S, Al-Kubaisi MW, Al-Kubaisi OW, Abdullah NN. Maternal hepatitis C (HCV) infection and Anti-D immunoglobulin therapy: study testing antibodies, RNA and Genotype of HCV in Baghdad. J Matern Fetal Neonatal Med 2019;32:3464-9. [PMID: 29656685 DOI: 10.1080/14767058.2018.1465557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
392 Dustin LB. Innate and Adaptive Immune Responses in Chronic HCV Infection. Curr Drug Targets 2017;18:826-43. [PMID: 26302811 DOI: 10.2174/1389450116666150825110532] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 8.8] [Reference Citation Analysis]
393 Kinchen VJ, Cox AL, Bailey JR. Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine? Trends Microbiol 2018;26:854-64. [PMID: 29703495 DOI: 10.1016/j.tim.2018.04.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
394 Uribe-Noguez LA, Ocaña-Mondragón A, Mata-Marín JA, Gómez-Torres ME, Ribas-Aparicio RM, de la Luz Martínez-Rodríguez M. Presence of rare hepatitis C virus subtypes, 2j, 2k, and 2r in Mexico City as identified by sequencing. J Med Virol 2018;90:1277-82. [PMID: 29508903 DOI: 10.1002/jmv.25070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
395 Ansari MA, Aranday-cortes E, Ip CL, Filipe ADS, Hin LS, Bamford CGG, Bonsall D, Trebes A, Piazza P, Sreenu V, Cowton VM, Hudson E, Bowden R, Patel AH, Foster GR, Irving WL, Agarwal K, Thomson EC, Simmonds P, Klenerman P, Holmes C, Barnes E, Spencer CC, Mclauchlan J, Pedergnana V, STOP-HCV Consortium. Interferon lambda 4 impacts broadly on hepatitis C virus diversity.. [DOI: 10.1101/305151] [Reference Citation Analysis]
396 Tarragô AM, Pereira GL, Victória FDS, Marie AMA, Victória MB. Sofosbuvir and daclatasvir combination therapy for current hepatitis C virus genotype 4 achieves SVR: a case report of HCV genotype 4 from the Amazon. Rev Soc Bras Med Trop 2017;50:861-3. [PMID: 29340469 DOI: 10.1590/0037-8682-0094-2017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
397 Gu J, Hardy J, Boo I, Vietheer P, McCaffrey K, Alhammad Y, Chopra A, Gaudieri S, Poumbourios P, Coulibaly F, Drummer HE. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes. J Virol 2018;92:e02066-17. [PMID: 29467319 DOI: 10.1128/JVI.02066-17] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
398 Gayam V, Khalid M, Mandal AK, Hussain MR, Mukhtar O, Gill A, Garlapati P, Shrestha B, Guss D, Sherigar J, Mansour M, Mohanty S. Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting. Gastroenterology Res 2018;11:130-7. [PMID: 29707080 DOI: 10.14740/gr999w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
399 Gottwein JM, Pham LV, Mikkelsen LS, Ghanem L, Ramirez S, Scheel TKH, Carlsen THR, Bukh J. Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants. Gastroenterology 2018;154:1435-48. [PMID: 29274866 DOI: 10.1053/j.gastro.2017.12.015] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 17.0] [Reference Citation Analysis]
400 Kanda T. Interferon-Free Treatment for Chronic Hepatitis C in Japan. Nichidai Igaku Zasshi 2018;77:123-125. [DOI: 10.4264/numa.77.2_123] [Reference Citation Analysis]
401 Li W, Xi L, Cai Q, Kang Y, Zeng Q, Ding R, Sun C, Shang J. Changes in the distribution of hepatitis C virus genotypes and their association with shifts in transmission routes in Henan, China. J Public Health 2018;26:157-162. [DOI: 10.1007/s10389-017-0845-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
402 Asselah T, Hassanein T, Waked I, Mansouri A, Dusheiko G, Gane E. Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6. J Hepatol 2018;68:814-26. [PMID: 29229584 DOI: 10.1016/j.jhep.2017.11.037] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
403 Wu N, Zhang P, Liu W, Wang X. Sogatella furcifera hepe-like virus: First member of a novel Hepeviridae clade identified in an insect. Virus Res 2018;250:81-6. [PMID: 29605729 DOI: 10.1016/j.virusres.2018.03.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
404 Wijesundara DK, Gummow J, Li Y, Yu W, Quah BJ, Ranasinghe C, Torresi J, Gowans EJ, Grubor-Bauk B. Induction of Genotype Cross-Reactive, Hepatitis C Virus-Specific, Cell-Mediated Immunity in DNA-Vaccinated Mice. J Virol 2018;92:e02133-17. [PMID: 29437963 DOI: 10.1128/JVI.02133-17] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
405 Pfaender S, Helfritz FA, Siddharta A, Todt D, Behrendt P, Heyden J, Riebesehl N, Willmann W, Steinmann J, Münch J, Ciesek S, Steinmann E. Environmental Stability and Infectivity of Hepatitis C Virus (HCV) in Different Human Body Fluids. Front Microbiol 2018;9:504. [PMID: 29636728 DOI: 10.3389/fmicb.2018.00504] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
406 Oyaro M, Wylie J, Chen CY, Ondondo RO, Kramvis A. Human immunodeficiency virus infection predictors and genetic diversity of hepatitis B virus and hepatitis C virus co-infections among drug users in three major Kenyan cities. South Afr J HIV Med 2018;19:737. [PMID: 29707384 DOI: 10.4102/sajhivmed.v19i1.737] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
407 Kozielewicz D, Grabińska A, Madej G, Wietlicka-Piszcz M. Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4. Prz Gastroenterol 2018;13:22-9. [PMID: 29657607 DOI: 10.5114/pg.2018.74558] [Reference Citation Analysis]
408 Li Q, Tong Y, Xu Y, Niu J, Zhong J. Genetic Analysis of Serum-Derived Defective Hepatitis C Virus Genomes Revealed Novel Viral cis Elements for Virus Replication and Assembly. J Virol. 2018;92. [PMID: 29367245 DOI: 10.1128/jvi.02182-17] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
409 Wyles DL. Resistance to DAAs: When to Look and When It Matters. Curr HIV/AIDS Rep. 2017;14:229-237. [PMID: 29116550 DOI: 10.1007/s11904-017-0369-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
410 Rodriguez C, Soulier A, Demontant V, Poiteau L, Mercier-Darty M, Bouvier-Alias M, Pawlotsky JM, Chevaliez S. A novel standardized deep sequencing-based assay for hepatitis C virus genotype determination. Sci Rep 2018;8:4180. [PMID: 29520035 DOI: 10.1038/s41598-018-22614-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
411 Chang SW, Cheng ML, Shiao MS, Yeh CT, Wang CH, Fan CM, Chiu CT, Chang ML. Recovery of lipid metabolic alterations in hepatitis C patients after viral clearance: Incomplete restoration with accelerated ω-oxidation. J Clin Lipidol 2018;12:756-66. [PMID: 29574072 DOI: 10.1016/j.jacl.2018.02.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
412 Morozov VA, Lagaye S. Hepatitis C virus: Morphogenesis, infection and therapy. World J Hepatol 2018; 10(2): 186-212 [PMID: 29527256 DOI: 10.4254/wjh.v10.i2.186] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 17.3] [Reference Citation Analysis]
413 Singer JB, Thomson EC, Mclauchlan J, Hughes J, Gifford RJ. GLUE: A flexible software system for virus sequence data.. [DOI: 10.1101/269274] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
414 Sorbo MC, Cento V, Di Maio VC, Howe AYM, Garcia F, Perno CF, Ceccherini-Silberstein F. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. Drug Resist Updat 2018;37:17-39. [PMID: 29525636 DOI: 10.1016/j.drup.2018.01.004] [Cited by in Crossref: 128] [Cited by in F6Publishing: 134] [Article Influence: 32.0] [Reference Citation Analysis]
415 Yusrina F, Chua CW, Lee CK, Chiu L, Png TS, Khoo MJ, Yan G, Lee GH, Yan B, Lee HK. Comparison of cobas HCV GT against Versant HCV Genotype 2.0 (LiPA) with confirmation by Sanger sequencing. J Virol Methods 2018;255:8-13. [PMID: 29428399 DOI: 10.1016/j.jviromet.2018.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
416 Ahmed AM, Doheim MF, Mattar OM, Sherif NA, Truong DH, Hoa PTL, Hirayama K, Huy NT. Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis. J Med Virol 2018;90:907-18. [PMID: 28892235 DOI: 10.1002/jmv.24947] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
417 Li Z, Liu Q. Hepatitis C virus regulates proprotein convertase subtilisin/kexin type 9 promoter activity. Biochem Biophys Res Commun 2018;496:1229-35. [PMID: 29397939 DOI: 10.1016/j.bbrc.2018.01.176] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
418 Sohrab SS, Suhail M, Ali A, Qadri I, Harakeh S, Azhar EI. Consequence of HIV and HCV co-infection on host immune response, persistence and current treatment options. Virusdisease 2018;29:19-26. [PMID: 29607354 DOI: 10.1007/s13337-018-0424-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
419 Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, Irvin M, Xie W, Fu B, Burroughs M. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. Antimicrob Agents Chemother. 2018;62:pii: e02217-17. [PMID: 29180522 DOI: 10.1128/aac.02217-17:] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
420 Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, Irvin M, Xie W, Fu B, Burroughs M. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. Antimicrob Agents Chemother. 2018;62. [PMID: 29180522 DOI: 10.1128/aac.02217-17] [Cited by in Crossref: 23] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
421 Mesci P, Macia A, Moore SM, Shiryaev SA, Pinto A, Huang CT, Tejwani L, Fernandes IR, Suarez NA, Kolar MJ, Montefusco S, Rosenberg SC, Herai RH, Cugola FR, Russo FB, Sheets N, Saghatelian A, Shresta S, Momper JD, Siqueira-Neto JL, Corbett KD, Beltrão-Braga PCB, Terskikh AV, Muotri AR. Blocking Zika virus vertical transmission. Sci Rep 2018;8:1218. [PMID: 29352135 DOI: 10.1038/s41598-018-19526-4] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 10.5] [Reference Citation Analysis]
422 Yin C, Goonawardane N, Stewart H, Harris M. A role for domain I of the hepatitis C virus NS5A protein in virus assembly. PLoS Pathog 2018;14:e1006834. [PMID: 29352312 DOI: 10.1371/journal.ppat.1006834] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
423 He C, Germer JJ, Ptacek ER, Bommersbach CE, Mitchell PS, Yao JDC. Utility of the Abbott RealTime HCV Genotype Plus RUO assay used in combination with the Abbott RealTime HCV Genotype II assay. J Clin Virol 2018;99-100:97-100. [PMID: 29396354 DOI: 10.1016/j.jcv.2018.01.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
424 El-Tahan RR, Ghoneim AM, Zaghloul H. 5' UTR and NS5B-based genotyping of hepatitis C virus in patients from Damietta governorate, Egypt. J Adv Res 2018;10:39-47. [PMID: 30046475 DOI: 10.1016/j.jare.2018.01.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
425 Charre C, Cotte L, Kramer R, Miailhes P, Godinot M, Koffi J, Scholtès C, Ramière C. Hepatitis C virus spread from HIV-positive to HIV-negative men who have sex with men. PLoS One 2018;13:e0190340. [PMID: 29293630 DOI: 10.1371/journal.pone.0190340] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 11.8] [Reference Citation Analysis]
426 Abrignani S, Neddermann P, Houghton M, De Francesco R. Hepatitis C Vaccines. Plotkin's Vaccines 2018. [DOI: 10.1016/b978-0-323-35761-6.00026-2] [Reference Citation Analysis]
427 Hong T. Direct Nucleotide Sequencing for Amplification Product Identification. Advanced Techniques in Diagnostic Microbiology 2018. [DOI: 10.1007/978-3-319-33900-9_19] [Reference Citation Analysis]
428 Tong L, Kozlowski JA, Campeau L, Yin J. Discovery and Development of Ruzasvir: An Investigational Next Generation Pan-Genotype HCV Nonstructural Protein 5A (NS5A) Inhibitor for the Cure of Hepatitis C Virus Infections. ACS Symposium Series 2018. [DOI: 10.1021/bk-2018-1307.ch005] [Reference Citation Analysis]
429 Bhattacharyya KK, Biswas A, Gupta D, Sadhukhan PC. Experience of hepatitis C virus seroprevalence and its genomic diversity among transfusion-dependent thalassemia patients in a transfusion center. Asian J Transfus Sci 2018;12:112-6. [PMID: 30692794 DOI: 10.4103/ajts.AJTS_73_17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
430 Schleiss MR, Marsh KJ. Viral Infections of the Fetus and Newborn. Avery's Diseases of the Newborn 2018. [DOI: 10.1016/b978-0-323-40139-5.00037-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
431 Bowsher M, Hiebert S, Li R, Wang AX, Friborg J, Yu F, Hernandez D, Wang Y, Klei H, Rajamani R, Mosure K, Knipe JO, Meanwell NA, Mcphee F, Scola PM. The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease. Bioorganic & Medicinal Chemistry Letters 2018;28:43-8. [DOI: 10.1016/j.bmcl.2017.11.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
432 Froes-meyer P, Musa OM, Eltahir Saeed WS, Ahmed ME, Osman OA, Mohammed HK, Gasim Khalil EA. Biochemical aberrations, viral genotypic patterns and viral loads among Sudanese patients with chronic hepatitis C virus infection. JHVRV 2018;6:51-54. [DOI: 10.15406/jhvrv.2018.06.00195] [Reference Citation Analysis]
433 Mignogna MD, Leuci S. Interface Between Oral and Systemic Disease. Contemporary Oral Medicine 2018. [DOI: 10.1007/978-3-319-28100-1_9-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
434 Acero Fernández D, Ferri Iglesias MJ, Buxó Pujolràs M, López Nuñez C, Serra Matamala I, Queralt Molés X, Aldeguer Manté X. Changes in the epidemiology and distribution of the hepatitis C virus genotypes in North-Eastern Spain over the last 35 years. Gastroenterología y Hepatología (English Edition) 2018;41:2-11. [DOI: 10.1016/j.gastre.2017.09.002] [Reference Citation Analysis]
435 Nolte FS. Molecular Microbiology. Principles and Applications of Molecular Diagnostics 2018. [DOI: 10.1016/b978-0-12-816061-9.00005-9] [Reference Citation Analysis]
436 Ward JW, Holtzman D. Epidemiology, Natural History, and Diagnosis of Hepatitis C. Zakim and Boyer's Hepatology 2018. [DOI: 10.1016/b978-0-323-37591-7.00029-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
437 Irshad M, Gupta P, Irshad K. Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection. World J Hepatol 2017; 9(36): 1305-1314 [PMID: 29359013 DOI: 10.4254/wjh.v9.i36.1305] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 8.6] [Reference Citation Analysis]
438 Tsukiyama-Kohara K, Kohara M. Hepatitis C Virus: Viral Quasispecies and Genotypes. Int J Mol Sci 2017;19:E23. [PMID: 29271914 DOI: 10.3390/ijms19010023] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
439 Ng TI, Tripathi R, Reisch T, Lu L, Middleton T, Hopkins TA, Pithawalla R, Irvin M, Dekhtyar T, Krishnan P, Schnell G, Beyer J, McDaniel KF, Ma J, Wang G, Jiang LJ, Or YS, Kempf D, Pilot-Matias T, Collins C. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir. Antimicrob Agents Chemother 2018;62:e01620-17. [PMID: 29084747 DOI: 10.1128/AAC.01620-17] [Cited by in Crossref: 53] [Cited by in F6Publishing: 60] [Article Influence: 10.6] [Reference Citation Analysis]
440 Del Campo JA, Parra-Sánchez M, Figueruela B, García-Rey S, Quer J, Gregori J, Bernal S, Grande L, Palomares JC, Romero-Gómez M. Hepatitis C virus deep sequencing for sub-genotype identification in mixed infections: A real-life experience. Int J Infect Dis 2018;67:114-7. [PMID: 29253705 DOI: 10.1016/j.ijid.2017.12.016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
441 Ordeig L, Garcia-Cehic D, Gregori J, Soria ME, Nieto-Aponte L, Perales C, Llorens M, Chen Q, Riveiro-Barciela M, Buti M, Esteban R, Esteban JI, Rodriguez-Frias F, Quer J. New hepatitis C virus genotype 1 subtype naturally harbouring resistance-associated mutations to NS5A inhibitors. J Gen Virol 2018;99:97-102. [PMID: 29239718 DOI: 10.1099/jgv.0.000996] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
442 Zhou T, Ren X, Adams RL, Pyle AM. NS3 from Hepatitis C Virus Strain JFH-1 Is an Unusually Robust Helicase That Is Primed To Bind and Unwind Viral RNA. J Virol 2018;92:e01253-17. [PMID: 29070684 DOI: 10.1128/JVI.01253-17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
443 Li Z, Liu Q. Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A. J Gen Virol. 2018;99:44-61. [PMID: 29235977 DOI: 10.1099/jgv.0.000987] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
444 Sun D, Dai M, Shen S, Li C, Yan X. Analysis of naturally occurring resistance-associated variants to NS3/4A protein inhibitors, NS5A protein inhibitors and NS5B polymerase inhibitors in patients with chronic hepatitis C. Gene Expr. 2017;. [PMID: 29221500 DOI: 10.3727/105221617x15100607143377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
445 Lu G, Huang J, Yang Q, Xu H, Wu P, Fu C, Li S. Identification and genetic characterization of hepacivirus and pegivirus in commercial equine serum products in China. PLoS One 2017;12:e0189208. [PMID: 29216266 DOI: 10.1371/journal.pone.0189208] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
446 von Delft A, Donnison TA, Lourenço J, Hutchings C, Mullarkey CE, Brown A, Pybus OG, Klenerman P, Chinnakannan S, Barnes E. The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes. Vaccine 2018;36:313-21. [PMID: 29203182 DOI: 10.1016/j.vaccine.2017.10.079] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
447 Taherkhani R, Farshadpour F. Global elimination of hepatitis C virus infection: Progresses and the remaining challenges. World J Hepatol 2017; 9(33): 1239-1252 [PMID: 29312527 DOI: 10.4254/wjh.v9.i33.1239] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 8.0] [Reference Citation Analysis]
448 Camus G, Xu S, Han B, Lu J, Dvory-Sobol H, Yu M, Cheng G, Miller MD, Doehle BP, Mo H. Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems. Virology 2018;514:134-41. [PMID: 29175627 DOI: 10.1016/j.virol.2017.11.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
449 Paolucci S, Premoli M, Novati S, Gulminetti R, Maserati R, Barbarini G, Sacchi P, Piralla A, Sassera D, De Marco L, Girello A, Mondelli MU, Baldanti F. Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs. Sci Rep. 2017;7:16017. [PMID: 29167469 DOI: 10.1038/s41598-017-15987-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
450 Baharlou R, Romani B, Kiani SJ, Sadeghi K, Shadmand E, Fazel H, Jalilian FA, Kord E, Yaghoubi S, Nikmanesh Y, Ahmadi Vasmehjani A. Genotype-related variations in proinflammatory and regulatory cytokine levels in treated and treatment-naive HCV-infected patients. Med Microbiol Immunol 2018;207:65-74. [PMID: 29147974 DOI: 10.1007/s00430-017-0527-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
451 Parsa Nahad M, Makvandi M, Teimoori A, Jalilian S, Kayedani GA, Mahmoodi S. MDR1 gene C3435T polymorphism in chronic hepatitis C patients. Microb Pathog 2018;114:63-7. [PMID: 29155127 DOI: 10.1016/j.micpath.2017.11.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
452 Acero Fernández D, Ferri Iglesias MJ, Buxó Pujolràs M, López Nuñez C, Serra Matamala I, Queralt Molés X, Aldeguer Manté X. Changes in the epidemiology and distribution of the hepatitis C virus genotypes in North-Eastern Spain over the last 35 years. Gastroenterol Hepatol 2018;41:2-11. [PMID: 29150360 DOI: 10.1016/j.gastrohep.2017.09.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
453 Hartlage AS, Cullen JM, Kapoor A. The Strange, Expanding World of Animal Hepaciviruses. Annu Rev Virol 2016;3:53-75. [PMID: 27741408 DOI: 10.1146/annurev-virology-100114-055104] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 13.2] [Reference Citation Analysis]
454 Romero-López C, Berzal-Herranz A. The 5BSL3.2 Functional RNA Domain Connects Distant Regions in the Hepatitis C Virus Genome. Front Microbiol 2017;8:2093. [PMID: 29163393 DOI: 10.3389/fmicb.2017.02093] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
455 Li Z, Chen ZW, Li H, Ren H, Hu P. Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China. Infect Drug Resist 2017;10:377-92. [PMID: 29184422 DOI: 10.2147/IDR.S146595] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
456 Dirani G, Paesini E, Mascetra E, Farabegoli P, Dalmo B, Bartolini B, Garbuglia AR, Capobianchi MR, Sambri V. A novel next generation sequencing assay as an alternative to currently available methods for hepatitis C virus genotyping. J Virol Methods 2018;251:88-91. [PMID: 29045810 DOI: 10.1016/j.jviromet.2017.10.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
457 Li Z, Liu Y, Zhang Y, Shao X, Luo Q, Guo X, Lin G, Cai Q, Zhao Z, Chong Y. Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients. Biomed Res Int 2017;2017:9849823. [PMID: 29164151 DOI: 10.1155/2017/9849823] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
458 Shin SR, Kim YS, Lim YS, Lee JS, Lee JW, Kim SM, Jeong SH, Sohn JH, Lee MS, Park SH. Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study. Gut Liver 2017;11:270-5. [PMID: 27728965 DOI: 10.5009/gnl16163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
459 Paraschiv S, Banica L, Nicolae I, Niculescu I, Abagiu A, Jipa R, Pineda-Peña AC, Pingarilho M, Neaga E, Theys K, Libin P, Otelea D, Abecasis A. Epidemic dispersion of HIV and HCV in a population of co-infected Romanian injecting drug users. PLoS One 2017;12:e0185866. [PMID: 29016621 DOI: 10.1371/journal.pone.0185866] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
460 Petruzziello A, Marigliano S, Loquercio G, Coppola N, Piccirillo M, Leongito M, Azzaro R, Izzo F, Botti G. Hepatitis C Virus (HCV) genotypes distribution among hepatocellular carcinoma patients in Southern Italy: a three year retrospective study. Infect Agents Cancer 2017;12. [DOI: 10.1186/s13027-017-0162-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
461 Fan Z, Zhang Q, Chen H, He P, Li Y, Si M, Jiao X. Circulating microRNAs as a biomarker to predict therapy efficacy in hepatitis C patients with different genotypes. Microb Pathog 2017;112:320-6. [PMID: 28993299 DOI: 10.1016/j.micpath.2017.10.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
462 Abd-Elsalam S, Sharaf-Eldin M, Soliman S, Elfert A, Badawi R, Ahmad YK. Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice. Arch Virol. 2018;163:51-56. [PMID: 28983675 DOI: 10.1007/s00705-017-3573-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
463 Smolić M, Omanović T, Božić I, Bilić-ćurčić I, Smolić R, Včev A. Pharmacogenomic Testing in the Era of Patient-Tailored HCV Treatment. Update on Hepatitis C 2017. [DOI: 10.5772/intechopen.70794] [Reference Citation Analysis]
464 Mehmood A, Asad MJ, Ovais M, Zaman N, Aziz H, Irfan J, Ahmad I, Raza A. The Absence of HCV RNA and NS5A Protein in Peripheral Blood Mononuclear Cells Is a Prognostic Tool for Sustained Virological Response. Viral Immunology 2017;30:568-75. [DOI: 10.1089/vim.2017.0030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
465 Susser S, Dietz J, Schlevogt B, Zuckerman E, Barak M, Piazzolla V, Howe A, Hinrichsen H, Passmann S, Daniel R, Cornberg M, Mangia A, Zeuzem S, Sarrazin C. Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras. J Hepatol 2017;67:680-6. [PMID: 28619439 DOI: 10.1016/j.jhep.2017.05.027] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
466 Kelly L, Badhan A, Roberts GC, Mbisa JL, Harris M. Manipulation of both virus- and cell-specific factors is required for robust transient replication of a hepatitis C virus genotype 3a sub-genomic replicon. J Gen Virol 2017;98:2495-506. [PMID: 28984238 DOI: 10.1099/jgv.0.000932] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
467 Rodriguez-frias F, Nieto-aponte L, Gregori J, Garcia-cehic D, Casillas R, Tabernero D, Homs M, Blasi M, Vila M, Chen Q, Vargas V, Castells L, Viladomiu L, Genesca J, Minguez B, Augustin S, Riveiro-barciela M, Carbonell J, Perales C, Soria M, Asensio M, Llorens M, Ordeig L, Godoy C, Buti M, Esteban R, Pumarola T, Esteban J, Quer J. High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping. Clinical Microbiology and Infection 2017;23:775.e1-6. [DOI: 10.1016/j.cmi.2017.02.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
468 Vanhommerig JW, Bezemer D, Molenkamp R, Van Sighem AI, Smit C, Arends JE, Lauw FN, Brinkman K, Rijnders BJ, Newsum AM, Bruisten SM, Prins M, Van Der Meer JT, Van De Laar TJ, Schinkel J; MOSAIC study and the ATHENA national observational cohort. Limited overlap between phylogenetic HIV and hepatitis C virus clusters illustrates the dynamic sexual network structure of Dutch HIV-infected MSM. AIDS 2017;31:2147-58. [PMID: 28692530 DOI: 10.1097/QAD.0000000000001592] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
469 Schnell G, Tripathi R, Krishnan P, Beyer J, Reisch T, Irvin M, Dekhtyar T, Setze C, Rodrigues L, Alves K, Burroughs M, Redman R, Chayama K, Kumada H, Collins C, Pilot-Matias T. Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir. J Med Virol. 2018;90:109-119. [PMID: 28842997 DOI: 10.1002/jmv.24923] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
470 Fakhriravari A. Sofosbuvir-Velpatasvir-Voxilaprevir for Chronic Hepatitis C - A Review. GHOA 2017;7. [DOI: 10.15406/ghoa.2017.07.00254] [Reference Citation Analysis]
471 Biswas A, Gupta D, Saha K, Sarkar K, Firdaus R, Sadhukhan PC. Emerging new HCV strains among intravenous drug users and their route of transmission in the north eastern state of Mizoram, India. Mol Phylogenet Evol 2017;116:239-47. [PMID: 28916154 DOI: 10.1016/j.ympev.2017.09.006] [Reference Citation Analysis]
472 Bessa LM, Launay H, Dujardin M, Cantrelle FX, Lippens G, Landrieu I, Schneider R, Hanoulle X. NMR reveals the intrinsically disordered domain 2 of NS5A protein as an allosteric regulator of the hepatitis C virus RNA polymerase NS5B. J Biol Chem 2017;292:18024-43. [PMID: 28912275 DOI: 10.1074/jbc.M117.813766] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
473 Pasternak AL, Ward KM, Luzum JA, Ellingrod VL, Hertz DL. Germline genetic variants with implications for disease risk and therapeutic outcomes. Physiol Genomics 2017;49:567-81. [PMID: 28887371 DOI: 10.1152/physiolgenomics.00035.2017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
474 Zhang M, Liu K, Hu Y, Lin Y, Li Y, Zhong P, Jin X, Zhu X, Zhang C. A novel quantitative PCR mediated by high-fidelity DNA polymerase. Sci Rep 2017;7:10365. [PMID: 28871131 DOI: 10.1038/s41598-017-10782-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
475 Shier MK, Iles JC, El-Wetidy MS, Ali HH, Al Qattan MM. Molecular characterization and epidemic history of hepatitis C virus using core sequences of isolates from Central Province, Saudi Arabia. PLoS One 2017;12:e0184163. [PMID: 28863156 DOI: 10.1371/journal.pone.0184163] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
476 Maya AAE, da Silveira Alves CF, Marangon CG, Frizon K, Gorziza RP, Lunge VR, Simon D. Influence of the IL6 − 147C/G polymorphism on clinical characteristics of chronic hepatitis C in Brazilian patients. Gene Reports 2017;8:75-78. [DOI: 10.1016/j.genrep.2017.05.009] [Reference Citation Analysis]
477 Manee N, Thongbaiphet N, Pasomsub E, Chantratita W. Clinical evaluation of a newly developed automated massively parallel sequencing assay for hepatitis C virus genotyping and detection of resistance-association variants. Comparison with a line probe assay. J Virol Methods 2017;249:31-7. [PMID: 28851606 DOI: 10.1016/j.jviromet.2017.08.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
478 Çevik RE, Cesarec M, Da Silva Filipe A, Licastro D, McLauchlan J, Marcello A. Hepatitis C Virus NS5A Targets Nucleosome Assembly Protein NAP1L1 To Control the Innate Cellular Response. J Virol 2017;91:e00880-17. [PMID: 28659470 DOI: 10.1128/JVI.00880-17] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
479 Weller R, Hueging K, Brown RJP, Todt D, Joecks S, Vondran FWR, Pietschmann T. Hepatitis C Virus Strain-Dependent Usage of Apolipoprotein E Modulates Assembly Efficiency and Specific Infectivity of Secreted Virions. J Virol. 2017;91. [PMID: 28659481 DOI: 10.1128/jvi.00422-17] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
480 Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017;17:1062-8. [PMID: 28818546 DOI: 10.1016/S1473-3099(17)30496-6] [Cited by in Crossref: 248] [Cited by in F6Publishing: 255] [Article Influence: 49.6] [Reference Citation Analysis]
481 Ellwanger JH, Kaminski VL, Valverde-Villegas JM, Simon D, Lunge VR, Chies JAB. Immunogenetic studies of the hepatitis C virus infection in an era of pan-genotype antiviral therapies - Effective treatment is coming. Infect Genet Evol 2018;66:376-91. [PMID: 28811194 DOI: 10.1016/j.meegid.2017.08.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
482 Bartolini B, Giombini E, Taibi C, Lionetti R, Montalbano M, Visco-Comandini U, D'Offizi G, Capobianchi MR, McPhee F, Garbuglia AR. Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents. Viruses 2017;9:E212. [PMID: 28783119 DOI: 10.3390/v9080212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
483 Nasir IA, Yakubu S, Mustapha JO. Epidemiology and Synergistic Hepatopathology of Malaria and Hepatitis C Virus Coinfection. Virology (Auckl) 2017;8:1178122X17724411. [PMID: 28814840 DOI: 10.1177/1178122X17724411] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
484 Welzel TM, Bhardwaj N, Hedskog C, Chodavarapu K, Camus G, McNally J, Brainard D, Miller MD, Mo H, Svarovskaia E, Jacobson I, Zeuzem S, Agarwal K. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. J Hepatol 2017;67:224-36. [PMID: 28343981 DOI: 10.1016/j.jhep.2017.03.014] [Cited by in Crossref: 94] [Cited by in F6Publishing: 93] [Article Influence: 18.8] [Reference Citation Analysis]
485 Tu T, Bühler S, Bartenschlager R. Chronic viral hepatitis and its association with liver cancer. Biol Chem 2017;398:817-37. [PMID: 28455951 DOI: 10.1515/hsz-2017-0118] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 11.6] [Reference Citation Analysis]
486 Han M, Park Y, Kim H. Comparison of Abbott RealTime genotype II, GeneMatrix restriction fragment mass polymorphism and Sysmex HISCL HCV Gr assays for hepatitis C virus genotyping. Clinical Chemistry and Laboratory Medicine (CCLM) 2017;55:1122-8. [DOI: 10.1515/cclm-2016-0130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
487 Manuylov VA, Chub EV, Kichatova VS, Soboleva NV, Isaeva OV, Zamyatnin AA Jr, Netesov SV. Hepatitis C virus subtype 3a was introduced in the USSR in the early 1980s. J Gen Virol 2017;98:2079-87. [PMID: 28742003 DOI: 10.1099/jgv.0.000878] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
488 Stelzl E, Haas B, Bauer B, Zhang S, Fiss EH, Hillman G, Hamilton AT, Mehta R, Heil ML, Marins EG, Santner BI, Kessler HH. First identification of a recombinant form of hepatitis C virus in Austrian patients by full-genome next generation sequencing. PLoS One 2017;12:e0181273. [PMID: 28742818 DOI: 10.1371/journal.pone.0181273] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
489 McComas CC, Palani A, Chang W, Holloway MK, Lesburg CA, Li P, Liverton N, Meinke PT, Olsen DB, Peng X, Soll RM, Ummat A, Wu J, Wu J, Zorn N, Ludmerer SW. Development of a New Structural Class of Broadly Acting HCV Non-Nucleoside Inhibitors Leading to the Discovery of MK-8876. ChemMedChem 2017;12:1436-48. [PMID: 28741898 DOI: 10.1002/cmdc.201700228] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
490 Zayed RA, Omran D, Zayed AA, Elmessery LO. Determinants of Infection Outcome in HCV-Genotype 4. Viral Immunol. 2017;30:560-567. [PMID: 28731371 DOI: 10.1089/vim.2017.0071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
491 Andre-Garnier E, Besse B, Rodallec A, Ribeyrol O, Ferre V, Luco C, Le Guen L, Bourgeois N, Gournay J, Billaud E, Raffi F, Coste-Burel M, Imbert-Marcille BM. An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains. PLoS One 2017;12:e0179562. [PMID: 28727784 DOI: 10.1371/journal.pone.0179562] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
492 Polo ML, Laufer N. Extrahepatic manifestations of HCV: the role of direct acting antivirals. Expert Rev Anti Infect Ther. 2017;15:737-746. [PMID: 28696154 DOI: 10.1080/14787210.2017.1354697] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
493 Hoornenborg E, Achterbergh RCA, Schim van der Loeff MF, Davidovich U, Hogewoning A, de Vries HJC, Schinkel J, Prins M, van de Laar TJW; Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam Initiative, MOSAIC study group. MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection. AIDS 2017;31:1603-10. [PMID: 28657964 DOI: 10.1097/QAD.0000000000001522] [Cited by in Crossref: 95] [Cited by in F6Publishing: 96] [Article Influence: 19.0] [Reference Citation Analysis]
494 Kassela K, Karakasiliotis I, Charpantidis S, Koskinas J, Mylopoulou T, Mimidis K, Sarrazin C, Grammatikos G, Mavromara P. High prevalence of antibodies to core+1/ARF protein in HCV-infected patients with advanced cirrhosis. J Gen Virol 2017;98:1713-9. [PMID: 28708052 DOI: 10.1099/jgv.0.000851] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
495 Asnavandi M, Zargar M, Vaziri F, Jamnani FR, Gharibzadeh S, Fateh A, Siadat SD. EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C. Genes Immun 2017;18:144-51. [DOI: 10.1038/gene.2017.12] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
496 Twagirumugabe T, Swaibu G, Bergström T, Walker TD, Gahutu JB, Norder H. Low prevalence of hepatitis C virus RNA in blood donors with anti-hepatitis C virus reactivity in Rwanda. Transfusion 2017;57:2420-32. [PMID: 28671283 DOI: 10.1111/trf.14204] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
497 Asante-Appiah E, Curry S, McMonagle P, Ingravallo P, Chase R, Nickle D, Qiu P, Howe A, Lahser FC. Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons. Antimicrob Agents Chemother 2017;61:e00363-17. [PMID: 28416549 DOI: 10.1128/AAC.00363-17] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
498 Fan JH, Xiang MQ, Li QL, Shi HT, Guo JJ. PNPLA3 rs738409 Polymorphism Associated with Hepatic Steatosis and Advanced Fibrosis in Patients with Chronic Hepatitis C Virus: A Meta-Analysis. Gut Liver 2016;10:456-63. [PMID: 26419236 DOI: 10.5009/gnl15261] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
499 Zheng BZ, D'Andrea SV, Hanumegowda U, Knipe JO, Mosure K, Zhuo X, Lemm JA, Liu M, Rigat KL, Wang YK, Fang H, Poronsky C, Cutrone J, Wu DR, Arunachalam PN, Balapragalathan TJ, Arumugam A, Mathur A, Meanwell NA, Gao M, Roberts SB, Kadow JF. Discovery of BMS-961955, an allosteric inhibitor of the hepatitis C virus NS5B polymerase. Bioorg Med Chem Lett 2017;27:3294-300. [PMID: 28633899 DOI: 10.1016/j.bmcl.2017.06.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
500 Chang ML, Hsu CM, Lin CH, Lin CY, Kuo CJ, Huang SW, Chen CW, Cheng HT, Yeh CT, Chiu CT. The Evolving Interplay among Abundant Adipokines in Patients with Hepatitis C during Viral Clearance. Nutrients. 2017;9. [PMID: 28574439 DOI: 10.3390/nu9060570] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
501 Hundie GB, Raj VS, GebreMichael D, Pas SD, Haagmans BL. Genetic diversity of hepatitis C virus in Ethiopia. PLoS One 2017;12:e0179064. [PMID: 28570623 DOI: 10.1371/journal.pone.0179064] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
502 Shahid I, AlMalki WH, Hassan S, Hafeez MH. Real-world challenges for hepatitis C virus medications: a critical overview. Crit Rev Microbiol 2018;44:143-60. [PMID: 28539069 DOI: 10.1080/1040841X.2017.1329277] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
503 Pham LV, Ramirez S, Carlsen THR, Li YP, Gottwein JM, Bukh J. Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors. Antimicrob Agents Chemother 2017;61:e00037-17. [PMID: 28348150 DOI: 10.1128/AAC.00037-17] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
504 Neesgaard B, Ruhwald M, Weis N. Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review. World J Hepatol 2017; 9(14): 677-688 [PMID: 28588752 DOI: 10.4254/wjh.v9.i14.677] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
505 Adams RL, Pirakitikulr N, Pyle AM. Functional RNA structures throughout the Hepatitis C Virus genome. Curr Opin Virol 2017;24:79-86. [PMID: 28511116 DOI: 10.1016/j.coviro.2017.04.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
506 Martin MT, Deming P. Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection. Pharmacotherapy 2017;37:735-47. [PMID: 28374965 DOI: 10.1002/phar.1933] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
507 Cuypers L, Libin P, Schrooten Y, Theys K, Di Maio VC, Cento V, Lunar MM, Nevens F, Poljak M, Ceccherini-Silberstein F, Nowé A, Van Laethem K, Vandamme AM. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning. Infect Genet Evol 2017;53:15-23. [PMID: 28499845 DOI: 10.1016/j.meegid.2017.05.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
508 Kanda T, Nakamura M, Yasui S, Haga Y, Tawada A, Suzuki E, Ooka Y, Takahashi K, Sasaki R, Wu S, Nakamoto S, Arai M, Imazeki F, Yokosuka O. Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. Biology (Basel). 2017;6. [PMID: 28486403 DOI: 10.3390/biology6020030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
509 V Picon R, Fendt L, Amaral K, D Picon P. Prediction of Sustained Virological Response to Peginterferon-based Therapy for Chronic Hepatitis C: Regression Analysis of a Cohort from Rio Grande do Sul, Brazil. Euroasian J Hepatogastroenterol 2017;7:27-33. [PMID: 29201768 DOI: 10.5005/jp-journals-10018-1207] [Reference Citation Analysis]
510 Wasitthankasem R, Vichaiwattana P, Siripon N, Posuwan N, Auphimai C, Klinfueng S, Thaneskongtong N, Vuthitanachot V, Saiyatha S, Thongmai C, Suwanpatoomlerd S, Sochoo S, Pongsuwan N, Poovorawan K, Tangkijvanich P, Vongpunsawad S, Poovorawan Y. Assessment of hepatitis C virus infection in two adjacent Thai provinces with drastically different seroprevalence. PLoS One 2017;12:e0177022. [PMID: 28475637 DOI: 10.1371/journal.pone.0177022] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
511 Yeung KS, Beno BR, Parcella K, Bender JA, Grant-Young KA, Nickel A, Gunaga P, Anjanappa P, Bora RO, Selvakumar K, Rigat K, Wang YK, Liu M, Lemm J, Mosure K, Sheriff S, Wan C, Witmer M, Kish K, Hanumegowda U, Zhuo X, Shu YZ, Parker D, Haskell R, Ng A, Gao Q, Colston E, Raybon J, Grasela DM, Santone K, Gao M, Meanwell NA, Sinz M, Soars MG, Knipe JO, Roberts SB, Kadow JF. Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies. J Med Chem 2017;60:4369-85. [PMID: 28430437 DOI: 10.1021/acs.jmedchem.7b00328] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
512 Lin CW, Dutta S, Asatryan A, Wang H, Clifton J 2nd, Campbell A, Liu W. Pharmacokinetics, Safety, and Tolerability Following Single and Multiple Doses of Pibrentasvir in a First-in-Human Study. Clin Pharmacol Drug Dev 2018;7:44-52. [PMID: 28464496 DOI: 10.1002/cpdd.350] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
513 Khan A, Al Balwi M, AlAyyar L, AlAbdulkareem I, Albekairy A, Aljumah A. Tracing the epidemic history of hepatitis C virus genotypes in Saudi Arabia. Infect Genet Evol 2017;52:82-8. [PMID: 28458032 DOI: 10.1016/j.meegid.2017.04.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
514 Chantratita W, Song KS, Nimse SB, Pongthanapisith V, Thongbaiphet N, Wongtabtim G, Pasomsub E, Angkanavin K, Sonawane MD, Warkad SD, Kim T. 6 HCV Genotyping 9G test for HCV 1a, 1b, 2, 3, 4 and 6 (6a, 6f, 6i and 6n) with high accuracy. J Virol Methods 2017;246:95-9. [PMID: 28456667 DOI: 10.1016/j.jviromet.2017.04.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
515 Ng TI, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J, Reisch T, Lu L, Dekhtyar T, Irvin M, Tripathi R, Maring C, Randolph JT, Wagner R, Collins C. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. Antimicrob Agents Chemother 2017;61:e02558-16. [PMID: 28193664 DOI: 10.1128/AAC.02558-16] [Cited by in Crossref: 95] [Cited by in F6Publishing: 101] [Article Influence: 19.0] [Reference Citation Analysis]
516 Salemovic D, Pesic-Pavlovic I, Jevtovic D, Bojovic K, Ranin J, Brmbolic B, Stanojevic M. Intravenous drug use - an independent predictor for HCV genotypes 3 and 4 infection among HIV/HCV co-infected patients. Arch Med Sci. 2017;13:652-658. [PMID: 28507583 DOI: 10.5114/aoms.2017.66022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
517 Biswas A, Firdaus R, Gupta D, Ghosh M, Saha K, Chowdhury P, Bhattacharyya M, Sadhukhan PC. Interferon λ3 gene (IL28B) is associated with spontaneous or treatment-induced viral clearance in hepatitis C virus-infected multitransfused patients with thalassemia. Transfusion 2017;57:1376-84. [PMID: 28419488 DOI: 10.1111/trf.14070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
518 Fernández-Caballero JA, Alvarez M, Chueca N, Pérez AB, García F. The cobas® HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice. PLoS One 2017;12:e0175564. [PMID: 28410425 DOI: 10.1371/journal.pone.0175564] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
519 Hayes CN, Chayama K. Why highly effective drugs are not enough: the need for an affordable solution to eliminating HCV. Expert Rev Clin Pharmacol 2017;10:583-94. [PMID: 28374641 DOI: 10.1080/17512433.2017.1313111] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
520 Ansari MA, Pedergnana V, L C Ip C, Magri A, Von Delft A, Bonsall D, Chaturvedi N, Bartha I, Smith D, Nicholson G, McVean G, Trebes A, Piazza P, Fellay J, Cooke G, Foster GR, Hudson E, McLauchlan J, Simmonds P, Bowden R, Klenerman P, Barnes E, Spencer CCA; STOP-HCV Consortium. Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. Nat Genet 2017;49:666-73. [PMID: 28394351 DOI: 10.1038/ng.3835] [Cited by in Crossref: 101] [Cited by in F6Publishing: 100] [Article Influence: 20.2] [Reference Citation Analysis]
521 Le Guillou-Guillemette H, Pivert A, Bouthry E, Henquell C, Petsaris O, Ducancelle A, Veillon P, Vallet S, Alain S, Thibault V, Abravanel F, Rosenberg AA, André-Garnier E, Bour JB, Baazia Y, Trimoulet P, André P, Gaudy-Graffin C, Bettinger D, Larrat S, Signori-Schmuck A, Saoudin H, Pozzetto B, Lagathu G, Minjolle-Cha S, Stoll-Keller F, Pawlotsky JM, Izopet J, Payan C, Lunel-Fabiani F, Lemaire C. Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma. PLoS One 2017;12:e0174651. [PMID: 28394908 DOI: 10.1371/journal.pone.0174651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
522 Torres-Cornejo A, Lauer GM. Hurdles to the Development of Effective HBV Immunotherapies and HCV Vaccines. Pathog Immun 2017;2:102-25. [PMID: 28664194 DOI: 10.20411/pai.v2i1.201] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
523 Guinoiseau T, Moreau A, Hohnadel G, Ngo-Giang-Huong N, Brulard C, Vourc'h P, Goudeau A, Gaudy-Graffin C. Deep sequencing is an appropriate tool for the selection of unique Hepatitis C virus (HCV) variants after single genomic amplification. PLoS One 2017;12:e0174852. [PMID: 28362878 DOI: 10.1371/journal.pone.0174852] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
524 Yoo ER, Perumpail RB, Cholankeril G, Jayasekera CR, Ahmed A. Expanding Treatment Access for Chronic Hepatitis C with Task-shifting in the Era of Direct-acting Antivirals. J Clin Transl Hepatol 2017;5:130-3. [PMID: 28660150 DOI: 10.14218/JCTH.2016.00059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
525 Zhao N, Liu J, Sun D. Detection of HCV genotypes 1b and 2a by a reverse transcription loop-mediated isothermal amplification assay. J Med Virol 2017;89:1048-54. [PMID: 27935066 DOI: 10.1002/jmv.24747] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
526 Kalafateli M, Buzzetti E, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis. Cochrane Database Syst Rev 2017;3:CD011644. [PMID: 28285495 DOI: 10.1002/14651858.CD011644.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
527 Mallory MA, Lucic D, Ebbert MT, Cloherty GA, Toolsie D, Hillyard DR. Evaluation of the Abbott RealTime HCV genotype II plus RUO (PLUS) assay with reference to core and NS5B sequencing. J Clin Virol 2017;90:26-31. [PMID: 28324789 DOI: 10.1016/j.jcv.2017.03.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
528 Safir Filho M, Martin AR, Benhida R. Assessment of new triplet forming artificial nucleobases as RNA ligands directed towards HCV IRES IIId loop. Bioorg Med Chem Lett 2017;27:1780-3. [PMID: 28274634 DOI: 10.1016/j.bmcl.2017.02.061] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
529 Velázquez-Moctezuma R, Law M, Bukh J, Prentoe J. Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A. PLoS Pathog 2017;13:e1006214. [PMID: 28231271 DOI: 10.1371/journal.ppat.1006214] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
530 Olmstead AD, Lee TD, Chow R, Gunadasa K, Auk B, Krajden M, Jassem AN. Development and validation of a real-time, reverse transcription PCR assay for rapid and low-cost genotyping of hepatitis C virus genotypes 1a, 1b, 2, and 3a. J Virol Methods 2017;244:17-22. [PMID: 28219761 DOI: 10.1016/j.jviromet.2017.02.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
531 Burstow NJ, Mohamed Z, Gomaa AI, Sonderup MW, Cook NA, Waked I, Spearman CW, Taylor-Robinson SD. Hepatitis C treatment: where are we now? Int J Gen Med 2017;10:39-52. [PMID: 28255252 DOI: 10.2147/IJGM.S127689] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 13.2] [Reference Citation Analysis]
532 Am E. Seroprevalence of Hepatitis C Virus among Population in Luxor Governorate, Egypt. JHVRV 2017;5. [DOI: 10.15406/jhvrv.2017.05.00144] [Reference Citation Analysis]
533 Oikonomopoulou M, Demetriou VL, Kostrikis LG, Paraskevis D. Re-analysis of unassigned hepatitis C virus (HCV) strain CYHCV025: Evidence of a highly divergent lineage within genotype 1. Mol Phylogenet Evol 2017;109:362-6. [PMID: 28179183 DOI: 10.1016/j.ympev.2017.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
534 Bruening J, Weigel B, Gerold G. The Role of Type III Interferons in Hepatitis C Virus Infection and Therapy. J Immunol Res 2017;2017:7232361. [PMID: 28255563 DOI: 10.1155/2017/7232361] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
535 Pierce VM, Eversley JS, Tran TK, Rosenberg ES. Differences between quantification of genotype 3 hepatitis C virus RNA by Versions 1.0 and 2.0 of the COBAS AmpliPrep/COBAS TaqMan HCV Test. Clinical Chemistry and Laboratory Medicine (CCLM) 2017;55. [DOI: 10.1515/cclm-2016-0799] [Reference Citation Analysis]
536 Sun G, Larsen CN, Baumgarth N, Klem EB, Scheuermann RH. Comprehensive Annotation of Mature Peptides and Genotypes for Zika Virus. PLoS One 2017;12:e0170462. [PMID: 28125631 DOI: 10.1371/journal.pone.0170462] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
537 Zhang GL, Chen YM, Zhang T, Cai QX, Zhang XH, Zhao ZX, Lin CS, Gao ZL. Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment. Biomed Res Int 2017;2017:8061091. [PMID: 28232944 DOI: 10.1155/2017/8061091] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
538 Danilau D, Litvinchuk D, Solovey N, Krasko O, Karpov I. Association of TNF-α and CCL5 with response to interferon-based therapy in patients with HCV 1 genotype. Clin Exp Hepatol 2017;3:16-22. [PMID: 28856285 DOI: 10.5114/ceh.2017.65279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
539 Saleem A, Akhtar MF, Mushtaq MF, Saleem M, Muhammad ST, Akhtar B, Sharif A, Peerzada S. Current trends in the treatment of hepatitis C: interventions to avoid adverse effects and increase effectiveness of anti-HCV drugs. EXCLI J 2016;15:578-88. [PMID: 28096788 DOI: 10.17179/excli2016-582] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
540 Win NN, Nakamoto S, Kanda T, Takahashi H, Takahashi-Nakaguchi A, Yasui S, Nakamura M, Wu S, Imazeki F, Mikami S, Yokosuka O, Gonoi T, Shirasawa H. Discrepancy between Hepatitis C Virus Genotypes and NS4-Based Serotypes: Association with Their Subgenomic Sequences. Int J Mol Sci 2017;18:E172. [PMID: 28106726 DOI: 10.3390/ijms18010172] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
541 Patiño-Galindo JÁ, González-Candelas F. Comparative analysis of variation and selection in the HCV genome. Infect Genet Evol 2017;49:104-10. [PMID: 28087495 DOI: 10.1016/j.meegid.2017.01.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
542 Rodrigo C, Walker MR, Leung P, Eltahla AA, Grebely J, Dore GJ, Applegate T, Page K, Dwivedi S, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Luciani F, Lloyd AR, Bull RA; InC(3) Study Group. Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection. Infect Genet Evol 2017;49:88-96. [PMID: 28065804 DOI: 10.1016/j.meegid.2017.01.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
543 Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Sanai F, Bicer C, Lenz O, Van Dooren G, Nalpas C, Lonjon-Domanec I, Schlag M, Buti M. Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response. PLoS One 2017;12:e0168713. [PMID: 28056030 DOI: 10.1371/journal.pone.0168713] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
544 Wang J, Qiao L, Hou Z, Luo G. TIM-1 Promotes Hepatitis C Virus Cell Attachment and Infection. J Virol. 2017;91. [PMID: 27807228 DOI: 10.1128/jvi.01583-16] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
545 Echeverría N, Moreno P, Cristina J. Molecular Evolution of Hepatitis C Virus: From Epidemiology to Antiviral Therapy (Current Research in Latin America). Human Virology in Latin America 2017. [DOI: 10.1007/978-3-319-54567-7_17] [Reference Citation Analysis]
546 Chevaliez S, Pawlotsky J. Hepatitis Viruses. Infectious Diseases 2017. [DOI: 10.1016/b978-0-7020-6285-8.00165-9] [Reference Citation Analysis]
547 Mondelli MU. Natural history of HCV infection: what is the public health impact of untreated disease? Future Virology 2017;12:9-12. [DOI: 10.2217/fvl-2016-0118] [Reference Citation Analysis]
548 Carlin J, Mendes-correa MC, Núñez M. Hepatitis B and C. Sexually Transmitted Infections in HIV-Infected Adults and Special Populations 2017. [DOI: 10.1007/978-3-319-56694-8_10] [Reference Citation Analysis]
549 Wyles D, Lin J. Clinical Manifestations of Acute and Chronic Hepatitis. Infectious Diseases 2017. [DOI: 10.1016/b978-0-7020-6285-8.00042-3] [Reference Citation Analysis]
550 Boland GJ. Virology. Molecular Diagnostics 2017. [DOI: 10.1007/978-981-10-4511-0_3] [Reference Citation Analysis]
551 Lee J, Ou JJ. Cell Death and Liver Injuries in Hepatitis C Virus Infection. Cellular Injury in Liver Diseases 2017. [DOI: 10.1007/978-3-319-53774-0_4] [Reference Citation Analysis]
552 Sadler MD, Agarwal K. Treatment of Genotype 3 Chronic Hepatitis C Virus Infection. Clinical Medicine Insights: Therapeutics 2017;9:1179559X1769433. [DOI: 10.1177/1179559x17694330] [Reference Citation Analysis]
553 Quer J, Rodríguez-Frias F, Gregori J, Tabernero D, Soria ME, García-Cehic D, Homs M, Bosch A, Pintó RM, Esteban JI, Domingo E, Perales C. Deep sequencing in the management of hepatitis virus infections. Virus Res 2017;239:115-25. [PMID: 28040474 DOI: 10.1016/j.virusres.2016.12.020] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
554 Hong CM, Liu CJ, Yeh SH, Chen PJ. Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response. J Formos Med Assoc 2017;116:295-9. [PMID: 28034492 DOI: 10.1016/j.jfma.2016.11.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
555 Harak C, Meyrath M, Romero-Brey I, Schenk C, Gondeau C, Schult P, Esser-Nobis K, Saeed M, Neddermann P, Schnitzler P, Gotthardt D, Perez-Del-Pulgar S, Neumann-Haefelin C, Thimme R, Meuleman P, Vondran FW, De Francesco R, Rice CM, Bartenschlager R, Lohmann V. Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture. Nat Microbiol 2016;2:16247. [PMID: 27991882 DOI: 10.1038/nmicrobiol.2016.247] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 7.3] [Reference Citation Analysis]
556 Walter S, Rasche A, Moreira-Soto A, Pfaender S, Bletsa M, Corman VM, Aguilar-Setien A, García-Lacy F, Hans A, Todt D, Schuler G, Shnaiderman-Torban A, Steinman A, Roncoroni C, Veneziano V, Rusenova N, Sandev N, Rusenov A, Zapryanova D, García-Bocanegra I, Jores J, Carluccio A, Veronesi MC, Cavalleri JMV, Drosten C, Lemey P, Steinmann E, Drexler JF. Differential Infection Patterns and Recent Evolutionary Origins of Equine Hepaciviruses in Donkeys. J Virol 2017;91:e01711-16. [PMID: 27795428 DOI: 10.1128/JVI.01711-16] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
557 Lee R, Kottilil S, Wilson E. Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy. Hepatol Int 2017;11:161-70. [PMID: 27928718 DOI: 10.1007/s12072-016-9776-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
558 Nieto-Aponte L, Quer J, Ruiz-Ripa A, Tabernero D, Gonzalez C, Gregori J, Vila M, Asensio M, Garcia-Cehic D, Ruiz G, Chen Q, Ordeig L, Llorens M, Saez M, Esteban JI, Esteban R, Buti M, Pumarola T, Rodriguez-Frias F. Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice: Comparison with Massive Sequencing. J Clin Microbiol 2017;55:504-9. [PMID: 27927921 DOI: 10.1128/JCM.01960-16] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
559 Малов, Malov I, Малов, Malov S, Степаненко, Stepanenko L, Парамонов, Paramonov A, Гаращенко, Garashchenko N, Колбасеева, Kolbaseeva O, Джиоев, Dzhioev Y, Злобин, Zlobin V. reconstructIon of recombination sites in genomic structures of the strains of genotype 6 of hepatitis c virus. Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук 2016;1:100-103. [DOI: 10.12737/23401] [Reference Citation Analysis]
560 Patel S. In silico analysis of Hepatitis C virus (HCV) polyprotein domains and their comparison with other pathogens and allergens to gain insight on pathogenicity mechanisms. Computational Biology and Chemistry 2016;65:91-102. [DOI: 10.1016/j.compbiolchem.2016.10.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
561 Miyazaki R, Miyagi K. Successful treatment of chronic hepatitis C virus genotype 1b infection of a patient with compensated cirrhosis after renal transplantation using daclatasvir-asunaprevir combination therapy: a case report and literature review. Ren Replace Ther 2016;2:61. [DOI: 10.1186/s41100-016-0075-6] [Reference Citation Analysis]
562 Radmehr H, Makvandi M, Samarbafzadeh A, Teimoori A, Neisi N, Rasti M, Abasifar S, Soltani H, Abbasi S, Kiani H, Mehravaran H, Azaran A, Shahani T. Prevalence of Hepatitis C virus Genotype 3a in patients with Hodgkin and Non-Hodgkin Lymphoma. Iran J Microbiol 2016;8:389-94. [PMID: 28491250] [Reference Citation Analysis]
563 Pronost S, Hue E, Fortier C, Foursin M, Fortier G, Desbrosse F, Rey FA, Pitel PH, Richard E, Saunier B. Prevalence of Equine Hepacivirus Infections in France and Evidence for Two Viral Subtypes Circulating Worldwide. Transbound Emerg Dis 2017;64:1884-97. [PMID: 27882682 DOI: 10.1111/tbed.12587] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
564 Palmer BA, Fanning LJ. Synonymous Co-Variation across the E1/E2 Gene Junction of Hepatitis C Virus Defines Virion Fitness. PLoS One 2016;11:e0167089. [PMID: 27880830 DOI: 10.1371/journal.pone.0167089] [Reference Citation Analysis]
565 da Silva RA, de Carvalho IM, de Matos RP, Yamasaki LH, Bittar C, Rahal P, Jardim AC. Evidence of bottleneck effect on hepatitis C virus transmission between a couple under interferon based therapy. Infect Genet Evol 2017;47:87-93. [PMID: 27888038 DOI: 10.1016/j.meegid.2016.11.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
566 Graci JD, Jung SP, Pichardo J, Lahser F, Tong X, Gu Z, Colacino JM. PTC725, an NS4B-Targeting Compound, Inhibits a Hepatitis C Virus Genotype 3 Replicon, as Predicted by Genome Sequence Analysis and Determined Experimentally. Antimicrob Agents Chemother 2016;60:7060-6. [PMID: 27620477 DOI: 10.1128/AAC.01272-16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
567 Siddharta A, Pfaender S, Malassa A, Doerrbecker J, Anggakusuma, Engelmann M, Nugraha B, Steinmann J, Todt D, Vondran FW, Mateu-Gelabert P, Goffinet C, Steinmann E. Inactivation of HCV and HIV by microwave: a novel approach for prevention of virus transmission among people who inject drugs. Sci Rep 2016;6:36619. [PMID: 27857152 DOI: 10.1038/srep36619] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
568 Tong L, Yu W, Chen L, Selyutin O, Dwyer MP, Nair AG, Mazzola R, Kim JH, Sha D, Yin J. Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms. J Med Chem. 2017;60:290-306. [PMID: 27808515 DOI: 10.1021/acs.jmedchem.6b01310] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
569 Zuiani A, Chen K, Schwarz MC, White JP, Luca VC, Fremont DH, Wang D, Evans MJ, Diamond MS. A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I. J Virol 2016;90:10499-512. [PMID: 27630236 DOI: 10.1128/JVI.01011-16] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
570 Daw MA, El-Bouzedi AA, Ahmed MO, Dau AA, Agnan MM, Drah AM. Geographic integration of hepatitis C virus: A global threat. World J Virol 2016; 5(4): 170-182 [PMID: 27878104 DOI: 10.5501/wjv.v5.i4.170] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
571 Yu W, Tong L, Hu B, Zhong B, Hao J, Ji T, Zan S, Coburn CA, Selyutin O, Chen L, Rokosz L, Agrawal S, Liu R, Curry S, McMonagle P, Ingravallo P, Asante-Appiah E, Chen S, Kozlowski JA. Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants. J Med Chem 2016;59:10228-43. [PMID: 27792320 DOI: 10.1021/acs.jmedchem.6b01234] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
572 Carter W, Connelly S, Struble K. Reinventing HCV Treatment: Past and Future Perspectives. J Clin Pharmacol. 2017;57:287-296. [PMID: 27654843 DOI: 10.1002/jcph.830] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
573 Ramirez S, Mikkelsen LS, Gottwein JM, Bukh J. Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir. Gastroenterology 2016;151:973-985.e2. [PMID: 27453546 DOI: 10.1053/j.gastro.2016.07.013] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 11.0] [Reference Citation Analysis]
574 Ikram A, Obaid A, Awan FM, Hanif R, Naz A, Paracha RZ, Ali A, Janjua HA. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine. Antiviral Res 2017;137:112-24. [PMID: 27984060 DOI: 10.1016/j.antiviral.2016.10.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
575 Chantratita W, Song KS, GunHo C, Pongthanapisith V, Thongbaiphet N, Wongtabtim G, Pasomsub E, Angkanavin K, Nimse SB, Sonawane MD, Warkad SD, Kim T. 6 HCV genotyping 9G test and its comparison with VERSANT HCV genotype 2.0 assay (LiPA) for the hepatitis C virus genotyping. J Virol Methods 2017;239:1-8. [PMID: 27793646 DOI: 10.1016/j.jviromet.2016.10.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
576 Gvinjilia L, Nasrullah M, Sergeenko D, Tsertsvadze T, Kamkamidze G, Butsashvili M, Gamkrelidze A, Imnadze P, Kvaratskhelia V, Chkhartishvili N, Sharvadze L, Drobeniuc J, Hagan L, Ward JW, Morgan J, Averhoff F. National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016. MMWR Morb Mortal Wkly Rep. 2016;65:1132-1135. [PMID: 27764081 DOI: 10.15585/mmwr.mm6541a2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 7.5] [Reference Citation Analysis]
577 Wilson EM, Rosenthal ES, Kattakuzhy S, Tang L, Kottilil S. Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C. Clin Microbiol Rev 2017;30:23-42. [PMID: 27795306 DOI: 10.1128/CMR.00037-16] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
578 Petruzziello A, Marigliano S, Loquercio G, Cacciapuoti C. Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe. Infect Agent Cancer. 2016;11:53. [PMID: 27752280 DOI: 10.1186/s13027-016-0099-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 55] [Article Influence: 8.2] [Reference Citation Analysis]
579 Minosse C, Giombini E, Bartolini B, Capobianchi MR, Garbuglia AR. Ultra-Deep Sequencing Characterization of HCV Samples with Equivocal Typing Results Determined with a Commercial Assay. Int J Mol Sci 2016;17:E1679. [PMID: 27739414 DOI: 10.3390/ijms17101679] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
580 Papachristou E, Tsagkovits A, Zavitsanou A, Hatzakis A, Paraskevis D. HCV dispersal patterns among intravenous drug users (IDUs) in Athens metropolitan area. Infect Genet Evol 2016;45:415-9. [PMID: 27721034 DOI: 10.1016/j.meegid.2016.10.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
581 Sedighimehr P, Irani S, Sakhaee F, Vaziri F, Aghasadeghi M, Sadat SM, Jamnani FR, Fateh A, Siadat SD. IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C. Arch Virol 2017;162:181-9. [DOI: 10.1007/s00705-016-3095-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
582 Mansoor S, Javed A, Ali A, Mansoor A. Heterogeneous genomic locations within NS3, NS4A and NS4B identified for genotyping and subtyping of Hepatitis C virus: A simple genome analysis approach. Infection, Genetics and Evolution 2016;44:61-8. [DOI: 10.1016/j.meegid.2016.06.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
583 Chahine EB, Sucher AJ, Hemstreet BA. Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C. Ann Pharmacother 2017;51:44-53. [PMID: 27609942 DOI: 10.1177/1060028016668897] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
584 Bukh J. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. J Hepatol 2016;65:S2-S21. [PMID: 27641985 DOI: 10.1016/j.jhep.2016.07.035] [Cited by in Crossref: 155] [Cited by in F6Publishing: 161] [Article Influence: 25.8] [Reference Citation Analysis]
585 Patiño-galindo JÁ, González-candelas F. Comparative analysis of variation and selection in the HCV genome.. [DOI: 10.1101/078584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
586 Smith DB, Becher P, Bukh J, Gould EA, Meyers G, Monath T, Muerhoff AS, Pletnev A, Rico-Hesse R, Stapleton JT, Simmonds P. Proposed update to the taxonomy of the genera Hepacivirus and Pegivirus within the Flaviviridae family. J Gen Virol 2016;97:2894-907. [PMID: 27692039 DOI: 10.1099/jgv.0.000612] [Cited by in Crossref: 113] [Cited by in F6Publishing: 119] [Article Influence: 18.8] [Reference Citation Analysis]
587 Klenerman P, Fitzmaurice K. An update on hepatitis C virus. Clin Med (Lond) 2015;15 Suppl 6:s33-6. [PMID: 26634679 DOI: 10.7861/clinmedicine.15-6-s33] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
588 Mac Donald-Ottevanger MS, Vreden S, van der Helm JJ, van de Laar T, Molenkamp R, Dams E, Roosblad J, Codrington J, Hindori-Mohangoo AD, Prins M. Prevalence, determinants and genetic diversity of hepatitis C virus in the multi-ethnic population living in Suriname. Virology 2016;499:114-20. [PMID: 27657832 DOI: 10.1016/j.virol.2016.07.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
589 Pierce BG, Keck ZY, Foung SK. Viral evasion and challenges of hepatitis C virus vaccine development. Curr Opin Virol 2016;20:55-63. [PMID: 27657659 DOI: 10.1016/j.coviro.2016.09.004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
590 Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol 2016; 22(34): 7824-7840 [PMID: 27678366 DOI: 10.3748/wjg.v22.i34.7824] [Cited by in CrossRef: 474] [Cited by in F6Publishing: 495] [Article Influence: 79.0] [Reference Citation Analysis]
591 Niu Z, Zhang P, Tong Y. Age and gender distribution of Hepatitis C virus prevalence and genotypes of individuals of physical examination in WuHan, Central China. Springerplus 2016;5:1557. [PMID: 27652130 DOI: 10.1186/s40064-016-3224-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
592 Zhou N, Han Z, Hartman-Neumann S, DeGray B, Ueland J, Vellucci V, Hernandez D, McPhee F. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens. J Antimicrob Chemother 2016;71:3495-505. [PMID: 27605597 DOI: 10.1093/jac/dkw336] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
593 Cuypers L, Li G, Neumann-Haefelin C, Piampongsant S, Libin P, Van Laethem K, Vandamme AM, Theys K. Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development. Virus Evol 2016;2:vew024. [PMID: 27774307 DOI: 10.1093/ve/vew024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
594 Tong L, Yu W, Coburn CA, Chen L, Selyutin O, Zeng Q, Dwyer MP, Nair AG, Shankar BB, Kim SH, Yang DY, Rosenblum SB, Ruck RT, Davies IW, Hu B, Zhong B, Hao J, Ji T, Zan S, Liu R, Agrawal S, Carr D, Curry S, McMonagle P, Bystol K, Lahser F, Ingravallo P, Chen S, Asante-Appiah E, Kozlowski JA. Structure-activity relationships of proline modifications around the tetracyclic-indole class of NS5A inhibitors. Bioorg Med Chem Lett 2016;26:5354-60. [PMID: 27680588 DOI: 10.1016/j.bmcl.2016.08.097] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
595 Ashraf NM, Bilal M, Mahmood MS, Hussain A, Mehboob MZ. In-silico analysis of putative HCV epitopes against Pakistani human leukocyte antigen background: An approach towards development of future vaccines for Pakistani population. Infection, Genetics and Evolution 2016;43:58-66. [DOI: 10.1016/j.meegid.2016.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
596 Schreiber J, McNally J, Chodavarapu K, Svarovskaia E, Moreno C. Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir. Hepatology 2016;64:983-5. [PMID: 27177605 DOI: 10.1002/hep.28636] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
597 Daniel HD, David J, Raghuraman S, Gnanamony M, Chandy GM, Sridharan G, Abraham P. Comparison of Three Different Hepatitis C Virus Genotyping Methods: 5'NCR PCR-RFLP, Core Type-Specific PCR, and NS5b Sequencing in a Tertiary Care Hospital in South India. J Clin Lab Anal 2017;31. [PMID: 27580956 DOI: 10.1002/jcla.22045] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
598 Gajurel K, Stapleton JT. Hepatitis Viruses in Kidney Transplantation. Seminars in Nephrology 2016;36:386-96. [DOI: 10.1016/j.semnephrol.2016.05.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
599 Dustin LB, Bartolini B, Capobianchi MR, Pistello M. Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. Clin Microbiol Infect 2016;22:826-32. [PMID: 27592089 DOI: 10.1016/j.cmi.2016.08.025] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 8.7] [Reference Citation Analysis]
600 Rodrigo C, Eltahla AA, Bull RA, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Estes C, Razavi H, Lloyd AR, Luciani F; International Collaborative of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study Group. Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. J Infect Dis 2016;214:1383-9. [PMID: 27571901 DOI: 10.1093/infdis/jiw389] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
601 Marascio N, Pavia G, Strazzulla A, Dierckx T, Cuypers L, Vrancken B, Barreca GS, Mirante T, Malanga D, Oliveira DM, Vandamme AM, Torti C, Liberto MC, Focà A; The SINERGIE-UMG Study Group. Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naïve Patients. Int J Mol Sci 2016;17:E1416. [PMID: 27618896 DOI: 10.3390/ijms17091416] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
602 Gimeno-Ballester V, Mar J, O'Leary A, Adams R, San Miguel R. Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients. Expert Rev Gastroenterol Hepatol 2017;11:85-93. [PMID: 27500437 DOI: 10.1080/17474124.2016.1222271] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
603 Yushchuk ND, Znoyko OO, Dudina KR, Kozina AN, Kalininа OV. [The efficiency of antiviral therapy in patients with chronic -hepatitis C infected with hepatitis C virus recombinants]. Ter Arkh 2016;88:101-5. [PMID: 27489903 DOI: 10.17116/terarkh2016886101-105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
604 Selvapatt N, Brown A. A real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies. F1000Res 2016;5:2061. [PMID: 27746906 DOI: 10.12688/f1000research.9114.1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
605 Ghaderi-Zefrehi H, Gholami-Fesharaki M, Sharafi H, Sadeghi F, Alavian SM. The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis. Hepat Mon 2016;16:e40357. [PMID: 27826320 DOI: 10.5812/hepatmon.40357] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
606 Rojas Á, Del Campo JA, Clement S, Lemasson M, García-Valdecasas M, Gil-Gómez A, Ranchal I, Bartosch B, Bautista JD, Rosenberg AR, Negro F, Romero-Gómez M. Effect of Quercetin on Hepatitis C Virus Life Cycle: From Viral to Host Targets. Sci Rep 2016;6:31777. [PMID: 27546480 DOI: 10.1038/srep31777] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 8.5] [Reference Citation Analysis]
607 Lawitz EJ, Dvory-Sobol H, Doehle BP, Worth AS, McNally J, Brainard DM, Link JO, Miller MD, Mo H. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein. Antimicrob Agents Chemother. 2016;60:5368-5378. [PMID: 27353271 DOI: 10.1128/aac.00763-16] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 11.2] [Reference Citation Analysis]
608 Foster GR, Chayama K, Chuang WL, Fainboim H, Farkkila M, Gadano A, Gaeta GB, Hézode C, Inada Y, Heo J, Kumada H, Lu SN, Marcellin P, Moreno C, Roberts SK, Strasser SI, Thompson AJ, Toyota J, Paik SW, Vierling JM, Zignego AL, Cohen D, McPhee F, Wind-Rotolo M, Srinivasan S, Hruska M, Myler H, Portsmouth SD. A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3. Springerplus 2016;5:1365. [PMID: 27588258 DOI: 10.1186/s40064-016-2920-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
609 Santos AF, Bello G, Vidal LL, Souza SL, Mir D, Soares MA. In-depth phylogenetic analysis of hepatitis C virus subtype 1a and occurrence of 80K and associated polymorphisms in the NS3 protease. Sci Rep 2016;6:31780. [PMID: 27531254 DOI: 10.1038/srep31780] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
610 Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, Mohraz M, Mardani M, Fattahi MR, Poustchi H, Nikbin M, Nabavi M, Adibi P, Ziaee M, Behnava B, Rezaee-Zavareh MS, Colombo M, Massoumi H, Bizri AR, Eghtesad B, Amiri M, Namvar A, Hesamizadeh K, Malekzadeh R. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon 2016;16:e40959. [PMID: 27799966 DOI: 10.5812/hepatmon.guideline] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 7.8] [Reference Citation Analysis]
611 Budzko L, Marcinkowska-Swojak M, Jackowiak P, Kozlowski P, Figlerowicz M. Copy number variation of genes involved in the hepatitis C virus-human interactome. Sci Rep 2016;6:31340. [PMID: 27510840 DOI: 10.1038/srep31340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
612 Lanini S, Easterbrook PJ, Zumla A, Ippolito G. Hepatitis C: global epidemiology and strategies for control. Clin Microbiol Infect. 2016;22:833-838. [PMID: 27521803 DOI: 10.1016/j.cmi.2016.07.035] [Cited by in Crossref: 100] [Cited by in F6Publishing: 110] [Article Influence: 16.7] [Reference Citation Analysis]
613 Poljak M. Next-Generation Sequencing: a Diagnostic One-Stop Shop for Hepatitis C? J Clin Microbiol 2016;54:2427-30. [PMID: 27510828 DOI: 10.1128/JCM.01423-16] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
614 Meanwell NA. 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. J Med Chem 2016;59:7311-51. [PMID: 27501244 DOI: 10.1021/acs.jmedchem.6b00915] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
615 Salmona M, Caporossi A, Simmonds P, Thélu MA, Fusillier K, Mercier-Delarue S, De Castro N, LeGoff J, Chaix ML, François O, Simon F, Morand P, Larrat S, Maylin S. First next-generation sequencing full-genome characterization of a hepatitis C virus genotype 7 divergent subtype. Clin Microbiol Infect 2016;22:947.e1-8. [PMID: 27515394 DOI: 10.1016/j.cmi.2016.07.032] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
616 Ashraf A, Chakravarti A, Roy P, Kar P, Siddiqui O. Frequency of nucleotide sequence variations in the internal ribosome entry site region of hepatitis C virus RNA isolated from responding and non-responding patients with hepatitis C virus genotype 3 infection. Virusdisease 2016;27:251-9. [PMID: 28466036 DOI: 10.1007/s13337-016-0335-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
617 Yu W, Zhou G, Coburn CA, Zeng Q, Tong L, Dwyer MP, Hu B, Zhong B, Hao J, Ji T, Zan S, Chen L, Mazzola R, Kim JH, Sha D, Selyutin O, Rosenblum SB, Lavey B, Nair AG, Heon Kim S, Keertikar KM, Rokosz L, Agrawal S, Liu R, Xia E, Zhai Y, Curry S, McMonagle P, Ingravallo P, Asante-Appiah E, Chen S, Kozlowski JA. Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742. Bioorg Med Chem Lett 2016;26:4851-6. [PMID: 27568086 DOI: 10.1016/j.bmcl.2016.08.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
618 Swadling L, Halliday J, Kelly C, Brown A, Capone S, Ansari MA, Bonsall D, Richardson R, Hartnell F, Collier J, Ammendola V, Del Sorbo M, Von Delft A, Traboni C, Hill AV, Colloca S, Nicosia A, Cortese R, Klenerman P, Folgori A, Barnes E. Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. Vaccines (Basel). 2016;4. [PMID: 27490575 DOI: 10.3390/vaccines4030027] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
619 Grzyb K, Czarnota A, Brzozowska A, Cieślik A, Rąbalski Ł, Tyborowska J, Bieńkowska-Szewczyk K. Immunogenicity and functional characterization of Leishmania-derived hepatitis C virus envelope glycoprotein complex. Sci Rep 2016;6:30627. [PMID: 27481352 DOI: 10.1038/srep30627] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
620 Kartashev V, Döring M, Nieto L, Coletta E, Kaiser R, Sierra S, Guerrero A, Stoiber H, Paar C, Vandamme A, Nevens F, Ranst MV, Cuypers L, Braun P, Ehret R, Obermeier M, Schneeweiss S, Scholten S, Römer K, Isernhagen K, Qurashi N, Heger E, Knops E, Neumann-fraune M, Timm J, Walker A, Lübke N, Wedemeyer H, Wiesch JSZ, Lütgehetmann M, Polywka S, Däumer M, Hoffmann D, Protzer U, Marascio N, Foca A, Liberto M, Barreca G, Galati L, Torti C, Pisani V, Perno C, Ceccherini-silberstein F, Cento V, Ciotti M, Zazzi M, Rossetti B, Luca A, Caudai C, Mor O, Devaux C, Staub T, Araujo F, Gomes P, Cabanas J, Markin N, Khomenko I, Govorukhina M, Lugovskaya G, Dontsov D, Mas A, Martró E, Saludes V, Rodríguez-frías F, García F, Casas P, Iglesia ADL, Alados J, Pena-lópez M, Rodríguez M, Galán J, Suárez A, Cardeñoso L, Guerrero M, Vegas-dominguez C, Blas-espada J, García R, García-bujalance S, Benítez-gutiérrez L, Mendoza CD, Montiel N, Santos J, Viciana I, Delgado A, Martínez-sanchez P, Fernández-alonso M, Reina G, Trigo M, Echeverría M, Aguilera A, Navarro D, Bernal S, Lozano M, Fernández-cuenca F, Orduña A, Eiros J, Lejarazu ROD, Martínez-sapiña A, García-díaz A, Haque T. New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. Journal of Clinical Virology 2016;81:82-9. [DOI: 10.1016/j.jcv.2016.05.010] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 8.2] [Reference Citation Analysis]
621 Chang ML, Liang KH, Ku CL, Lo CC, Cheng YT, Hsu CM, Yeh CT, Chiu CT. Resistin reinforces interferon λ-3 to eliminate hepatitis C virus with fine-tuning from RETN single-nucleotide polymorphisms. Sci Rep 2016;6:30799. [PMID: 27477870 DOI: 10.1038/srep30799] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
622 Wahyuni TS, Utsubo CA, Hotta H. Promising Anti-Hepatitis C Virus Compounds from Natural Resources. Natural Product Communications 2016;11:1934578X1601100. [DOI: 10.1177/1934578x1601100840] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
623 Bastos JCS, Padilla MA, Caserta LC, Miotto N, Vigani AG, Arns CW. Hepatitis C virus: Promising discoveries and new treatments. World J Gastroenterol 2016; 22(28): 6393-6401 [PMID: 27605875 DOI: 10.3748/wjg.v22.i28.6393] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
624 Cowton VM, Angus AGN, Cole SJ, Markopoulou CK, Owsianka A, Dunlop JI, Gardner DE, Krey T, Patel AH. Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection. J Virol 2016;90:7456-68. [PMID: 27279607 DOI: 10.1128/JVI.00685-16] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
625 Riaz S, Bashir MF, Haider S, Rahid N. Association of genotypes with viral load and biochemical markers in HCV-infected Sindhi patients. Braz J Microbiol 2016;47:980-6. [PMID: 27528079 DOI: 10.1016/j.bjm.2016.07.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
626 Barsoum RS, William EA, Khalil SS. Hepatitis C and kidney disease: A narrative review. J Adv Res. 2017;8:113-130. [PMID: 28149647 DOI: 10.1016/j.jare.2016.07.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
627 Tong L, Yu W, Coburn CA, Meinke PT, Nair AG, Dwyer MP, Chen L, Selyutin O, Rosenblum SB, Jiang Y, Fells J, Hu B, Zhong B, Soll RM, Liu R, Agrawal S, Xia E, Zhai Y, Kong R, Ingravallo P, Nomeir A, Asante-Appiah E, Kozlowski JA. Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors. Bioorg Med Chem Lett 2016;26:5132-7. [PMID: 27634194 DOI: 10.1016/j.bmcl.2016.07.057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
628 Win NN, Kanda T, Nakamoto S, Yokosuka O, Shirasawa H. Hepatitis C virus genotypes in Myanmar. World J Gastroenterol 2016; 22(27): 6095-6099 [PMID: 27468202 DOI: 10.3748/wjg.v22.i27.6095] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
629 Liu T, Wan Z, Liu J, Zhang L, Zhou Y, Lan K, Hu Y, Zhang C. A novel real-time reverse transcription-polymerase chain reaction assay with partially double-stranded linear DNA probe for sensitive detection of hepatitis C viral RNA. J Virol Methods 2016;236:132-8. [PMID: 27451264 DOI: 10.1016/j.jviromet.2016.07.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
630 Echeverría N, Betancour G, Gámbaro F, Hernández N, López P, Chiodi D, Sánchez A, Boschi S, Fajardo A, Sóñora M, Moratorio G, Cristina J, Moreno P. Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries. Virus Res 2016;223:140-6. [PMID: 27449600 DOI: 10.1016/j.virusres.2016.07.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
631 Esposito I, Trinks J, Soriano V. Hepatitis C virus resistance to the new direct-acting antivirals. Expert Opin Drug Metab Toxicol. 2016;12:1197-1209. [PMID: 27384079 DOI: 10.1080/17425255.2016.1209484] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 6.3] [Reference Citation Analysis]
632 De Conto F, Medici MC, Ferraglia F, Pinardi F, Fazzi A, Arcangeletti MC, Chezzi C, Calderaro A. Temporal dynamics of hepatitis C genotypes in a five-year hospital-based surveillance in Northern Italy. Arch Virol 2016;161:2727-37. [DOI: 10.1007/s00705-016-2975-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
633 Cuypers L, Ceccherini-Silberstein F, Van Laethem K, Li G, Vandamme AM, Rockstroh JK. Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Rev Med Virol 2016;26:408-34. [PMID: 27401933 DOI: 10.1002/rmv.1895] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
634 Alberti A, Lacoin L, Morais E, Lefevre C, Abogunrin S, Iheanacho I. Literature review of the distribution of hepatitis C virus genotypes across Europe: HCV Genotype Distribution in Europe Review. J Med Virol 2016;88:2157-69. [DOI: 10.1002/jmv.24573] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
635 Bonaventura A, Montecucco F. Sofosbuvir/velpatasvir: A promising combination. World J Hepatol 2016; 8(19): 785-789 [PMID: 27429714 DOI: 10.4254/wjh.v8.i19.785] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
636 Wei B, Kang J, Kibukawa M, Chen L, Qiu P, Lahser F, Marton M, Levitan D. Development and Validation of a Template-Independent Next-Generation Sequencing Assay for Detecting Low-Level Resistance-Associated Variants of Hepatitis C Virus. J Mol Diagn 2016;18:643-56. [PMID: 27393904 DOI: 10.1016/j.jmoldx.2016.04.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
637 Thomson E, Ip CL, Badhan A, Christiansen MT, Adamson W, Ansari MA, Bibby D, Breuer J, Brown A, Bowden R, Bryant J, Bonsall D, Da Silva Filipe A, Hinds C, Hudson E, Klenerman P, Lythgow K, Mbisa JL, McLauchlan J, Myers R, Piazza P, Roy S, Trebes A, Sreenu VB, Witteveldt J, Barnes E, Simmonds P; STOP-HCV Consortium. Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes. J Clin Microbiol 2016;54:2470-84. [PMID: 27385709 DOI: 10.1128/JCM.00330-16] [Cited by in Crossref: 86] [Cited by in F6Publishing: 90] [Article Influence: 14.3] [Reference Citation Analysis]
638 Salvatierra K, Florez H. Análisis del virus de la hepatitis C en pacientes en hemodiálisis. Infectio 2016;20:130-7. [DOI: 10.1016/j.infect.2015.10.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
639 Cuypers L, Snoeck J, Kerremans L, Libin P, Crabbé R, Van Dooren S, Vuagniaux G, Vandamme AM. HCV1b genome evolution under selective pressure of the cyclophilin inhibitor alisporivir during the DEB-025-HCV-203 phase II clinical trial. Infect Genet Evol 2016;44:169-81. [PMID: 27374748 DOI: 10.1016/j.meegid.2016.06.050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
640 Jiao Y, Zhang X, Wang C, Li L, Liu J, Bar KJ, Wei H, Hu Y, Huang P, Zeng Z, Jiang S, Du J, Shao Y, Metzger D, Li S, Ma L. Hepatitis C Virus Subtype and Evolution Characteristic Among Drug Users, Men Who Have Sex With Men, and the General Population in Beijing, China. Medicine (Baltimore) 2016;95:e2688. [PMID: 26871798 DOI: 10.1097/MD.0000000000002688] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
641 FakhriRavari A, Malakouti M, Brady R. Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection. J Clin Transl Hepatol 2016;4:97-112. [PMID: 27350940 DOI: 10.14218/JCTH.2016.00007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
642 Yu W, Coburn CA, Nair AG, Wong M, Rosenblum SB, Zhou G, Dwyer MP, Tong L, Hu B, Zhong B, Hao J, Ji T, Zan S, Kim SH, Zeng Q, Selyutin O, Chen L, Masse F, Agrawal S, Liu R, Xia E, Zhai Y, Curry S, McMonagle P, Ingravallo P, Asante-Appiah E, Lin M, Kozlowski JA. Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742. Bioorg Med Chem Lett 2016;26:3414-20. [PMID: 27394665 DOI: 10.1016/j.bmcl.2016.06.056] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
643 Bell AM, Wagner JL, Barber KE, Stover KR. Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C. Int J Hepatol. 2016;2016:3852126. [PMID: 27403342 DOI: 10.1155/2016/3852126] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
644 Yang R, Yang X, Xiu B, Rao H, Fei R, Guan W, Liu Y, Wang Q, Feng X, Zhang H, Wei L. Hepatitis C Virus Genotype Analyses in Chronic Hepatitis C Patients and Individuals With Spontaneous Virus Clearance Using a Newly Developed Serotyping Assay. J Clin Lab Anal 2017;31. [PMID: 27292225 DOI: 10.1002/jcla.22014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
645 Shi R, Cui Y. Global analysis of a mathematical model for Hepatitis C virus transmissions. Virus Research 2016;217:8-17. [DOI: 10.1016/j.virusres.2016.02.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
646 Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int. 2016;10:681-701. [PMID: 27229718 DOI: 10.1007/s12072-016-9736-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 66] [Article Influence: 9.7] [Reference Citation Analysis]
647 Lam JT, Salazar L. New combination antiviral for the treatment of hepatitis C. Am J Health Syst Pharm 2016;73:1042-50. [PMID: 27217519 DOI: 10.2146/ajhp150163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
648 Serre SB, Jensen SB, Ghanem L, Humes DG, Ramirez S, Li YP, Krarup H, Bukh J, Gottwein JM. Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle. Antimicrob Agents Chemother 2016;60:3563-78. [PMID: 27021330 DOI: 10.1128/AAC.02929-15] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
649 Champeimont R, Laine E, Hu SW, Penin F, Carbone A. Coevolution analysis of Hepatitis C virus genome to identify the structural and functional dependency network of viral proteins. Sci Rep 2016;6:26401. [PMID: 27198619 DOI: 10.1038/srep26401] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
650 Kalaghatgi P, Sikorski AM, Knops E, Rupp D, Sierra S, Heger E, Neumann-Fraune M, Beggel B, Walker A, Timm J. Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents. PLoS One. 2016;11:e0155869. [PMID: 27196673 DOI: 10.1371/journal.pone.0155869] [Cited by in Crossref: 79] [Cited by in F6Publishing: 83] [Article Influence: 13.2] [Reference Citation Analysis]
651 Ning G, Lin CS. History and future of antiviral therapy of chronic hepatitis C. Shijie Huaren Xiaohua Zazhi 2016; 24(14): 2117-2130 [DOI: 10.11569/wcjd.v24.i14.2117] [Reference Citation Analysis]
652 Gaspareto KV, Ribeiro RM, de Mello Malta F, Gomes-Gouvêa MS, Muto NH, Mendes-Correa MC, Rozanski A, Carrilho FJ, Sabino EC, Pinho JR. HCV inter-subtype 1a/1b recombinant detected by complete-genome next-generation sequencing. Arch Virol 2016;161:2161-8. [PMID: 27194536 DOI: 10.1007/s00705-016-2889-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
653 Souii A, Elargoubi A, Fallecker C, Mastouri M, Drouet E. Hepatitis C Genotype Prevalence in Monastir Region, Tunisia: Correlation between 5' Untranslated Region (5'UTR), Non-structural 5B (NS5B), and Core Sequences in HCV Subtyping. Curr Microbiol 2016;73:324-34. [PMID: 27189386 DOI: 10.1007/s00284-016-1064-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
654 Lu G, Sun L, Xu T, He D, Wang Z, Ou S, Jia K, Yuan L, Li S. First Description of Hepacivirus and Pegivirus Infection in Domestic Horses in China: A Study in Guangdong Province, Heilongjiang Province and Hong Kong District. PLoS One 2016;11:e0155662. [PMID: 27182887 DOI: 10.1371/journal.pone.0155662] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
655 Yu W, Coburn CA, Nair AG, Wong M, Tong L, Dwyer MP, Hu B, Zhong B, Hao J, Yang DY, Selyutin O, Jiang Y, Rosenblum SB, Kim SH, Lavey BJ, Zhou G, Rizvi R, Shankar BB, Zeng Q, Chen L, Agrawal S, Carr D, Rokosz L, Liu R, Curry S, McMonagle P, Ingravallo P, Lahser F, Asante-Appiah E, Nomeir A, Kozlowski JA. Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742. Bioorg Med Chem Lett 2016;26:3800-5. [PMID: 27282742 DOI: 10.1016/j.bmcl.2016.05.041] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
656 Wu D, Fu X, Wen Y, Liu B, Deng Z, Dai L, Tan D. High-resolution melting combines with Bayes discriminant analysis: a novel hepatitis C virus genotyping method. Clin Exp Med 2017;17:325-32. [PMID: 27178340 DOI: 10.1007/s10238-016-0424-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
657 Manolakopoulos S, Zacharakis G, Zissis M, Giannakopoulos V. Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C. Ann Gastroenterol 2016;29:282-96. [PMID: 27366028 DOI: 10.20524/aog.2016.0041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
658 Walker MR, Li H, Teutsch S, Betz-Stablein B, Luciani F, Lloyd AR, Bull RA. Incident Hepatitis C Virus Genotype Distribution and Multiple Infection in Australian Prisons. J Clin Microbiol 2016;54:1855-61. [PMID: 27170021 DOI: 10.1128/JCM.00287-16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
659 Ku KS, Chodavarapu RK, Martin R, Miller MD, Mo H, Svarovskaia ES. Sequencing Analysis of NS3/4A, NS5A, and NS5B Genes from Patients Infected with Hepatitis C Virus Genotypes 5 and 6. J Clin Microbiol 2016;54:1835-41. [PMID: 27147726 DOI: 10.1128/JCM.00238-16] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
660 Walter S, Bollenbach A, Doerrbecker J, Pfaender S, Brown RJP, Vieyres G, Scott C, Foster R, Kumar A, Zitzmann N, Griffin S, Penin F, Pietschmann T, Steinmann E. Ion Channel Function and Cross-Species Determinants in Viral Assembly of Nonprimate Hepacivirus p7. J Virol 2016;90:5075-89. [PMID: 26962224 DOI: 10.1128/JVI.00132-16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
661 Chi X, Niu Y, Cheng M, Liu X, Feng Y, Zheng F, Fan J, Li X, Jin Q, Zhong J, Li YP, Yang W. Identification of a Potent and Broad-Spectrum Hepatitis C Virus Fusion Inhibitory Peptide from the E2 Stem Domain. Sci Rep 2016;6:25224. [PMID: 27121372 DOI: 10.1038/srep25224] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
662 Rajhi M, Ghedira K, Chouikha A, Djebbi A, Cheikh I, Ben Yahia A, Sadraoui A, Hammami W, Azouz M, Ben Mami N, Triki H. Phylogenetic Analysis and Epidemic History of Hepatitis C Virus Genotype 2 in Tunisia, North Africa. PLoS One 2016;11:e0153761. [PMID: 27100294 DOI: 10.1371/journal.pone.0153761] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
663 Miyazaki R, Miyagi K. Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis: Daclatasvir Plus Asunaprevir. Ther Apher Dial 2016;20:462-7. [DOI: 10.1111/1744-9987.12407] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
664 Chueca N, Rivadulla I, Lovatti R, Reina G, Blanco A, Fernandez-Caballero JA, Cardeñoso L, Rodriguez-Granjer J, Fernandez-Alonso M, Aguilera A, Alvarez M, Galán JC, García F. Using NS5B Sequencing for Hepatitis C Virus Genotyping Reveals Discordances with Commercial Platforms. PLoS One 2016;11:e0153754. [PMID: 27097040 DOI: 10.1371/journal.pone.0153754] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
665 Gul A, Zahid N, Ahmed J, Zahir F, Khan IA, Ali I. Molecular characterization of Hepatitis C virus 3a in Peshawar. BMC Infect Dis 2016;16:163. [PMID: 27090517 DOI: 10.1186/s12879-016-1488-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
666 Mallory M, Hillyard D. Hepatitis C Virus. Clinical Virology Manual 2016. [DOI: 10.1128/9781555819156.ch25] [Reference Citation Analysis]
667 Trémeaux P, Caporossi A, Thélu MA, Blum M, Leroy V, Morand P, Larrat S. Hepatitis C virus whole genome sequencing: Current methods/issues and future challenges. Crit Rev Clin Lab Sci 2016;53:341-51. [PMID: 27068766 DOI: 10.3109/10408363.2016.1163663] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
668 Chaiwong S, Sistayanarain A. Characterization of partial NS5B region among hepatitis C virus genotype 6 subtypes isolated from Thai blood donors. J Med Virol 2016;88:1785-90. [PMID: 27018495 DOI: 10.1002/jmv.24536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
669 Wang SR, Min YQ, Wang JQ, Liu CX, Fu BS, Wu F, Wu LY, Qiao ZX, Song YY, Xu GH, Wu ZG, Huang G, Peng NF, Huang R, Mao WX, Peng S, Chen YQ, Zhu Y, Tian T, Zhang XL, Zhou X. A highly conserved G-rich consensus sequence in hepatitis C virus core gene represents a new anti-hepatitis C target. Sci Adv 2016;2:e1501535. [PMID: 27051880 DOI: 10.1126/sciadv.1501535] [Cited by in Crossref: 88] [Cited by in F6Publishing: 74] [Article Influence: 14.7] [Reference Citation Analysis]
670 Colson P, Borentain P, Dhiver C, Benhaim S, Gerolami R, Tamalet C. Recombinant hepatitis C viruses that might hamper accurate genotype classification and choice of treatment with direct-acting agents, southeastern France. Hepatology 2016;63:1400-2. [PMID: 26418048 DOI: 10.1002/hep.28261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
671 Coppola N, Minichini C, Starace M, Sagnelli C, Sagnelli E. Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals: HCV Mutations Versus DAAs. J Med Virol 2016;88:1659-71. [DOI: 10.1002/jmv.24527] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
672 Kosack CS, Nick S. Evaluation of two rapid screening assays for detecting hepatitis C antibodies in resource-constrained settings. Trop Med Int Health 2016;21:603-9. [DOI: 10.1111/tmi.12688] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
673 Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener T, Hughes EA, Yin PD, Noviello S. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. World J Gastroenterol 2016; 22(12): 3418-3431 [PMID: 27022224 DOI: 10.3748/wjg.v22.i12.3418] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
674 Patiño-Galindo JÁ, Salvatierra K, González-Candelas F, López-Labrador FX. Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6. Antimicrob Agents Chemother 2016;60:2402-16. [PMID: 26856832 DOI: 10.1128/AAC.02776-15] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
675 Wei K, Li Y, Chen H, Zhang Q. Genomic Surveillance Elucidates HCV 1a Phylodynamics and Molecular Evolution. Evol Biol 2016;43:380-91. [DOI: 10.1007/s11692-016-9379-2] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
676 Diatta T, Chavade D, Degos F, d'Andon A, Guillevin L. [Hepatitis C infection: Therapeutic strategies]. Presse Med 2016;45:495-508. [PMID: 27006245 DOI: 10.1016/j.lpm.2016.02.006] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
677 Yang L, Jiang C, Hu S, Diao Q, Li J, Si W, Chen M, Zhao RY. Evolving Diversity of Hepatitis C Viruses in Yunnan Honghe, China. Int J Mol Sci 2016;17:403. [PMID: 26999127 DOI: 10.3390/ijms17030403] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
678 Bull RA, Eltahla AA, Rodrigo C, Koekkoek SM, Walker M, Pirozyan MR, Betz-Stablein B, Toepfer A, Laird M, Oh S, Heiner C, Maher L, Schinkel J, Lloyd AR, Luciani F. A method for near full-length amplification and sequencing for six hepatitis C virus genotypes. BMC Genomics. 2016;17:247. [PMID: 26988550 DOI: 10.1186/s12864-016-2575-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
679 Li Y, Wang R, Du X, Zhang M, Xie M. Genome-wide analysis for identification of adaptive diversification between hepatitis C virus subtypes 1a and 1b. Can J Microbiol 2016;62:608-16. [PMID: 27277863 DOI: 10.1139/cjm-2016-0156] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
680 Koh C, Li Q, Liang J. Hepatitis C Virus. Clinical Virology 2016. [DOI: 10.1128/9781555819439.ch54] [Reference Citation Analysis]
681 Seignères B, Descamps F, Croise R, Barlet V, Bouvier-Alias M, Chevaliez S, Pawlotsky JM, Abdelhady W, Rafik M, Avellon AM, Echevarria JM, Hausmann M, Dugua JM. Multicenter clinical evaluation of the new 3rd generation assay for detection of antibodies against hepatitis C virus on the VIDAS(®) system. J Clin Virol 2016;78:20-6. [PMID: 26962723 DOI: 10.1016/j.jcv.2016.03.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
682 Ha S, Totten S, Pogany L, Wu J, Gale-Rowe M. Hepatitis C in Canada and the importance of risk-based screening. Can Commun Dis Rep 2016;42:57-62. [PMID: 29770005 DOI: 10.14745/ccdr.v42i03a02] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
683 Li YP, Van Pham L, Uzcategui N, Bukh J. Functional analysis of microRNA-122 binding sequences of hepatitis C virus and identification of variants with high resistance against a specific antagomir. J Gen Virol 2016;97:1381-94. [PMID: 26935756 DOI: 10.1099/jgv.0.000445] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
684 Saludes V, Quer J, Gregori J, Bascuñana E, García-Cehic D, Esteban JI, Ausina V, Martró E. Identification of hepatitis C virus genotype 3 by a commercial assay challenged by natural polymorphisms detected in Spain from patients with diverse origins. J Clin Virol 2016;78:14-9. [PMID: 26946155 DOI: 10.1016/j.jcv.2016.02.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
685 Butt AM, Raja AJ, Siddique S, Khan JS, Shahid M, Tayyab GU, Minhas Z, Umar M, Idrees M, Tong Y. Parallel expression profiling of hepatic and serum microRNA-122 associated with clinical features and treatment responses in chronic hepatitis C patients. Sci Rep. 2016;6:21510. [PMID: 26898400 DOI: 10.1038/srep21510] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
686 Lu L, Wu T, Xiong L, Li C, Nguyen MH, Murphy DG. Analysis of HCV-6 isolates among Asian-born immigrants in North America reveals their high genetic diversity and a new subtype. Virology 2016;492:25-31. [PMID: 26896932 DOI: 10.1016/j.virol.2016.01.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
687 Semenov AV, Ostankova JV, Gerasimova VV, Bichurina MA, Kozlov AV, Mukomolov SL, Totolian AA. MOLECULAR EPIDEMIOLOGY FEATURES OF HEPATITIS C VIRUS ISOLATES FROM DIFFERENT REGIONS OF THE REPUBLIC SAKHA (YAKUTIA). Russian Journal of Infection and Immunity 2016;5:359-372. [DOI: 10.15789/2220-7619-2015-4-359-372] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
688 Deming P, Martin MT, Chan J, Dilworth TJ, El-Lababidi R, Love BL, Mohammad RA, Nguyen A, Spooner LM, Wortman SB. Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2016;36:203-17. [PMID: 26846728 DOI: 10.1002/phar.1700] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
689 Ederth J, Jern C, Norder H, Magnius L, Alm E, Rognsvåg BK, Sundin CG, Brytting M, Esbjörnsson J, Mild M. Molecular characterization of HCV in a Swedish county over 8 years (2002-2009) reveals distinct transmission patterns. Infect Ecol Epidemiol 2016;6:30670. [PMID: 26854010 DOI: 10.3402/iee.v6.30670] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
690 Zeuzem S, Hézode C, Bronowicki JP, Loustaud-Ratti V, Gea F, Buti M, Olveira A, Banyai T, Al-Assi MT, Petersen J, Thabut D, Gadano A, Pruitt R, Makara M, Bourlière M, Pol S, Beumont-Mauviel M, Ouwerkerk-Mahadevan S, Picchio G, Bifano M, McPhee F, Boparai N, Cheung K, Hughes EA, Noviello S; LEAGUE-1 Study Team. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. J Hepatol 2016;64:292-300. [PMID: 26453968 DOI: 10.1016/j.jhep.2015.09.024] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
691 Cornberg M, Wedemeyer H. Hepatitis C virus infection from the perspective of heterologous immunity. Current Opinion in Virology 2016;16:41-8. [DOI: 10.1016/j.coviro.2016.01.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
692 Hewawasam P, Tu Y, Gao M, Hanumegowda U, Knipe J, Lemm JA, Parker DD, Rigat KL, Roberts SB, Meanwell NA, Kadow JF. Discovery and preclinical evaluation of potent, orally bioavailable, metabolically stable cyclopropylindolobenzazepine acylsulfonamides as thumb site 1 inhibitors of the hepatitis c virus NS5B RNA-dependent, RNA polymerase. Bioorganic & Medicinal Chemistry Letters 2016;26:936-40. [DOI: 10.1016/j.bmcl.2015.12.058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
693 Gowin E, Bereszyńska I, Adamek A, Kowala-piaskowska A, Mozer-lisewska I, Wysocki J, Michalak M, Januszkiewicz-lewandowska D. The prevalence of mixed genotype infections in Polish patients with hepatitis C. International Journal of Infectious Diseases 2016;43:13-6. [DOI: 10.1016/j.ijid.2015.12.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
694 Crosignani A, Riva A, Della Bella S. Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C. World J Gastroenterol 2016; 22(4): 1393-1404 [PMID: 26819508 DOI: 10.3748/wjg.v22.i4.1393] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
695 Sukowati CH, El-Khobar KE, Ie SI, Anfuso B, Muljono DH, Tiribelli C. Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World J Gastroenterol 2016; 22(4): 1497-1512 [PMID: 26819517 DOI: 10.3748/wjg.v22.i4.1497] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 41] [Article Influence: 6.5] [Reference Citation Analysis]
696 Trémeaux P, Caporossi A, Ramière C, Santoni E, Tarbouriech N, Thélu MA, Fusillier K, Geneletti L, François O, Leroy V, Burmeister WP, André P, Morand P, Larrat S. Amplification and pyrosequencing of near-full-length hepatitis C virus for typing and monitoring antiviral resistant strains. Clin Microbiol Infect 2016;22:460.e1-460.e10. [PMID: 26827671 DOI: 10.1016/j.cmi.2016.01.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
697 Niesters HGM, Riezebos-brilman A, Van Leer-buter CC. Viral Hepatitis. Manual of Molecular and Clinical Laboratory Immunology 2016. [DOI: 10.1128/9781555818722.ch65] [Reference Citation Analysis]
698 Sandomenico A, Leonardi A, Berisio R, Sanguigno L, Focà G, Focà A, Ruggiero A, Doti N, Muscariello L, Barone D, Farina C, Owsianka A, Vitagliano L, Patel AH, Ruvo M. Generation and Characterization of Monoclonal Antibodies against a Cyclic Variant of Hepatitis C Virus E2 Epitope 412-422. J Virol 2016;90:3745-59. [PMID: 26819303 DOI: 10.1128/JVI.02397-15] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 5.2] [Reference Citation Analysis]
699 Henquell C, Yameogo S, Sangaré L. First genome characterization of a novel hepatitis C virus genotype 5 variant. Infect Genet Evol 2016;39:173-5. [PMID: 26807921 DOI: 10.1016/j.meegid.2016.01.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
700 Swallow E, Kelley C, Signorovitch J, Wygant G, McPhee F. Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison. J Comp Eff Res 2016;5:273-9. [PMID: 26793987 DOI: 10.2217/cer.15.69] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
701 Blanco JR, Rivero-Juarez A. HCV genotype 3: a wolf in sheep's clothing. Expert Rev Anti Infect Ther 2016;14:149-52. [PMID: 26635242 DOI: 10.1586/14787210.2016.1127757] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
702 Abdelwahab KS, Ahmed Said ZN. Status of hepatitis C virus vaccination: Recent update. World J Gastroenterol 2016; 22(2): 862-873 [PMID: 26811632 DOI: 10.3748/wjg.v22.i2.862] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
703 Bretaña NA, Boelen L, Bull R, Teutsch S, White PA, Lloyd AR, Luciani F; HITS-p investigators. Transmission of Hepatitis C Virus among Prisoners, Australia, 2005-2012. Emerg Infect Dis 2015;21:765-74. [PMID: 25897788 DOI: 10.3201/eid2105.141832] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.8] [Reference Citation Analysis]
704 Perin PM, Haid S, Brown RJ, Doerrbecker J, Schulze K, Zeilinger C, von Schaewen M, Heller B, Vercauteren K, Luxenburger E, Baktash YM, Vondran FW, Speerstra S, Awadh A, Mukhtarov F, Schang LM, Kirschning A, Müller R, Guzman CA, Kaderali L, Randall G, Meuleman P, Ploss A, Pietschmann T. Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1. Hepatology 2016;63:49-62. [PMID: 26248546 DOI: 10.1002/hep.28111] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 10.0] [Reference Citation Analysis]
705 Domingo E. Long-Term Virus Evolution in Nature. Virus as Populations 2016. [DOI: 10.1016/b978-0-12-800837-9.00007-1] [Reference Citation Analysis]
706 Cristina J, Recarey R. Identification of MicroRNA-Like Molecules Derived from the Antigenome RNA of Hepatitis C Virus: A Bioinformatics Approach. NS 2016;08:180-191. [DOI: 10.4236/ns.2016.84021] [Reference Citation Analysis]
707 Hézode C, Bronowicki JP. Ideal oral combinations to eradicate HCV: The role of ribavirin. J Hepatol 2016;64:215-25. [PMID: 26409316 DOI: 10.1016/j.jhep.2015.09.009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
708 Gul A, Ahmed J, Zahir F, Ali Khan I, Ali I. New patterns of HCV subtypes distribution in the Khyber Pakhtunkhwa province of Pakistan. The Brazilian Journal of Infectious Diseases 2016;20:107-8. [DOI: 10.1016/j.bjid.2015.09.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
709 Cox AL. Prophylactic Vaccines for the Hepatitis C Virus. Hepatitis C Virus II 2016. [DOI: 10.1007/978-4-431-56101-9_13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
710 Goossens N, Clément S, Negro F. Introduction. Handbook of Hepatitis C 2016. [DOI: 10.1007/978-3-319-28053-0_1] [Reference Citation Analysis]
711 Freissmuth M. Antivirale Pharmaka. Pharmakologie und Toxikologie 2016. [DOI: 10.1007/978-3-662-46689-6_58] [Reference Citation Analysis]
712 Nolte FS. Hepatitis B and C Viruses. Molecular Pathology in Clinical Practice 2016. [DOI: 10.1007/978-3-319-19674-9_46] [Reference Citation Analysis]
713 Goossens N, Clément S, Negro F. Diagnosis. Handbook of Hepatitis C 2016. [DOI: 10.1007/978-3-319-28053-0_5] [Reference Citation Analysis]
714 Shin-i T, Sugiyama M, Mizokami M. Hepatitis C Virus Genotypes and Their Evolution. Hepatitis C Virus I 2016. [DOI: 10.1007/978-4-431-56098-2_2] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
715 Houghton M. Towards the Control of Hepatitis C. Hepatitis C Virus I 2016. [DOI: 10.1007/978-4-431-56098-2_1] [Reference Citation Analysis]
716 Molecular Detection and Characterization of Hepatitis C Virus. Molecular Microbiology 2016. [DOI: 10.1128/9781555819071.ch31] [Reference Citation Analysis]
717 Palmer BA, Schmidt-Martin D, Dimitrova Z, Skums P, Crosbie O, Kenny-Walsh E, Fanning LJ. Network Analysis of the Chronic Hepatitis C Virome Defines Hypervariable Region 1 Evolutionary Phenotypes in the Context of Humoral Immune Responses. J Virol 2015;90:3318-29. [PMID: 26719263 DOI: 10.1128/JVI.02995-15] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
718 Gonçalves Rossi LM, Escobar-Gutierrez A, Rahal P. Multiregion deep sequencing of hepatitis C virus: An improved approach for genetic relatedness studies. Infect Genet Evol 2016;38:138-45. [PMID: 26733442 DOI: 10.1016/j.meegid.2015.12.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
719 Kumthip K, Maneekarn N. The role of HCV proteins on treatment outcomes. Virol J 2015;12:217. [PMID: 26666318 DOI: 10.1186/s12985-015-0450-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
720 Schinazi RF, Shi J, Whitaker T. Sofosbuvir (Sovaldi): The First-in-Class HCV NS5B Nucleotide Polymerase Inhibitor. Innovative Drug Synthesis 2015. [DOI: 10.1002/9781118819951.ch4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
721 Nyan DC, Swinson KL. A method for rapid detection and genotype identification of hepatitis C virus 1-6 by one-step reverse transcription loop-mediated isothermal amplification. Int J Infect Dis 2016;43:30-6. [PMID: 26686938 DOI: 10.1016/j.ijid.2015.12.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
722 Elsebai MF, Koutsoudakis G, Saludes V, Pérez-Vilaró G, Turpeinen A, Mattila S, Pirttilä AM, Fontaine-Vive F, Mehiri M, Meyerhans A, Diez J. Pan-genotypic Hepatitis C Virus Inhibition by Natural Products Derived from the Wild Egyptian Artichoke. J Virol 2016;90:1918-30. [PMID: 26656684 DOI: 10.1128/JVI.02030-15] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
723 Abdel-Ghaffar TY, Sira MM, El Naghi S. Hepatitis C genotype 4: The past, present, and future. World J Hepatol 2015; 7(28): 2792-2810 [PMID: 26668691 DOI: 10.4254/wjh.v7.i28.2792] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
724 Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Zhang X, Setze C, Rodrigues L Jr, Burroughs M, Redman R, Chayama K, Kumada H, Collins C, Pilot-Matias T. Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir. Antimicrob Agents Chemother. 2015;60:1106-1113. [PMID: 26643326 DOI: 10.1128/aac.02606-15] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
725 Fourati S, Pawlotsky JM. Virologic Tools for HCV Drug Resistance Testing. Viruses 2015;7:6346-59. [PMID: 26690198 DOI: 10.3390/v7122941] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
726 Sundaram V, Kowdley KV. Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection. Expert Rev Gastroenterol Hepatol 2016;10:13-20. [PMID: 26560449 DOI: 10.1586/17474124.2016.1116937] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
727 Li X, Shi H, Chen X, Li W, Wang S. Research on collaborative allocation of the multi-agent based on equivalent time. 2015 International Conference on Orange Technologies (ICOT) 2015. [DOI: 10.1109/icot.2015.7498510] [Reference Citation Analysis]
728 Bartlett SR, Jacka B, Bull RA, Luciani F, Matthews GV, Lamoury FM, Hellard ME, Hajarizadeh B, Teutsch S, White B, Maher L, Dore GJ, Lloyd AR, Grebely J, Applegate TL. HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection. Infect Genet Evol 2016;37:252-8. [PMID: 26631810 DOI: 10.1016/j.meegid.2015.11.028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
729 Mokhtari C, Ebel A, Reinhardt B, Merlin S, Proust S, Roque-Afonso AM. Characterization of Samples Identified as Hepatitis C Virus Genotype 1 without Subtype by Abbott RealTime HCV Genotype II Assay Using the New Abbott HCV Genotype Plus RUO Test. J Clin Microbiol 2016;54:296-9. [PMID: 26582834 DOI: 10.1128/JCM.02264-15] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
730 Mohamed AA, Elbedewy TA, El-Serafy M, El-Toukhy N, Ahmed W, Ali El Din Z. Hepatitis C virus: A global view. World J Hepatol 2015; 7(26): 2676-2680 [PMID: 26609344 DOI: 10.4254/wjh.v7.i26.2676] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 10.3] [Reference Citation Analysis]
731 Mordecai GJ, Wilfert L, Martin SJ, Jones IM, Schroeder DC. Diversity in a honey bee pathogen: first report of a third master variant of the Deformed Wing Virus quasispecies. ISME J 2016;10:1264-73. [PMID: 26574686 DOI: 10.1038/ismej.2015.178] [Cited by in Crossref: 109] [Cited by in F6Publishing: 118] [Article Influence: 15.6] [Reference Citation Analysis]
732 Gondeau C, Pageaux GP, Larrey D. Hepatitis C virus infection: Are there still specific problems with genotype 3? World J Gastroenterol 2015; 21(42): 12101-12113 [PMID: 26576095 DOI: 10.3748/wjg.v21.i42.12101] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
733 Gentile I, Maraolo AE, Buonomo AR, Zappulo E, Borgia G. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opin Drug Discov. 2015;10:1363-1377. [PMID: 26563720 DOI: 10.1517/17460441.2015.1094051] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
734 Chen M, Ma Y, Chen H, Luo H, Dai J, Song L, Yang C, Mei J, Yang L, Dong L, Jia M, Lu L. Multiple Introduction and Naturally Occuring Drug Resistance of HCV among HIV-Infected Intravenous Drug Users in Yunnan: An Origin of China's HIV/HCV Epidemics. PLoS One 2015;10:e0142543. [PMID: 26562015 DOI: 10.1371/journal.pone.0142543] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
735 Villar LM, Cruz HM, Barbosa JR, Bezerra CS, Portilho MM, Scalioni LP. Update on hepatitis B and C virus diagnosis. World J Virology 2015; 4(4): 323-342 [PMID: 26568915 DOI: 10.5501/wjv.v4.i4.323] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 50] [Article Influence: 6.7] [Reference Citation Analysis]
736 Perales C, Quer J, Gregori J, Esteban JI, Domingo E. Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications. Viruses. 2015;7:5746-5766. [PMID: 26561827 DOI: 10.3390/v7112902] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.7] [Reference Citation Analysis]
737 Yang SS, Kao JH. Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection. Hepatol Int 2016;10:258-66. [PMID: 26542068 DOI: 10.1007/s12072-015-9668-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
738 Cusato J, Allegra S, Boglione L, De Nicolò A, Cariti G, Di Perri G, D'Avolio A. VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. Pharmacogenet Genomics 2015;25:164-72. [PMID: 25713999 DOI: 10.1097/FPC.0000000000000123] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
739 Rao X, Hoof I, van Baarle D, Keşmir C, Textor J. HLA Preferences for Conserved Epitopes: A Potential Mechanism for Hepatitis C Clearance. Front Immunol 2015;6:552. [PMID: 26579127 DOI: 10.3389/fimmu.2015.00552] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
740 Pybus OG, Thézé J. Hepacivirus cross-species transmission and the origins of the hepatitis C virus. Curr Opin Virol 2016;16:1-7. [PMID: 26517843 DOI: 10.1016/j.coviro.2015.10.002] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 7.6] [Reference Citation Analysis]
741 Murira A, Lapierre P, Lamarre A. Evolution of the Humoral Response during HCV Infection: Theories on the Origin of Broadly Neutralizing Antibodies and Implications for Vaccine Design. Adv Immunol 2016;129:55-107. [PMID: 26791858 DOI: 10.1016/bs.ai.2015.09.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
742 Figueiredo AS, Lampe E, do Espírito-Santo MP, Mello FC, de Almeida FQ, de Lemos ER, Godoi TL, Dimache LA, Dos Santos DR, Villar LM. Identification of two phylogenetic lineages of equine hepacivirus and high prevalence in Brazil. Vet J 2015;206:414-6. [PMID: 26545848 DOI: 10.1016/j.tvjl.2015.10.015] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
743 Yi G, Wen Y, Shu C, Han Q, Konan KV, Li P, Kao CC. Hepatitis C Virus NS4B Can Suppress STING Accumulation To Evade Innate Immune Responses. J Virol 2016;90:254-65. [PMID: 26468527 DOI: 10.1128/JVI.01720-15] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
744 Ruta S, Cernescu C. Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. World J Gastroenterol 2015; 21(38): 10811-10823 [PMID: